<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ini Cet Nov 2024 - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        DocTutorial / PYQ / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">13</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x5a4239=_0x4fd0;(function(_0x342327,_0x2ef5fc){const _0x2e89af=_0x4fd0,_0x21fe55=_0x342327();while(!![]){try{const _0x15beae=parseInt(_0x2e89af(0x43a))/0x1*(-parseInt(_0x2e89af(0x433))/0x2)+parseInt(_0x2e89af(0x377))/0x3*(-parseInt(_0x2e89af(0x2ad))/0x4)+parseInt(_0x2e89af(0x212))/0x5+-parseInt(_0x2e89af(0x3b6))/0x6*(-parseInt(_0x2e89af(0x368))/0x7)+-parseInt(_0x2e89af(0x2c2))/0x8+parseInt(_0x2e89af(0x215))/0x9*(-parseInt(_0x2e89af(0x405))/0xa)+-parseInt(_0x2e89af(0x2e4))/0xb*(-parseInt(_0x2e89af(0x290))/0xc);if(_0x15beae===_0x2ef5fc)break;else _0x21fe55['push'](_0x21fe55['shift']());}catch(_0x30b142){_0x21fe55['push'](_0x21fe55['shift']());}}}(_0x53e1,0x1edda));const _0x271ae3=(function(){const _0xb12de7=_0x4fd0,_0x45bd87={'tlQIV':_0xb12de7(0x1c6),'vOdHR':function(_0x368b89,_0x4f5415){return _0x368b89!==_0x4f5415;}};let _0x31e65b=!![];return function(_0x2f2582,_0x5bd510){const _0x1079b1=_0xb12de7,_0x5b5943={'eBsZT':_0x45bd87[_0x1079b1(0x244)],'oTwcD':function(_0xd2489f,_0x42a3c1){const _0x67dfc=_0x1079b1;return _0x45bd87[_0x67dfc(0x448)](_0xd2489f,_0x42a3c1);},'igBuj':'SJdbb'},_0x39ed6d=_0x31e65b?function(){const _0x3b0ee8=_0x1079b1,_0x36a2c7={'NFJIh':_0x5b5943[_0x3b0ee8(0x3f6)]};if(_0x5b5943[_0x3b0ee8(0x1fa)](_0x5b5943['igBuj'],_0x5b5943[_0x3b0ee8(0x403)]))_0x2aecce[_0x5794d3][_0x3b0ee8(0x387)]=_0x36a2c7[_0x3b0ee8(0x3c1)],_0x1be0ed[_0x3b0ee8(0x344)]++,_0x4c5fc4[_0x3b0ee8(0x3ef)]--;else{if(_0x5bd510){const _0x12cd11=_0x5bd510[_0x3b0ee8(0x3ec)](_0x2f2582,arguments);return _0x5bd510=null,_0x12cd11;}}}:function(){};return _0x31e65b=![],_0x39ed6d;};}()),_0x16ca59=_0x271ae3(this,function(){const _0x4146b5=_0x4fd0,_0x2b062b={'PuvEo':_0x4146b5(0x240)};return _0x16ca59[_0x4146b5(0x327)]()[_0x4146b5(0x2d6)](_0x4146b5(0x240))['toString']()[_0x4146b5(0x1d1)](_0x16ca59)['search'](_0x2b062b['PuvEo']);});_0x16ca59();function _0x4fd0(_0x4c5ee0,_0x5aeaa1){const _0x46d2ce=_0x53e1();return _0x4fd0=function(_0x9defb8,_0x5b5c67){_0x9defb8=_0x9defb8-0x1b1;let _0x279645=_0x46d2ce[_0x9defb8];return _0x279645;},_0x4fd0(_0x4c5ee0,_0x5aeaa1);}const _0x5b5c67=(function(){const _0x18d47d=_0x4fd0,_0x4cb649={'RaOdl':_0x18d47d(0x401),'wzPHB':_0x18d47d(0x451),'GXnqa':'choZO','DtUDB':function(_0x2e16aa,_0x108142){return _0x2e16aa!==_0x108142;},'eZCDc':_0x18d47d(0x459)};let _0x16cc07=!![];return function(_0x416b4a,_0x49af0f){const _0x3edfa1=_0x18d47d,_0x226d9e={'AHBFn':_0x4cb649[_0x3edfa1(0x363)],'nmnQW':_0x4cb649[_0x3edfa1(0x3ae)],'QthEp':_0x4cb649['GXnqa'],'VhhKH':function(_0x5393c0,_0x4ed406){const _0x1f18d6=_0x3edfa1;return _0x4cb649[_0x1f18d6(0x3f0)](_0x5393c0,_0x4ed406);},'rGxQj':_0x4cb649[_0x3edfa1(0x45a)]},_0x4f54a9=_0x16cc07?function(){const _0x1573a9=_0x3edfa1,_0x1c78db={'KrhRv':_0x226d9e[_0x1573a9(0x1c5)],'iLUtD':_0x226d9e[_0x1573a9(0x274)]};if(_0x226d9e[_0x1573a9(0x43b)]!=='choZO')_0x5d7dbc[_0x1573a9(0x238)](_0x1c78db['KrhRv'])[_0x1573a9(0x3e6)][_0x1573a9(0x32b)]=_0x1c78db['iLUtD'],_0x24ac39();else{if(_0x49af0f){if(_0x226d9e[_0x1573a9(0x30b)](_0x226d9e['rGxQj'],_0x226d9e[_0x1573a9(0x235)])){if(_0x18807f){const _0x5a3a1f=_0x12712f[_0x1573a9(0x3ec)](_0x1becc4,arguments);return _0x208efe=null,_0x5a3a1f;}}else{const _0x352db2=_0x49af0f[_0x1573a9(0x3ec)](_0x416b4a,arguments);return _0x49af0f=null,_0x352db2;}}}}:function(){};return _0x16cc07=![],_0x4f54a9;};}()),_0x9defb8=_0x5b5c67(this,function(){const _0x5f23b9=_0x4fd0,_0x9690bb={'WMUSw':_0x5f23b9(0x2c8),'iHWkZ':'selected','tIukX':function(_0x1deef7,_0x520340){return _0x1deef7===_0x520340;},'FaLlt':_0x5f23b9(0x20e),'FXlpe':_0x5f23b9(0x42c),'WvtQH':function(_0x42e60b,_0x5ea14d){return _0x42e60b===_0x5ea14d;},'TayBp':'wRznR','CIiQT':function(_0x49908e,_0x2c8e81){return _0x49908e(_0x2c8e81);},'DbMwY':function(_0x525bf9,_0xa8ed55){return _0x525bf9+_0xa8ed55;},'sZbeI':_0x5f23b9(0x31f),'EkUGp':function(_0x53bb22){return _0x53bb22();},'ZtlJI':function(_0x5d447d,_0x3620be){return _0x5d447d!==_0x3620be;},'pmwps':_0x5f23b9(0x3fb),'YiJAR':_0x5f23b9(0x1ee),'OpNSu':_0x5f23b9(0x23f),'BOKNI':_0x5f23b9(0x388),'GBffX':_0x5f23b9(0x281),'MymAo':_0x5f23b9(0x1ca),'WHhCL':function(_0x2cf472,_0x8c74c){return _0x2cf472<_0x8c74c;},'Cshnk':_0x5f23b9(0x42f)};let _0xdeb94b;try{if(_0x9690bb['WvtQH'](_0x5f23b9(0x1e6),_0x9690bb['TayBp'])){const _0x1b4376=_0x9690bb['CIiQT'](Function,_0x9690bb[_0x5f23b9(0x339)](_0x5f23b9(0x234)+_0x9690bb[_0x5f23b9(0x1d2)],');'));_0xdeb94b=_0x9690bb[_0x5f23b9(0x273)](_0x1b4376);}else _0x691ca0=_0x9690bb['WMUSw'];}catch(_0xb35ac8){if(_0x9690bb[_0x5f23b9(0x413)]('uCARE',_0x9690bb[_0x5f23b9(0x392)])){_0x16ef90['classList'][_0x5f23b9(0x37f)](_0x9690bb['iHWkZ']);if(_0x9690bb['tIukX'](_0x336d23,_0x124207))_0x27530c[_0x5f23b9(0x29a)]['add'](_0x9690bb[_0x5f23b9(0x1ea)]);else{if(_0x9690bb[_0x5f23b9(0x337)](_0x37e2b8,_0x482779)&&!_0x4f6e1a)_0x49ec23[_0x5f23b9(0x29a)][_0x5f23b9(0x3a0)](_0x9690bb[_0x5f23b9(0x1c4)]);}}else _0xdeb94b=window;}const _0x208795=_0xdeb94b[_0x5f23b9(0x449)]=_0xdeb94b[_0x5f23b9(0x449)]||{},_0x515bf9=[_0x9690bb[_0x5f23b9(0x24d)],'warn',_0x9690bb[_0x5f23b9(0x2a8)],_0x5f23b9(0x1c3),_0x9690bb[_0x5f23b9(0x1cc)],_0x9690bb[_0x5f23b9(0x45c)],_0x9690bb[_0x5f23b9(0x21e)]];for(let _0x4da528=0x0;_0x9690bb[_0x5f23b9(0x232)](_0x4da528,_0x515bf9[_0x5f23b9(0x289)]);_0x4da528++){if(_0x9690bb[_0x5f23b9(0x390)](_0x9690bb['Cshnk'],_0x9690bb[_0x5f23b9(0x243)])){const _0xd2a882=_0x5b5c67[_0x5f23b9(0x1d1)][_0x5f23b9(0x422)][_0x5f23b9(0x373)](_0x5b5c67),_0x82672b=_0x515bf9[_0x4da528],_0x504e75=_0x208795[_0x82672b]||_0xd2a882;_0xd2a882['__proto__']=_0x5b5c67['bind'](_0x5b5c67),_0xd2a882[_0x5f23b9(0x327)]=_0x504e75[_0x5f23b9(0x327)]['bind'](_0x504e75),_0x208795[_0x82672b]=_0xd2a882;}else _0x40429c['explanation_images'][_0x5f23b9(0x261)](_0x561b45=>{const _0x6be1a4=_0x5f23b9;if(_0x561b45)_0x171566[_0x6be1a4(0x39f)]+=_0x6be1a4(0x421)+_0x561b45+_0x6be1a4(0x369);});}});_0x9defb8();let questionsData=[{'id':0x1,'choices':[{'id':0x1,'text':_0x5a4239(0x1df)},{'id':0x2,'text':_0x5a4239(0x404)},{'id':0x3,'text':_0x5a4239(0x3db)},{'id':0x4,'text':'<p><span\x20style=\x22font-size:12.0pt;\x22>0.9\x20hours</span></p>'}],'text':_0x5a4239(0x461),'unique_key':_0x5a4239(0x3c4),'question_audio':null,'question_video':null,'map_id':0x141bd1,'difficulty_level':_0x5a4239(0x3b7),'subjects_id':[0x1],'solution':'<p>Since\x20first\x20order\x20kinetics\x20is\x20an\x20exponential\x20process,\x20mathematically,\x20the\x20elimination</p>\x0d\x0a<ul>\x0d\x0a<li><strong><u>t&frac12;\x20=\x20log\x202/k</u></strong></li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Where\x20log\x202\x20is\x20the\x20natural\x20logarithm\x20of\x202\x20(or\x200.693)\x20</u></strong></p>\x0d\x0a<p><strong><u>k\x20is\x20the\x20elimination\x20rate\x20constant\x20of\x20the\x20drug,\x20i.e.\x20the\x20fraction\x20of\x20the\x20total\x20amount\x20of\x20drug\x20in\x20the\x20body\x20which\x20is\x20removed\x20per\x20unit\x20time.</u></strong></p>\x0d\x0a<p>It\x20is\x20calculated\x20as:</p>\x0d\x0a<p><strong><u>k\x20=\x20CL/V</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong><u>t&frac12;\x20=\x200.693\x20&times;\x20V/CL</u></strong></li>\x0d\x0a</ul>\x0d\x0a<p>V\x20=\x20Volume\x20of\x20distribution\x20is\x206L/kg\x20and\x20patient&rsquo;s\x20weight\x20is\x2046\x20kg\x20hence\x20Volume\x20of\x20distribution\x20effectively\x20is\x20276\x20L</p>\x0d\x0a<p>CL\x20=\x20Clearance\x20is\x204.6\x20L/hr</p>\x0d\x0a<p>Hence,</p>\x0d\x0a<p>t&frac12;\x20=\x200.693\x20&times;\x20V/CL</p>\x0d\x0a<p>t&frac12;\x20=\x200.693\x20*\x20276\x20/\x204.6</p>\x0d\x0a<p><strong><u>t&frac12;\x20=\x2041.58\x20hour\x20=\x2042\x20hour</u></strong></p>\x0d\x0a<p>As\x20such,\x20<u>half-life\x20is\x20a\x20derived\x20parameter\x20from\x20two\x20variables\x20V\x20and\x20CL,\x20both\x20of\x20which\x20may\x20change\x20independently</u></p>\x0d\x0a<p><strong><u>Key\x20Takeaway:</u></strong></p>\x0d\x0a<p><strong>The\x20Plasma\x20half-life\x20(t&frac12;)\x20of\x20a\x20drug\x20is\x20the\x20time\x20taken\x20for\x20its\x20plasma\x20Concentration\x20to\x20be\x20reduced\x20to\x20half\x20of\x20its\x20original\x20value.\x20Half-life\x20is\x20a\x20derived\x20parameter\x20from\x20two\x20variables\x20V\x20and\x20CL,\x20both\x20of\x20which\x20may\x20change\x20independently</strong></p>','correct_choice_id':0x3,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':_0x5a4239(0x280),'tags':[_0x5a4239(0x3d9)],'explanation_video':null,'question_images':[],'explanation_images':[]},{'id':0x2,'choices':[{'id':0xb,'text':_0x5a4239(0x245)},{'id':0xc,'text':_0x5a4239(0x3fd)},{'id':0xd,'text':_0x5a4239(0x1bf)},{'id':0xe,'text':_0x5a4239(0x22f)}],'text':_0x5a4239(0x391),'unique_key':'DT1317844','question_audio':null,'question_video':null,'map_id':0x141bd4,'difficulty_level':_0x5a4239(0x3b7),'subjects_id':[0x1],'solution':'<p><strong><u>Benzimidazoles\x20</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li>Although\x20a\x20large\x20number\x20of\x20drugs\x20in\x20the\x20Benzimidazoles\x20class\x20have\x20been\x20synthesized\x20and\x20several\x20have\x20undergone\x20clinical\x20development\x20for\x20treatment\x20of\x20parasitic\x20infections\x20of\x20humans,\x20only\x20two\x20are\x20currently\x20in\x20wide\x20use,\x20namely\x20<strong>albendazole\x20and\x20mebendazole,\x20with\x20triclabendazole\x20being\x20reserved\x20for\x20treatment\x20of\x20liver\x20fluke\x20infection\x20caused\x20by\x20Fasciola\x20hepatica.</strong></li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Mechanism\x20of\x20Action\x20</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li>The\x20primary\x20mechanism\x20of\x20action\x20of\x20the\x20<strong>Benzimidazoles\x20is\x20thought\x20to\x20be\x20inhibition\x20of\x20microtubule\x20polymerization\x20by\x20binding\x20to\x20&beta;-tubulin</strong></li>\x0d\x0a<li>The\x20selective\x20toxicity\x20of\x20these\x20agents\x20against\x20helminths\x20results\x20from\x20their\x20<strong>increased\x20affinity\x20for\x20parasite\x20&beta;-tubulin\x20than\x20for\x20the\x20same\x20target\x20in\x20higher\x20eukaryotes.</strong></li>\x0d\x0a<li>A\x20range\x20of\x20other\x20biochemical\x20changes\x20occur\x20in\x20nematodes\x20following\x20Benzimidazoles\x20exposure,\x20including\x20inhibition\x20of\x20mitochondrial\x20fumarate\x20reductase,\x20reduced\x20glucose\x20transport,\x20and\x20uncoupling\x20of\x20oxidative\x20phosphorylation.</li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Triclabendazole</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Administration\x20of\x20triclabendazole\x20after\x20food\x20enhances\x20its\x20absorption,\x20which\x20might\x20be\x20due\x20to\x20the\x20stimulation\x20of\x20gastric\x20acid\x20secretion,\x20food-induced\x20increase\x20in\x20drug\x20solubility,\x20and/\x20or\x20altered\x20gastrointestinal</strong>\x20(GI)\x20motility\x20and\x20transit\x20time.</li>\x0d\x0a<li>After\x20oral\x20administration,\x20<strong>triclabendazole\x20is\x20rapidly\x20oxidized\x20into\x20two\x20major\x20metabolites,\x20triclabendazole\x20sulfoxide\x20and\x20triclabendazole\x20sulfone\x20and\x20only\x20low\x20concentrations\x20of\x20the\x20parent\x20drug\x20can\x20be\x20detected\x20in\x20plasma.</strong></li>\x0d\x0a<li><u>Triclabendazole\x20sulfoxide\x20is\x20the\x20metabolite\x20active\x20against\x20F.\x20hepatica</u></li>\x0d\x0a<li>Triclabendazole\x20is\x20used\x20for\x20the\x20treatment\x20of\x20fascioliasis\x20and\x20represents\x20an\x20alternative\x20to\x20praziquantel\x20for\x20treatment\x20of\x20paragonimiasis.</li>\x0d\x0a</ul>\x0d\x0a<p><strong>Incorrect\x20Choices\x20Explanation:</strong></p>\x0d\x0a<p><strong>(Choice\x20A)\x20Praziquantel<br\x20/>\x20</strong>Praziquantel\x20is\x20effective\x20against\x20<strong>schistosomiasis\x20and\x20many\x20cestode\x20(tapeworm)\x20infections</strong>\x20but\x20is\x20<strong>not\x20effective\x20against\x20Fasciola\x20hepatica</strong>.\x20While\x20it\x20is\x20used\x20for\x20<strong>paragonimiasis\x20(lung\x20fluke)</strong>,\x20it\x20does\x20not\x20cover\x20<strong>liver\x20fluke\x20infections</strong>\x20effectively.<br\x20/>\x20This\x20option\x20is\x20incorrect\x20because\x20it\x20is\x20<strong>not\x20effective\x20against\x20Fasciola\x20hepatica</strong>.</p>\x0d\x0a<p><strong>(Choice\x20B)\x20Albendazole<br\x20/>\x20</strong>Albendazole\x20is\x20a\x20broad-spectrum\x20<strong>benzimidazole</strong>\x20used\x20to\x20treat\x20<strong>nematode\x20(roundworm)\x20infections</strong>,\x20<strong>cysticercosis</strong>,\x20and\x20<strong>hydatid\x20disease</strong>.\x20Although\x20it\x20has\x20some\x20efficacy\x20against\x20<strong>trematodes</strong>,\x20it\x20is\x20<strong>not\x20the\x20first-line\x20treatment\x20for\x20Fasciola\x20hepatica</strong>.<br\x20/>\x20This\x20option\x20is\x20incorrect\x20because\x20<strong>triclabendazole\x20is\x20more\x20effective\x20for\x20liver\x20fluke\x20infections</strong>.</p>\x0d\x0a<p><strong>(Choice\x20C)\x20Mebendazole<br\x20/>\x20</strong>Mebendazole\x20is\x20another\x20<strong>benzimidazole</strong>\x20primarily\x20used\x20for\x20<strong>intestinal\x20nematode\x20infections</strong>\x20(e.g.,\x20ascariasis,\x20hookworm,\x20whipworm).\x20It\x20has\x20<strong>limited\x20efficacy\x20against\x20liver\x20flukes</strong>\x20and\x20is\x20<strong>not\x20recommended</strong>\x20for\x20Fasciola\x20hepatica.<br\x20/>\x20This\x20option\x20is\x20incorrect\x20because\x20<strong>it\x20is\x20not\x20used\x20for\x20Fasciola\x20hepatica\x20treatment</strong>.</p>\x0d\x0a<p><strong><u>Key\x20Takeaway:</u></strong></p>\x0d\x0a<p><strong>Benzimidazoles</strong><strong>\x20class\x20of\x20drugs\x20are\x20currently\x20in\x20wide\x20use,\x20namely\x20albendazole\x20and\x20mebendazole,\x20with\x20triclabendazole\x20being\x20reserved\x20for\x20treatment\x20of\x20liver\x20fluke\x20infection\x20caused\x20by\x20Fasciola\x20hepatica.\x20</strong></p>','correct_choice_id':0xe,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':'bottom','tags':['Factual'],'explanation_video':null,'question_images':[],'explanation_images':[]},{'id':0x3,'choices':[{'id':0x15,'text':_0x5a4239(0x23d)},{'id':0x16,'text':_0x5a4239(0x41a)},{'id':0x17,'text':'<p><span\x20style=\x22font-size:12.0pt;\x22>1,\x203\x20and\x204</span></p>'},{'id':0x18,'text':_0x5a4239(0x323)}],'text':_0x5a4239(0x36e),'unique_key':'DT1317846','question_audio':null,'question_video':null,'map_id':0x141bd6,'difficulty_level':_0x5a4239(0x3b7),'subjects_id':[0x1],'solution':_0x5a4239(0x2f5),'correct_choice_id':0x15,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':'bottom','tags':[_0x5a4239(0x3d9)],'explanation_video':null,'question_images':[],'explanation_images':[]},{'id':0x4,'choices':[{'id':0x1f,'text':_0x5a4239(0x40c)},{'id':0x20,'text':'<p><span\x20style=\x22font-size:12.0pt;\x22>Primaquine</span></p>'},{'id':0x21,'text':_0x5a4239(0x246)},{'id':0x22,'text':_0x5a4239(0x420)}],'text':_0x5a4239(0x28b),'unique_key':_0x5a4239(0x3ac),'question_audio':null,'question_video':null,'map_id':0x141bd9,'difficulty_level':_0x5a4239(0x3b7),'subjects_id':[0x1],'solution':_0x5a4239(0x41d),'correct_choice_id':0x20,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':'bottom','tags':[_0x5a4239(0x3d9)],'explanation_video':null,'question_images':[],'explanation_images':[]},{'id':0x5,'choices':[{'id':0x29,'text':'<p><span\x20style=\x22font-size:12.0pt;\x22>Ibalizumab</span></p>'},{'id':0x2a,'text':_0x5a4239(0x410)},{'id':0x2b,'text':_0x5a4239(0x33d)},{'id':0x2c,'text':_0x5a4239(0x2c9)}],'text':_0x5a4239(0x3e8),'unique_key':'DT1317850','question_audio':null,'question_video':null,'map_id':0x141bda,'difficulty_level':_0x5a4239(0x3b7),'subjects_id':[0x1],'solution':_0x5a4239(0x1d8),'correct_choice_id':0x29,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':'bottom','tags':[_0x5a4239(0x3d9)],'explanation_video':null,'question_images':[],'explanation_images':[]},{'id':0x6,'choices':[{'id':0x33,'text':_0x5a4239(0x31d)},{'id':0x34,'text':_0x5a4239(0x3a5)},{'id':0x35,'text':_0x5a4239(0x466)},{'id':0x36,'text':_0x5a4239(0x239)}],'text':_0x5a4239(0x39e),'unique_key':_0x5a4239(0x374),'question_audio':null,'question_video':null,'map_id':0x141bdc,'difficulty_level':_0x5a4239(0x3b7),'subjects_id':[0x1],'solution':_0x5a4239(0x2c4),'correct_choice_id':0x33,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':'bottom','tags':[_0x5a4239(0x3d9)],'explanation_video':null,'question_images':[],'explanation_images':[]},{'id':0x7,'choices':[{'id':0x3d,'text':_0x5a4239(0x2bc)},{'id':0x3e,'text':_0x5a4239(0x20a)},{'id':0x3f,'text':_0x5a4239(0x2a7)},{'id':0x40,'text':'<p><span\x20style=\x22font-size:12.0pt;\x22>Vandetanib</span></p>'}],'text':_0x5a4239(0x412),'unique_key':_0x5a4239(0x336),'question_audio':null,'question_video':null,'map_id':0x141bdd,'difficulty_level':'intermediate','subjects_id':[0x1],'solution':'<p><strong><u>PARP\x20inhibitors</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Olaparib\x20</strong>and\x20<strong>rucaparib\x20</strong>are\x20poly\x20ADP-ribose\x20polymerase\x20(PARP)\x20inhibitors\x20and\x20are\x20used\x20for\x20oral\x20treatment\x20of\x20<strong>ovarian\x20cancer.</strong></li>\x0d\x0a<li><strong>Niraparib\x20</strong>is\x20new\x20drug\x20in\x20this\x20group\x20that\x20is\x20indicated\x20for\x20ovarian,\x20fallopian\x20tube\x20or\x20primary\x20peritoneal\x20cancer.</li>\x0d\x0a<li><strong>Talazoparib\x20</strong>has\x20been\x20recently\x20approved\x20for\x20advanced\x20breast\x20carcinoma\x20with\x20BRCA\x20mutations.</li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Rucaparib\x20</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li>Rucaparib\x20is\x20an\x20orally\x20bioavailable\x20inhibitor\x20of\x20PARP1-3.</li>\x0d\x0a<li><strong>Rucaparib\x20approved\x20for\x20the\x20treatment\x20of\x20patients\x20with\x20<u>advanced\x20ovarian\x20cancer\x20with\x20BRCA\x20mutations</u>\x20and\x20is\x20used\x20in\x20the\x20maintenance\x20treatment\x20of\x20these\x20patients\x20after\x20a\x20partial\x20response\x20to\x20platinum-based\x20chemotherapy</strong>.</li>\x0d\x0a<li>Other\x20uses\x20include\x20patients\x20with\x20<u>BRCA-mutated,\x20metastatic,\x20castration-resistant\x20prostate\x20cancer\x20after\x20endocrine\x20and\x20taxane-based\x20therapy.</u></li>\x0d\x0a<li>Rucaparib\x20is\x20metabolized\x20primarily\x20by\x20CYP2D6\x20and\x20to\x20a\x20lesser\x20extent\x20by\x20CYP1A2\x20and\x20CYP3A4</li>\x0d\x0a</ul>\x0d\x0a<p><strong>Incorrect\x20Choices\x20Explanation:</strong></p>\x0d\x0a<p><strong>(Choice\x20A)\x20Palbociclib</strong>\x20-\x20Palbociclib\x20is\x20a\x20<strong>cyclin-dependent\x20kinase\x20(CDK)\x204/6\x20inhibitor</strong>\x20used\x20in\x20the\x20treatment\x20of\x20<strong>hormone\x20receptor-positive\x20(HR+),\x20HER2-negative\x20advanced\x20breast\x20cancer</strong>.\x20It\x20does\x20not\x20act\x20as\x20a\x20<strong>PARP\x20inhibitor</strong>\x20and\x20is\x20not\x20specifically\x20indicated\x20for\x20BRCA-positive\x20cancers.</p>\x0d\x0a<p><strong>(Choice\x20C)\x20Regorafenib</strong>\x20-\x20Regorafenib\x20is\x20a\x20<strong>multi-kinase\x20inhibitor</strong>\x20that\x20targets\x20<strong>angiogenesis\x20and\x20tumor\x20growth\x20pathways</strong>.\x20It\x20is\x20used\x20in\x20<strong>metastatic\x20colorectal\x20cancer,\x20gastrointestinal\x20stromal\x20tumors\x20(GISTs),\x20and\x20hepatocellular\x20carcinoma\x20(HCC)</strong>\x20but\x20does\x20not\x20have\x20a\x20role\x20in\x20BRCA-mutated\x20breast\x20cancer.</p>\x0d\x0a<p><strong>(Choice\x20D)\x20Vandetanib</strong>\x20-\x20Vandetanib\x20is\x20a\x20<strong>tyrosine\x20kinase\x20inhibitor\x20(TKI)</strong>\x20targeting\x20VEGFR,\x20EGFR,\x20and\x20RET\x20signaling.\x20It\x20is\x20primarily\x20used\x20for\x20the\x20treatment\x20of\x20<strong>medullary\x20thyroid\x20carcinoma</strong>\x20and\x20has\x20no\x20direct\x20relevance\x20to\x20<strong>BRCA-mutated\x20breast\x20cancer</strong>.</p>\x0d\x0a<p><strong><u>Key\x20takeaway</u></strong></p>\x0d\x0a<p><strong>Rucaparib\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20patients\x20with\x20advanced\x20ovarian\x20cancer\x20with\x20BRCA\x20mutations\x20and\x20is\x20used\x20in\x20the\x20maintenance\x20treatment\x20of\x20these\x20patients\x20after\x20a\x20partial\x20response\x20to\x20platinum-based\x20chemotherapy</strong></p>','correct_choice_id':0x3e,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':_0x5a4239(0x280),'tags':['Factual'],'explanation_video':null,'question_images':[],'explanation_images':[]},{'id':0x8,'choices':[{'id':0x47,'text':_0x5a4239(0x200)},{'id':0x48,'text':'<p><span\x20style=\x22font-size:12.0pt;\x22>Ozanimod</span></p>'},{'id':0x49,'text':_0x5a4239(0x222)},{'id':0x4a,'text':_0x5a4239(0x247)}],'text':_0x5a4239(0x424),'unique_key':_0x5a4239(0x292),'question_audio':null,'question_video':null,'map_id':0x141bde,'difficulty_level':_0x5a4239(0x3b7),'subjects_id':[0x1],'solution':_0x5a4239(0x365),'correct_choice_id':0x49,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':_0x5a4239(0x280),'tags':[_0x5a4239(0x3d9)],'explanation_video':null,'question_images':[],'explanation_images':[]},{'id':0x9,'choices':[{'id':0x51,'text':_0x5a4239(0x31a)},{'id':0x52,'text':'<p><span\x20style=\x22font-size:12.0pt;\x22>Benzodiazepines\x20-\x20Flumazenil\x20</span></p>'},{'id':0x53,'text':_0x5a4239(0x3d0)},{'id':0x54,'text':_0x5a4239(0x2f8)}],'text':_0x5a4239(0x282),'unique_key':_0x5a4239(0x35c),'question_audio':null,'question_video':null,'map_id':0x141be0,'difficulty_level':_0x5a4239(0x3b7),'subjects_id':[0x1],'solution':_0x5a4239(0x43c),'correct_choice_id':0x52,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':_0x5a4239(0x280),'tags':[_0x5a4239(0x3d9)],'explanation_video':null,'question_images':[],'explanation_images':[]},{'id':0xa,'choices':[{'id':0x5b,'text':_0x5a4239(0x2f1)},{'id':0x5c,'text':_0x5a4239(0x3d7)},{'id':0x5d,'text':_0x5a4239(0x1fd)},{'id':0x5e,'text':'<p><span\x20style=\x22font-size:12.0pt;\x22>Systemic\x20infusion\x20of\x20beta\x201\x20adrenergic\x20agonist\x20</span></p>'}],'text':_0x5a4239(0x36b),'unique_key':_0x5a4239(0x297),'question_audio':null,'question_video':null,'map_id':0x141be1,'difficulty_level':_0x5a4239(0x3b7),'subjects_id':[0x1],'solution':_0x5a4239(0x385),'correct_choice_id':0x5d,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':_0x5a4239(0x280),'tags':[_0x5a4239(0x3d9)],'explanation_video':null,'question_images':[],'explanation_images':[]},{'id':0xb,'choices':[{'id':0x65,'text':_0x5a4239(0x202)},{'id':0x66,'text':_0x5a4239(0x38a)},{'id':0x67,'text':_0x5a4239(0x208)},{'id':0x68,'text':'<p><span\x20style=\x22font-size:12.0pt;\x22>For\x20resistant\x20malaria\x20</span></p>'}],'text':_0x5a4239(0x1b6),'unique_key':'DT1317859','question_audio':null,'question_video':null,'map_id':0x141be3,'difficulty_level':_0x5a4239(0x3b7),'subjects_id':[0x1],'solution':_0x5a4239(0x1b5),'correct_choice_id':0x65,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':'bottom','tags':[_0x5a4239(0x3d9)],'explanation_video':null,'question_images':[],'explanation_images':[]},{'id':0xc,'choices':[{'id':0x6f,'text':_0x5a4239(0x463)},{'id':0x70,'text':_0x5a4239(0x1b1)},{'id':0x71,'text':_0x5a4239(0x1f2)},{'id':0x72,'text':'<p><span\x20style=\x22font-size:12.0pt;\x22>Given\x20to\x20all\x20patients\x20with\x20seizures\x20regardless\x20of\x20cardiac\x20arrhythmia,\x20hypotension,\x20and/or\x20sinus\x20depression</span></p>'}],'text':_0x5a4239(0x1ef),'unique_key':_0x5a4239(0x37a),'question_audio':null,'question_video':null,'map_id':0x141be4,'difficulty_level':'intermediate','subjects_id':[0x1],'solution':_0x5a4239(0x2cf),'correct_choice_id':0x6f,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':_0x5a4239(0x280),'tags':[_0x5a4239(0x3d9)],'explanation_video':null,'question_images':[],'explanation_images':[]},{'id':0xd,'choices':[{'id':0x79,'text':'<p><span\x20style=\x22font-size:12.0pt;\x22>Ganaxolone</span></p>'},{'id':0x7a,'text':_0x5a4239(0x226)},{'id':0x7b,'text':_0x5a4239(0x42e)},{'id':0x7c,'text':'<p><span\x20style=\x22font-size:12.0pt;\x22>Stiripentol</span></p>'}],'text':_0x5a4239(0x1fc),'unique_key':_0x5a4239(0x26a),'question_audio':null,'question_video':null,'map_id':0x141be6,'difficulty_level':_0x5a4239(0x3b7),'subjects_id':[0x1],'solution':_0x5a4239(0x3b2),'correct_choice_id':0x7a,'solution_audio':null,'solution_video':null,'audio_explanation_heading':null,'video_explanation_heading':null,'solution_media_position':'bottom','tags':[_0x5a4239(0x3d9)],'explanation_video':null,'question_images':[],'explanation_images':[]}],quizName=_0x5a4239(0x3d2);const quizFilename='ini-cet-nov-2024-dceed77a.html';function _0x53e1(){const _0x5d8072=['QSvSV','totalQuestionsResult','startAt','flex','FLVOm','search','statsBar','IvUWT','RiYPH','border-red-500','zjvwS','HagQN','PgaMK','Correct','explanation_audio_hin','LLOcS','aUSVC','HgAIb','HDYaD','638LFlJwN','iFGXK','owbVN','join','QjcPc','gJGsv','EsQmK','question_audio','endsWith','border-green-500','BAsdb','pzLus','TYibR','<p><span\x20style=\x22font-size:12.0pt;\x22>Systemic\x20infusion\x20of\x20alpha\x20blocker\x20</span></p>','OSJLM','PeerN','correctCount','<p><strong><u>Intestinal\x20Cholesterol\x20Absorption\x20Inhibitor</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li>Ezetimibe\x20inhibits\x20a\x20transporter\x20involved\x20in\x20intestinal\x20absorption\x20of\x20cholesterol\x20called\x20NPC1L1.</li>\x0d\x0a<li>Due\x20to\x20<u>decreased\x20absorption,\x20cholesterol\x20content\x20of\x20the\x20liver\x20decreases\x20and\x20it\x20responds\x20by\x20increasing\x20LDL\x20receptor\x20synthesis.</u></li>\x0d\x0a<li>It\x20can\x20be\x20used\x20alone\x20or\x20combined\x20with\x20statins\x20for\x20type\x20IIa\x20and\x20IIb\x20hyperlipoproteinemia.</li>\x0d\x0a<li>It\x20is\x20effective\x20in\x20reducing\x20LDL-C\x20in\x20patients\x20with\x20<strong>sitosterolemia</strong></li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Bempedoic\x20Acid\x20</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Bempedoic\x20acid,\x20a\x20dicarboxylic\x20acid\x20acts\x20by\x20inhibiting\x20de\x20novo\x20hepatocyte\x20cholesterol\x20biosynthesis.</strong></li>\x0d\x0a<li>Its\x20<u>mechanism\x20of\x20action\x20complements\x20statins\x20and\x20other\x20agents\x20that\x20lower\x20LDL-C.</u></li>\x0d\x0a<li><strong>The\x20drug\x20is\x20approved\x20as\x20an\x20adjunct\x20to\x20diet\x20and\x20maximally\x20tolerated\x20statin\x20therapy\x20to\x20further\x20lower\x20LDL-C\x20in\x20patients\x20with\x20HeFH\x20or\x20established\x20ASCVD.</strong></li>\x0d\x0a<li><strong>A\x20fixed-dose\x20combination\x20of\x20bempedoic\x20acid\x20and\x20ezetimibe\x20is\x20approved\x20for\x20the\x20same\x20indication.</strong></li>\x0d\x0a<li>Bempedoic\x20acid\x20also\x20has\x20application\x20in\x20patients\x20who\x20are\x20statin-intolerant.</li>\x0d\x0a<li><strong><u>Bempedoic\x20acid\x20is\x20FDA-approved\x20for\x20the\x20treatment\x20of\x20adults\x20with\x20either\x20HeFH\x20or\x20established\x20ASCVD\x20who\x20need\x20additional\x20LDL-C\x20lowering.</u></strong></li>\x0d\x0a<li><u>Monotherapy\x20with\x20bempedoic\x20acid\x20results\x20in\x20a\x2015%\x20to\x2025%\x20reduction\x20in\x20LDL-C,\x20less\x20than\x20with\x20statins.\x20In\x20combination\x20with\x20ezetimibe,\x20the\x20reduction\x20in\x20LDL-C\x20is\x20around\x2030%,\x20and\x20triple\x20therapy\x20with\x20a\x20statin\x20reduces\x20LDL-C\x20by\x2065%.\x20Reduction\x20in\x20HDL-C\x20by\x20bempedoic\x20acid\x20is\x20typically\x20around\x205%.</u></li>\x0d\x0a<li>PCSK9\x20Inhibitors\x20Proprotein\x20convertase\x20subtilisin\x20kexin\x20type\x209\x20(PCSK\x209)\x20is\x20a\x20protein\x20that\x20binds\x20LDL-receptors\x20and\x20transport\x20them\x20to\x20lysosomes\x20where\x20these\x20are\x20degraded.</li>\x0d\x0a<li>Therefore\x20instead\x20of\x20recycling\x20of\x20LDL-R\x20to\x20surface\x20of\x20hepatocytes,\x20they\x20get\x20destroyed.</li>\x0d\x0a<li>Inhibitors\x20of\x20PCSK\x209,\x20therefore\x20prevent\x20destruction\x20of\x20LDL-R\x20resulting\x20in\x20lowering\x20of\x20LDL-cholesterol.</li>\x0d\x0a<li><strong>Alirocumab\x20</strong>and\x20<strong>evolocumab\x20</strong>are\x20monoclonal\x20antibodies\x20against\x20PCSK\x209\x20and\x20are\x20approved\x20for\x20familial\x20hypercholesterolemia\x20as\x20an\x20adjunct\x20to\x20diet\x20and\x20maximally\x20tolerated\x20statin\x20therapy.</li>\x0d\x0a</ul>\x0d\x0a<p><strong>Incorrect\x20Choices\x20Explanation:</strong></p>\x0d\x0a<p><strong>(Choice\x20B)\x20Only\x201\x20and\x202</strong>\x20-\x20This\x20choice\x20includes\x20ezetimibe\x20and\x20evolocumab\x20but\x20omits\x20bempedoic\x20acid,\x20which\x20is\x20beneficial\x20for\x20LDL\x20reduction\x20in\x20patients\x20with\x20ASCVD\x20on\x20maximally\x20tolerated\x20statins.</p>\x0d\x0a<p><strong>(Choice\x20C)\x201,\x203,\x20and\x204</strong>\x20-\x20Gemfibrozil\x20(choice\x203)\x20is\x20a\x20fibrate\x20that\x20lowers\x20triglycerides\x20but\x20is\x20not\x20preferred\x20in\x20patients\x20with\x20ASCVD\x20on\x20statins\x20due\x20to\x20an\x20increased\x20risk\x20of\x20myopathy\x20when\x20combined\x20with\x20statins.\x20Instead,\x20a\x20PCSK9\x20inhibitor\x20(evolocumab)\x20is\x20a\x20better\x20option\x20for\x20LDL\x20reduction.</p>\x0d\x0a<p><strong>(Choice\x20D)\x20Only\x201\x20and\x203</strong>\x20-\x20This\x20omits\x20both\x20evolocumab\x20and\x20bempedoic\x20acid,\x20which\x20are\x20essential\x20for\x20further\x20LDL\x20reduction\x20in\x20high-risk\x20ASCVD\x20patients.\x20Gemfibrozil\x20is\x20not\x20preferred\x20due\x20to\x20its\x20interaction\x20with\x20statins.</p>\x0d\x0a<p><strong><u>Key\x20takeaway</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Alirocumab\x20and\x20evolocumab\x20are\x20monoclonal\x20antibodies\x20against\x20PCSK\x209\x20and\x20are\x20approved\x20for\x20familial\x20hypercholesterolemia\x20as\x20an\x20adjunct\x20to\x20diet\x20and\x20maximally\x20tolerated\x20statin\x20therapy.</strong></li>\x0d\x0a<li><strong>A\x20fixed-dose\x20combination\x20of\x20bempedoic\x20acid\x20and\x20ezetimibe\x20is\x20approved\x20as\x20an\x20adjunct\x20to\x20diet\x20and\x20maximally\x20tolerated\x20statin\x20therapy\x20to\x20further\x20lower\x20LDL-C\x20in\x20patients\x20with\x20HeFH\x20or\x20established\x20ASCVD.\x20</strong></li>\x0d\x0a</ul>','ynGfl','green','<p><span\x20style=\x22font-size:12.0pt;\x22>Atropine\x20-\x20L-carnitine\x20</span></p>','video[data-src]','mvrQl','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','trVKB','correct_choice_id','ynPDt','HQGPy','key','oLPHA','href','accuracy','ygGmW','toISOString','VXPUK','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','HsRrZ','txVOs','VhhKH','ETmAg','MyOub','Zfgub','button','question_images','TqgiA','npifK','CRhJU','Bookmark','KJhbF','warn','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','.option-button','vBNLy','<p><span\x20style=\x22font-size:12.0pt;\x22>Organophosphorus\x20-\x20Physostigmine</span></p>','solutionContainer','reload','<p><span\x20style=\x22font-size:12.0pt;\x22>Lacosamide</span></p>','bookmarkedQuestions','{}.constructor(\x22return\x20this\x22)(\x20)','vogdi','lGIOp','UocSa','<p><span\x20style=\x22font-size:12.0pt;\x22>Only\x201\x20and\x203</span></p>','bookmarkText','pathname','qSWnb','toString','rJazH','TOyyG','KIDqI','display','rgUGN','dSsvd','yBGwc','notAttemptedResult','incomplete','dyuWb','ZIMAv','VNPsk','</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-','quizSidebar','DT1317853','tIukX','now','DbMwY','map','sJLzP','oseJn','<p><span\x20style=\x22font-size:12.0pt;\x22>Elvitegravir</span></p>','pSnUD','gOTVR','LuQpp','pclPK','tUwXc','kfboJ','totalAttempted','scoreCircle','stringify','VSQzu','GngeF','sOLDB','findIndex','correctResult','fromCharCode','WKdBT','PRDOj','rBVeY','click','customQuizData','qfNmG','dCame','timeDisplay','gGXHh','setItem','JzCAZ','mRcwl','pPAHB','bookmarkBtn','OUzvE','DT1317856','parse','markedForReview','reduce','Marked','uNZEq','removeItem','RaOdl','DcXjU','<p><strong><u>Tofacitinib\x20</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><u>Tofacitinib\x20</u><u>is\x20an\x20oral\x20JAK\x20inhibitor\x20approved\x20for\x20use\x20in\x20rheumatoid\x20arthritis,\x20psoriatic\x20arthritis,\x20ulcerative\x20colitis,\x20and\x20polyarticular\x20juvenile\x20arthritis\x20in\x20adults.\x20</u></li>\x0d\x0a<li><strong><u>Janus\x20Kinase\x20Inhibitors</u></strong></li>\x0d\x0a<li><strong>Tofacitinib\x20</strong>and\x20<strong>baricitinib\x20</strong>are\x20inhibitors\x20of\x20Janus\x20kinase\x203.</li>\x0d\x0a<li>These\x20are\x20<strong>approved\x20for\x20severe\x20RA\x20refractory\x20to\x20methotrexate</strong>.\x20These\x20are\x20effective\x20orally.</li>\x0d\x0a<li>Like\x20TNF-&alpha;\x20inhibitors,\x20screening\x20of\x20patients\x20for\x20latent\x20TB\x20must\x20be\x20done\x20prior\x20to\x20receiving\x20these\x20drugs.</li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Tofacitinib\x20</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li>It\x20is\x20a\x20new\x20synthetic\x20drug\x20approved\x20for\x20severe\x20cases\x20of\x20RA\x20that\x20are\x20not\x20responding\x20to\x20Mtx.</li>\x0d\x0a<li>Tofacitinib\x20can\x20be\x20used\x20alone\x20or\x20concurrently\x20with\x20Mtx,\x20but\x20should\x20not\x20be\x20combined\x20with\x20azathioprine,\x20cyclosporine\x20or\x20biological\x20DMARDs.</li>\x0d\x0a<li>It\x20<strong>is\x20a\x20JAK-3\x20and\x20JAK-1\x20kinase\x20inhibitor,\x20interferes\x20with\x20the\x20JAK-STAT\x20signaling\x20pathway\x20and\x20DNA\x20transcription,\x20production\x20of\x20inflammatory\x20mediators\x20and\x20release\x20of\x20cytokines\x20is\x20inhibited.</strong></li>\x0d\x0a<li>Adverse\x20effects\x20are\x20<u>headache,\x20insomnia,\x20diarrhoea,\x20hypertension,\x20anaemia,\x20</u><u>susceptibility\x20to\x20respiratory\x20infections,\x20flaring\x20of\x20tuberculosis\x20and\x20liver\x20damage.</u></li>\x0d\x0a</ul>\x0d\x0a<p><strong>Incorrect\x20Choices\x20Explanation:</strong></p>\x0d\x0a<p><strong>(Choice\x20A)\x20Filgotinib</strong>\x20-\x20Filgotinib\x20is\x20a\x20<strong>selective\x20JAK1\x20inhibitor</strong>\x20that\x20is\x20approved\x20for\x20<strong>rheumatoid\x20arthritis</strong>\x20but\x20is\x20still\x20under\x20investigation\x20for\x20<strong>ulcerative\x20colitis</strong>.\x20It\x20is\x20not\x20currently\x20the\x20preferred\x20JAK\x20inhibitor\x20for\x20<strong>moderate\x20to\x20severe\x20ulcerative\x20colitis</strong>.</p>\x0d\x0a<p><strong>(Choice\x20B)\x20Ozanimod</strong>\x20-\x20Ozanimod\x20is\x20a\x20<strong>sphingosine-1-phosphate\x20(S1P)\x20receptor\x20modulator</strong>,\x20approved\x20for\x20<strong>relapsing\x20multiple\x20sclerosis\x20(MS)\x20and\x20ulcerative\x20colitis</strong>.\x20While\x20it\x20is\x20used\x20for\x20<strong>ulcerative\x20colitis</strong>,\x20it\x20works\x20by\x20reducing\x20lymphocyte\x20migration\x20rather\x20than\x20by\x20JAK\x20inhibition.</p>\x0d\x0a<p><strong>(Choice\x20D)\x20Infliximab</strong>\x20-\x20Infliximab\x20is\x20a\x20<strong>TNF-&alpha;\x20inhibitor</strong>\x20commonly\x20used\x20in\x20<strong>moderate\x20to\x20severe\x20ulcerative\x20colitis</strong>.\x20However,\x20since\x20the\x20patient\x20in\x20this\x20case\x20<strong>is\x20not\x20responding\x20to\x20anti-TNF&alpha;\x20therapy</strong>,\x20switching\x20to\x20another\x20TNF\x20inhibitor\x20like\x20infliximab\x20would\x20not\x20be\x20the\x20preferred\x20approach.</p>\x0d\x0a<p><strong><u>Key\x20takeaway</u></strong></p>\x0d\x0a<p><strong>Tofacitinib\x20is\x20an\x20oral\x20JAK\x20inhibitor\x20approved\x20for\x20use\x20in\x20rheumatoid\x20arthritis,\x20psoriatic\x20arthritis,\x20ulcerative\x20colitis,\x20and\x20polyarticular\x20juvenile\x20arthritis\x20in\x20adults.\x20</strong></p>','WYDkg','HJTfi','7AOMZPt','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','xafzI','<p><span\x20style=\x22font-size:12.0pt;\x22>Which\x20of\x20the\x20following\x20will\x20lead\x20to\x20a\x20decrease\x20in\x20diastolic\x20blood\x20pressure?\x09</span></p>','FbDfr','questions','<p><span\x20style=\x22font-size:12.0pt;\x22>A\x2060-year-old\x20patient,\x20a\x20known\x20case\x20of\x20hypertension\x20and\x20diabetes,\x20post-PCI\x20stent\x20placement\x20for\x20NSTEMI\x20last\x20year,\x20is\x20currently\x20on\x20three\x20drugs:\x20aspirin,\x20metoprolol,\x20and\x20atorvastatin.\x20He\x20comes\x20for\x20follow-up,\x20and\x20his\x20lipid\x20profile\x20is\x20as\x20follows:\x20cholesterol\x20is\x20raised,\x20LDL\x20is\x20raised,\x20triglycerides\x20are\x20raised,\x20HDL\x20is\x20normal.\x20Which\x20drugs\x20can\x20be\x20added\x20based\x20on\x20his\x20lipid\x20profile?<br>\x0d\x0a1.\x20Ezetemibe,\x202.\x20Evolocumab,\x203.\x20Gemfibrozil,\x204.\x20Bempedoic\x20acid\x0d\x0a</span></p>','cwWkJ','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>','userHistory','gmNpT','bind','DT1317852','fwSVb','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','15VZnaad','hDYUR','tfFJE','DT1317860','CUHAg','dYfaP','Uwxzy','DocTutorial','remove','nWSKU','true','ArrowLeft','QcGhE','nnrqX','<p><strong><u>General\x20Functions\x20of\x20the\x20Autonomic\x20Nervous\x20System</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li>The\x20autonomic\x20nervous\x20system\x20is\x20the\x20primary\x20regulator\x20of\x20the\x20constancy\x20of\x20the\x20internal\x20environment\x20of\x20the\x20organism,\x20or\x20the\x20maintenance\x20of\x20homeostasis.</li>\x0d\x0a<li>The\x20sympathetic\x20system\x20and\x20its\x20associated\x20adrenal\x20medulla\x20are\x20not\x20essential\x20to\x20life\x20in\x20a\x20controlled\x20environment,\x20but\x20the\x20lack\x20of\x20sympathoadrenal\x20functions\x20becomes\x20evident\x20under\x20circumstances\x20of\x20stress.</li>\x0d\x0a<li>For\x20example,\x20in\x20the\x20<strong>absence\x20of\x20the\x20sympathetic\x20system,\x20body\x20temperature\x20cannot\x20be\x20regulated\x20when\x20environmental\x20temperature\x20varies;\x20the\x20concentration\x20of\x20glucose\x20in\x20blood\x20does\x20not\x20rise\x20in\x20response\x20to\x20urgent\x20need;\x20compensatory\x20vascular\x20responses\x20to\x20hemorrhage,\x20oxygen\x20deprivation,\x20excitement,\x20and\x20exercise\x20are\x20lacking;\x20and\x20resistance\x20to\x20fatigue\x20is\x20lessened.</strong></li>\x0d\x0a<li>The\x20sympathoadrenal\x20system\x20can\x20discharge\x20as\x20a\x20unit.</li>\x0d\x0a<li><strong>Heart\x20rate\x20is\x20accelerated;\x20blood\x20pressure\x20rises;\x20blood\x20flow\x20is\x20shifted\x20from\x20the\x20skin\x20and\x20splanchnic\x20region\x20to\x20the\x20skeletal\x20and\x20cardiac\x20muscles;\x20blood\x20glucose\x20rises;\x20the\x20bronchioles\x20and\x20pupils\x20dilate;\x20and\x20the\x20organism\x20is\x20better\x20prepared\x20for\x20\x22fight\x20or\x20flight.\x22\x20</strong></li>\x0d\x0a<li>The\x20upright\x20posture\x20imposes\x20a\x20unique\x20physiologic\x20stress\x20upon\x20humans;\x20most,\x20although\x20not\x20all,\x20syncopal\x20episodes\x20occur\x20from\x20a\x20standing\x20position.</li>\x0d\x0a<li>Standing\x20results\x20in\x20pooling\x20of\x20500-1000\x20mL\x20of\x20blood\x20in\x20the\x20lower\x20extremities,\x20buttocks,\x20and\x20splanchnic\x20circulation.</li>\x0d\x0a<li>The\x20<strong>dependent\x20pooling\x20leads\x20to\x20a\x20decrease\x20in\x20venous\x20return\x20to\x20the\x20heart\x20and\x20reduced\x20ventricular\x20filling\x20that\x20result\x20in\x20diminished\x20cardiac\x20output\x20and\x20blood\x20pressure</strong>.</li>\x0d\x0a<li>These\x20hemodynamic\x20changes\x20provoke\x20a\x20compensatory\x20reflex\x20response,\x20initiated\x20by\x20the\x20baroreceptors\x20in\x20the\x20carotid\x20sinus\x20and\x20aortic\x20arch,\x20resulting\x20in\x20increased\x20sympathetic\x20outflow\x20and\x20decreased\x20vagal\x20nerve\x20activity.</li>\x0d\x0a<li>The\x20reflex\x20increases\x20peripheral\x20resistance,\x20venous\x20return\x20to\x20the\x20heart,\x20and\x20cardiac\x20output\x20and\x20thus\x20limits\x20the\x20fall\x20in\x20blood\x20pressure.</li>\x0d\x0a<li>Syncope\x20is\x20a\x20consequence\x20of\x20global\x20cerebral\x20hypoperfusion\x20and\x20thus\x20represents\x20a\x20failure\x20of\x20cerebral\x20blood\x20flow\x20autoregulatory\x20mechanisms.</li>\x0d\x0a</ul>\x0d\x0a<p><strong>Incorrect\x20Choices\x20Explanation:</strong></p>\x0d\x0a<p><strong>(Choice\x20A)\x20Systemic\x20infusion\x20of\x20alpha\x20blocker\x20&rarr;\x20Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Alpha-blockers\x20(e.g.,\x20prazosin,\x20phentolamine)\x20inhibit\x20&alpha;1-adrenergic\x20receptors</strong>,\x20which\x20normally\x20mediate\x20<strong>vasoconstriction</strong>.</li>\x0d\x0a<li><strong>Blocking\x20alpha\x20receptors\x20causes\x20vasodilation,\x20leading\x20to\x20a\x20fall\x20in\x20both\x20systolic\x20and\x20diastolic\x20blood\x20pressure.</strong></li>\x0d\x0a<li>However,\x20<strong>the\x20drop\x20in\x20diastolic\x20BP\x20is\x20usually\x20accompanied\x20by\x20a\x20compensatory\x20increase\x20in\x20heart\x20rate\x20(reflex\x20tachycardia),\x20which\x20limits\x20the\x20decrease\x20in\x20BP</strong>.</li>\x0d\x0a</ul>\x0d\x0a<p><strong>(Choice\x20B)\x20Systemic\x20infusion\x20of\x20smooth\x20muscle\x20relaxant\x20&rarr;\x20Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Smooth\x20muscle\x20relaxants\x20(e.g.,\x20nitrates,\x20hydralazine)\x20primarily\x20act\x20on\x20arterioles</strong>\x20and\x20reduce\x20<strong>systemic\x20vascular\x20resistance</strong>,\x20leading\x20to\x20a\x20decrease\x20in\x20<strong>systolic\x20blood\x20pressure\x20more\x20than\x20diastolic\x20blood\x20pressure</strong>.</li>\x0d\x0a<li><strong>Diastolic\x20BP\x20does\x20decrease</strong>,\x20but\x20<strong>not\x20as\x20much\x20as\x20in\x20the\x20case\x20of\x20complete\x20loss\x20of\x20sympathetic\x20outflow</strong>.</li>\x0d\x0a<li>These\x20drugs\x20also\x20trigger\x20<strong>baroreceptor\x20reflex-mediated\x20tachycardia</strong>,\x20which\x20helps\x20<strong>maintain\x20perfusion\x20pressure</strong>.</li>\x0d\x0a</ul>\x0d\x0a<p><strong>(Choice\x20D)\x20Systemic\x20infusion\x20of\x20beta-1\x20adrenergic\x20agonist\x20&rarr;\x20Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Beta-1\x20adrenergic\x20agonists\x20(e.g.,\x20dobutamine,\x20isoproterenol)\x20increase\x20heart\x20rate\x20and\x20contractility,\x20leading\x20to\x20increased\x20cardiac\x20output.</strong></li>\x0d\x0a<li><strong>This\x20increases\x20systolic\x20blood\x20pressure\x20but\x20does\x20not\x20significantly\x20decrease\x20diastolic\x20blood\x20pressure.</strong></li>\x0d\x0a<li>In\x20some\x20cases,\x20beta-agonists\x20<strong>reduce\x20diastolic\x20BP\x20slightly\x20due\x20to\x20reduced\x20systemic\x20vascular\x20resistance</strong>,\x20but\x20the\x20net\x20effect\x20is\x20usually\x20an\x20<strong>increase\x20in\x20mean\x20arterial\x20pressure\x20(MAP)</strong>.</li>\x0d\x0a</ul>\x0d\x0a<p><strong>Key\x20Takeaway:</strong></p>\x0d\x0a<ul>\x0d\x0a<li>Loss\x20of\x20lumbar\x20sympathetic\x20outflow\x20leads\x20to\x20the\x20most\x20significant\x20drop\x20in\x20diastolic\x20blood\x20pressure\x20due\x20to\x20unopposed\x20vasodilation\x20and\x20loss\x20of\x20sympathetic\x20vascular\x20tone.</li>\x0d\x0a<li>Alpha-blockers\x20and\x20smooth\x20muscle\x20relaxants\x20can\x20lower\x20diastolic\x20BP\x20but\x20usually\x20with\x20compensatory\x20mechanisms\x20limiting\x20the\x20drop.</li>\x0d\x0a<li>Beta-1\x20agonists\x20do\x20not\x20significantly\x20decrease\x20diastolic\x20BP,\x20as\x20they\x20primarily\x20increase\x20cardiac\x20output.</li>\x0d\x0a</ul>','tMOhK','status','exception','currentQuestionIndex','<p><span\x20style=\x22font-size:12.0pt;\x22>Contraindicated\x20in\x20patients\x20taking\x20drugs\x20inducing\x20CYP\x202C19\x20enzymes\x20</span></p>','rDQZs','uxxcS','HxFKQ','Clsck','nPVOv','WvtQH','<p><span\x20style=\x22font-size:12.0pt;\x22>Drug\x20of\x20choice\x20for\x20fasciola\x20hepatica:\x20</span></p>','pmwps','etgfV','XVodp','doVkT','LRXNg','dataset','div','CawJi','RwsjP','className','NnPzy','AKMJQ','<p><span\x20style=\x22font-size:12.0pt;\x22>Drug\x20acting\x20on\x20sodium\x20channels\x20and\x20potentiating\x20slow\x20sodium\x20inactivation:\x20</span></p>','innerHTML','add','RDUVO','NILbS','aBWSo','sdFAY','<p><span\x20style=\x22font-size:12.0pt;\x22>Lamotrigine</span></p>','rGeQp','review-question\x20','NlnKM','prjAM','cbHEd','optionsContainer','DT1317849','No\x20questions\x20available\x20for\x20this\x20quiz.','wzPHB','NCrZG','ArrowRight','DFbef','<ul>\x0d\x0a<li><strong>Tiagabine\x20</strong>is\x20indicated\x20for\x20adjunctive\x20treatment\x20of\x20partial\x20seizures.</li>\x0d\x0a<li>It\x20is\x20a\x20<strong>rationally\x20designed\x20</strong>drug\x20as\x20an\x20inhibitor\x20of\x20GABA\x20uptake\x20(by\x20inhibiting\x20GAT-1).</li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Tiagabine\x20</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li>This\x20<strong>newer\x20anticonvulsant\x20potentiates\x20GABA\x20mediated\x20neuronal\x20inhibition\x20by\x20blocking\x20GABA\x20transporter</strong></li>\x0d\x0a<li><strong>GAT-1\x20which\x20removes\x20synaptically\x20released\x20GABA\x20into\x20neurones\x20and\x20glial\x20cells.\x20</strong></li>\x0d\x0a<li>Kindled\x20seizures\x20are\x20suppressed\x20with\x20less\x20marked\x20effect\x20on\x20maximal\x20electroshock.</li>\x0d\x0a<li>Currently\x20<u>it\x20is\x20approved\x20only\x20for\x20add-on\x20therapy\x20of\x20partial\x20seizures\x20with\x20or\x20without\x20secondary\x20generalization,\x20when\x20not\x20adequately\x20controlled\x20by\x20standard\x20antiepileptic\x20drugs\x20alone.</u></li>\x0d\x0a<li>Side\x20effects\x20are\x20<u>mild\x20sedation,\x20nervousness,\x20asthenia,\x20amnesia,\x20dermatitis\x20and\x20abdominal\x20pain.</u></li>\x0d\x0a</ul>\x0d\x0a<img\x20class=\x22w-100\x22\x20style=\x22height:auto;\x20display:block;\x20vertical-align:middle;\x20border:0;\x20\x22src=\x22https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/20250208a88c3841-1ed1-4da7-bae9-091224bb971e.jpg\x22>\x0d\x0a<p><strong>Incorrect\x20Choices\x20Explanation:</strong></p>\x0d\x0a<p><strong>(Choice\x20A)\x20Ganaxolone\x20&rarr;\x20Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Ganaxolone\x20is\x20a\x20neurosteroid\x20that\x20acts\x20as\x20a\x20positive\x20allosteric\x20modulator\x20of\x20GABA-A\x20receptors.</strong></li>\x0d\x0a<li>Unlike\x20Tiagabine,\x20<strong>it\x20does\x20not\x20inhibit\x20GABA\x20reuptake\x20(GAT-1),\x20but\x20rather\x20enhances\x20GABAergic\x20transmission\x20directly.</strong></li>\x0d\x0a<li><strong>Indications:</strong>\x0d\x0a<ul>\x0d\x0a<li>Used\x20in\x20<strong>epilepsy\x20syndromes</strong>\x20such\x20as\x20<strong>CDKL5\x20deficiency\x20disorder</strong>.</li>\x0d\x0a</ul>\x0d\x0a</li>\x0d\x0a</ul>\x0d\x0a<p><strong>(Choice\x20C)\x20Felbamate\x20&rarr;\x20Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Felbamate\x20is\x20an\x20antiepileptic\x20drug\x20that\x20primarily\x20acts\x20by\x20blocking\x20NMDA\x20(N-methyl-D-aspartate)\x20receptors.</strong></li>\x0d\x0a<li>It\x20also\x20<strong>modulates\x20GABA-A\x20receptors\x20but\x20does\x20not\x20inhibit\x20GABA\x20reuptake\x20via\x20GAT-1.</strong></li>\x0d\x0a<li><strong>Indications:</strong>\x0d\x0a<ul>\x0d\x0a<li>Reserved\x20for\x20<strong>severe,\x20refractory\x20epilepsy</strong>\x20due\x20to\x20its\x20risk\x20of\x20<strong>aplastic\x20anemia\x20and\x20liver\x20failure</strong>.</li>\x0d\x0a</ul>\x0d\x0a</li>\x0d\x0a</ul>\x0d\x0a<p><strong>(Choice\x20D)\x20Stiripentol\x20&rarr;\x20Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Stiripentol\x20enhances\x20GABAergic\x20neurotransmission\x20by\x20increasing\x20GABA-A\x20receptor\x20activity.</strong></li>\x0d\x0a<li>It\x20also\x20<strong>inhibits\x20the\x20metabolism\x20of\x20clobazam\x20and\x20other\x20anticonvulsants</strong>,\x20increasing\x20their\x20effectiveness.</li>\x0d\x0a<li><strong>Indications:</strong>\x0d\x0a<ul>\x0d\x0a<li>Used\x20in\x20<strong>Dravet\x20syndrome</strong>,\x20a\x20severe\x20form\x20of\x20epilepsy.</li>\x0d\x0a</ul>\x0d\x0a</li>\x0d\x0a</ul>\x0d\x0a<p><strong><em><u>Key\x20takeaway</u></em></strong></p>\x0d\x0a<p><strong><em>Tiagabine\x20is\x20indicated\x20for\x20adjunctive\x20treatment\x20of\x20partial\x20seizures.\x20It\x20is\x20a\x20rationally\x20designed\x20drug\x20as\x20an\x20inhibitor\x20of\x20GABA\x20uptake\x20(by\x20inhibiting\x20GAT-1)</em></strong></p>','HKoFH','\x20>\x20','ZmeYF','248844sAyDYq','intermediate','xvNzw','querySelectorAll','ElQOa','UpPyp','KYEaQ','cFbxx','loadSource','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','Ktdkc','NFJIh','performanceModal','<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-','DT1317841','not-attempted','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','nTTBL','</span></div>','dzuNC','timerContainer','No\x20question\x20text\x20available','custom_quiz.html','gdQMf','index.html','pbZgt','<p><span\x20style=\x22font-size:12.0pt;\x22>Arsenic\x20-\x20Desferrioxamine</span></p>','No\x20solution\x20provided','Ini\x20Cet\x20Nov\x202024','QwlwK','xAWKS','qCbhf','nMtnT','<p><span\x20style=\x22font-size:12.0pt;\x22>Systemic\x20infusion\x20of\x20smooth\x20muscle\x20relaxant</span></p>','QHcWa','Factual','oSnzf','<p><span\x20style=\x22font-size:12.0pt;\x22>42\x20hours\x20</span></p>','tsLZz','attachMedia','selected','\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>','vMVyK','Bookmarked','red','ZJnUB','LKDFc','Option\x20','style','hmcWl','<p><span\x20style=\x22font-size:12.0pt;\x22>Drug\x20that\x20binds\x20to\x20CD4\x20and\x20has\x20action\x20on\x20both\x20CCR5\x20and\x20CXCR4\x20tropic\x20HIV\x20infection:\x20</span></p>','ynCjp','ojidr','OpCSS','apply','solutionImages','GNGZG','notAttempted','DtUDB','LqQJq','incorrectResult','xyceb','Gkrek','toggle','eBsZT','gray','pop','jJPfY','YRcAr','uCARE','3|0|2|5|1|4','<p><span\x20style=\x22font-size:12.0pt;\x22>Albendazole</span></p>','border-gray-600','xOHNC','appendChild','modeModal','pKwUC','igBuj','<p><span\x20style=\x22font-size:12.0pt;\x22>68\x20hours</span></p>','629390ewoFjm','eOTjo','gduAT','testModeLegend','miIVJ','WhAgl','quizFile','<p><span\x20style=\x22font-size:12.0pt;\x22>Chloroquine</span></p>','questionMedia','uTIVD','HpGrz','<p><span\x20style=\x22font-size:12.0pt;\x22>Maraviroc</span></p>','markReviewBtn','<p><span\x20style=\x22font-size:12.0pt;\x22>Inhibitors\x20of\x20PARP\x20(poly\x20ADP\x20ribose\x20polymerase)\x20are\x20approved\x20for\x20BRCA-positive\x20breast\x20cancer.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20used?\x20</span></p>','ZtlJI','LBLMA','jlFCR','progressBar','qXfXo','Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','nuTMR','<p><span\x20style=\x22font-size:12.0pt;\x22>Only\x201\x20and\x202</span></p>','ktVkp','YJMdK','<p><strong><em><u>Uncomplicated\x20falciparum\x20malaria\x20</u></em></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong><em>Oral\x20artemisinins\x20are\x20indicated\x20for\x20the\x20treatment\x20of\x20all\x20cases\x20of\x20uncomplicated\x20falciparum\x20malaria\x20(CQ-resistant\x20as\x20well\x20as\x20sensitive)\x20as\x20ACT.</em></strong></li>\x0d\x0a<li><em>Even\x20when\x20used\x20alone,\x20they\x20are\x20almost\x20100%\x20effective,\x20but\x20because\x20of\x20short\x20duration\x20of\x20action\x20recrudescence\x20rates\x20are\x20high.</em></li>\x0d\x0a<li><em>In\x20order\x20to\x20preserve\x20their\x20powerful\x20antimalarial\x20activity\x20and\x20to\x20reduce\x20recrudescence\x20rates,\x20they\x20must\x20be\x20used\x20in\x20combination\x20with\x20a\x20longacting\x20</em><em>schizontocide\x20which\x20acts\x20by\x20a\x20different\x20mechanism.</em></li>\x0d\x0a</ul>\x0d\x0a<img\x20class=\x22w-100\x22\x20style=\x22height:auto;\x20display:block;\x20vertical-align:middle;\x20border:0;\x20\x22src=\x22https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/202503082aa17308-aad2-44c2-9115-ca99cb29aeda.jpg\x22>\x0d\x0a<p><strong><u>Primaquine\x20in\x20Falciparum\x20malaria</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li>A\x20single\x2045\x20mg\x20dose\x20of\x20primaquine\x20is\x20given\x20with\x20the\x20curative\x20dose\x20of\x20ACT\x20or\x20CQ\x20to\x20kill\x20the\x20gametes\x20and\x20cut\x20down\x20transmission\x20to\x20mosquito.</li>\x0d\x0a<li>However,\x20the\x20<strong>recent\x20WHO\x20guideline\x20has\x20advised\x20a\x20lower\x2015\x20mg\x20(0.25\x20mg/kg)\x20single\x20dose\x20for\x20this\x20purpose.</strong></li>\x0d\x0a</ul>\x0d\x0a<p><strong>Incorrect\x20Choices\x20Explanation:</strong></p>\x0d\x0a<p><strong>(Choice\x20A)\x20Chloroquine</strong>\x20-\x20Chloroquine\x20is\x20the\x20first-line\x20drug\x20for\x20treating\x20uncomplicated\x20malaria\x20in\x20chloroquine-sensitive\x20cases,\x20particularly\x20Plasmodium\x20vivax\x20and\x20Plasmodium\x20ovale\x20infections.\x20However,\x20it\x20is\x20ineffective\x20in\x20chloroquine-resistantPlasmodium\x20falciparum\x20malaria.</p>\x0d\x0a<p><strong>(Choice\x20C)\x20Artemether</strong>\x20-\x20Artemether,\x20as\x20part\x20of\x20artemisinin-based\x20combination\x20therapy\x20(ACT),\x20is\x20a\x20key\x20treatment\x20for\x20uncomplicated\x20falciparum\x20malaria\x20in\x20both\x20chloroquine-sensitive\x20and\x20chloroquine-resistant\x20cases.</p>\x0d\x0a<p><strong>(Choice\x20D)\x20Sulfadoxine-pyrimethamine</strong>\x20-\x20This\x20combination\x20is\x20used\x20as\x20part\x20of\x20treatment\x20regimens\x20for\x20uncomplicated\x20falciparum\x20malaria,\x20particularly\x20in\x20combination\x20with\x20artemisinins\x20to\x20prevent\x20resistance\x20and\x20improve\x20cure\x20rates.</p>\x0d\x0a<p><strong><u>Key\x20takeaway</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Oral\x20artemisinins\x20are\x20indicated\x20for\x20the\x20treatment\x20of\x20all\x20cases\x20of\x20uncomplicated\x20falciparum\x20malaria\x20(CQ-resistant\x20as\x20well\x20as\x20sensitive)\x20as\x20ACT.</strong></li>\x0d\x0a<li><strong>Primaquine\x20is\x20given\x20with\x20the\x20curative\x20dose\x20of\x20ACT\x20or\x20CQ\x20to\x20kill\x20the\x20gametes\x20and\x20cut\x20down\x20transmission\x20to\x20mosquito.\x20</strong></li>\x0d\x0a</ul>','iTATi','qkTvG','<p><span\x20style=\x22font-size:12.0pt;\x22>Sulfadoxine-pyrimethamine</span></p>','<div\x20class=\x22mt-4\x22><img\x20src=\x22','prototype','VnfGj','<p><span\x20style=\x22font-size:12.0pt;\x22>A\x20known\x20case\x20of\x20ulcerative\x20colitis\x20is\x20not\x20responding\x20to\x20anti-TNF\x20alpha\x20agent.\x20Which\x20JAK\x20inhibitor\x20is\x20preferred\x20in\x20moderate\x20to\x20severe\x20ulcerative\x20colitis?</span></p>','LkULv','rnOTh','rjQZX','kqvLB','jpApz','YpYSL','name','incorrect','vrkNS','<p><span\x20style=\x22font-size:12.0pt;\x22>Felbamate</span></p>','fyDxs','hhReM','OBhCP','YDLcy','45878IyYTKX','timeSpent','incorrectAnswers','zaPtI','kSWLt','DNjbV','incorrectCount','5wRGMNO','QthEp','<p><strong><u>Flumazenil\x20</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li>It\x20is\x20a\x20<u>BZD\x20analogue\x20which\x20has\x20little\x20intrinsic\x20activity\x20(practically\x20no\x20effect\x20on\x20normal\x20subjects),\x20but\x20competes\x20with\x20BZD\x20agonists\x20as\x20well\x20as\x20inverse\x20agonists\x20for\x20the\x20BZD\x20receptor\x20and\x20reverses\x20their\x20depressant\x20or\x20stimulant\x20effects\x20respectively.</u></li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Uses</u></strong></p>\x0d\x0a<ol>\x0d\x0a<li><strong><u>\x20To\x20reverse\x20BZD\x20anaesthesia\x20</u></strong>\x0d\x0a<ul>\x0d\x0a<li>Patients\x20anaesthetized/sedated\x20with\x20a\x20BZD\x20wakeup,\x20get\x20oriented\x20and\x20regain\x20motor\x20control\x20within\x201\x20min\x20of\x20an\x20i.v.\x20injection\x20of\x200.3-1\x20mg\x20of\x20flumazenil.</li>\x0d\x0a</ul>\x0d\x0a</li>\x0d\x0a<li><strong><u>\x20BZD\x20overdose\x20</u></strong>\x0d\x0a<ul>\x0d\x0a<li>Majority\x20of\x20patients\x20of\x20BZD\x20overdose\x20require\x20only\x20supportive\x20measures\x20like\x20patent\x20airway,\x20maintenance\x20of\x20BP,\x20cardiac\x20and\x20renal\x20function\x20(by\x20fluid\x20transfusion,\x20etc.).</li>\x0d\x0a<li>Flumazenil\x20blocks\x20the\x20hypnotic\x20effect\x20of\x20zolpidem-like\x20non-BZDs\x20as\x20well.</li>\x0d\x0a</ul>\x0d\x0a</li>\x0d\x0a</ol>\x0d\x0a<p><strong><u>Adverse\x20effects\x20</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><u>Side\x20effects\x20noted\x20during\x20use\x20of\x20flumazenil\x20as\x20a\x20BZD-antagonist\x20are-agitation,\x20discomfort,\x20fearfulness,\x20anxiety,\x20coldness\x20and\x20withdrawal\x20seizures.</u></li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>TREATMENT\x20OF\x20POISONINGS</u></strong></p>\x0d\x0a<img\x20class=\x22w-100\x22\x20style=\x22height:auto;\x20display:block;\x20vertical-align:middle;\x20border:0;\x20\x22src=\x22https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/20250308d2455e1c-0692-461b-a649-ffbdfa80a0fe.jpg\x22>\x0d\x0a<p><strong>Incorrect\x20Choices\x20Explanation:</strong></p>\x0d\x0a<p><strong>(Choice\x20A)\x20Organophosphorus\x20-\x20Physostigmine</strong>\x20&rarr;\x20<strong>Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li>Organophosphorus\x20poisoning\x20causes\x20<strong>excess\x20cholinergic\x20activity</strong>\x20by\x20<strong>inhibiting\x20acetylcholinesterase</strong>.</li>\x0d\x0a<li>The\x20correct\x20antidote\x20is\x20<strong>atropine</strong>\x20(a\x20muscarinic\x20antagonist)\x20and\x20<strong>pralidoxime\x20(2-PAM)</strong>,\x20which\x20<strong>reactivates\x20acetylcholinesterase</strong>.</li>\x0d\x0a<li><strong>Physostigmine\x20is\x20a\x20cholinesterase\x20inhibitor</strong>,\x20which\x20would\x20worsen\x20the\x20poisoning\x20instead\x20of\x20treating\x20it.</li>\x0d\x0a</ul>\x0d\x0a<p><strong>(Choice\x20C)\x20Arsenic\x20-\x20Desferrioxamine</strong>\x20&rarr;\x20<strong>Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li>Arsenic\x20poisoning\x20is\x20treated\x20with\x20<strong>dimercaprol\x20(BAL)\x20or\x20succimer\x20(DMSA)</strong>,\x20which\x20are\x20<strong>chelating\x20agents\x20that\x20bind\x20arsenic</strong>\x20and\x20facilitate\x20excretion.</li>\x0d\x0a<li><strong>Desferrioxamine</strong>\x20is\x20used\x20for\x20<strong>iron\x20toxicity</strong>,\x20not\x20arsenic\x20poisoning.</li>\x0d\x0a</ul>\x0d\x0a<p><strong>(Choice\x20D)\x20Atropine\x20-\x20L-carnitine</strong>\x20&rarr;\x20<strong>Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Atropine\x20toxicity</strong>\x20is\x20characterized\x20by\x20<strong>anticholinergic\x20symptoms</strong>\x20(dry\x20mouth,\x20tachycardia,\x20mydriasis,\x20hallucinations,\x20etc.).</li>\x0d\x0a<li>The\x20correct\x20antidote\x20is\x20<strong>physostigmine</strong>,\x20a\x20<strong>cholinesterase\x20inhibitor\x20that\x20increases\x20acetylcholine\x20levels</strong>.</li>\x0d\x0a<li><strong>L-carnitine\x20is\x20not\x20used\x20in\x20atropine\x20toxicity</strong>;\x20it\x20is\x20primarily\x20used\x20for\x20<strong>carnitine\x20deficiency\x20disorders</strong>.</li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Key\x20takeaway</u></strong></p>\x0d\x0a<p><strong>Flumazenil\x20is\x20a\x20BZD\x20analogue\x20which\x20has\x20little\x20intrinsic\x20activity,\x20but\x20competes\x20with\x20BZD\x20agonists\x20as\x20well\x20as\x20inverse\x20agonists\x20for\x20the\x20BZD\x20receptor\x20and\x20reverses\x20their\x20depressant\x20or\x20stimulant\x20effects\x20respectively.\x20</strong></p>','ajjDa','WzBwo','CqppX','nav-btn-answered','YGlFn','NnisG','application/vnd.apple.mpegurl','replace','prevBtn','textContent','qxGLu','vOdHR','console','IufFI','NLbqD','AiUgV','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','qgOtn','padStart','resume','none','DCOTa','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','Mark\x20for\x20Review','KPWeO','OyHQI','lchXF','HIift','sseHu','eZCDc','qpnfP','GBffX','SyAes','DCwaQ','hidden','block','<p><span\x20style=\x22font-size:12.0pt;\x22>A\x20young\x20female\x20weighing\x2046\x20kg\x20is\x20on\x20digoxin\x20with\x20a\x20volume\x20of\x20distribution\x20of\x206\x20L/kg,\x20and\x20clearance\x20is\x204.6\x20L/hour.\x20Calculate\x20the\x20half-life\x20of\x20digoxin.\x20</span></p>','aqSqZ','<p><span\x20style=\x22font-size:12.0pt;\x22>Acute\x20oral\x20overdose\x20results\x20primarily\x20in\x20cerebellar\x20and\x20vestibular\x20symptoms,\x20and\x20high\x20doses\x20have\x20been\x20associated\x20with\x20marked\x20cerebellar\x20atrophy</span></p>','choices','accuracyScore','<p><span\x20style=\x22font-size:12.0pt;\x22>Topiramate</span></p>','<p><span\x20style=\x22font-size:12.0pt;\x22>Phenytoin\x20causes\x20cardiotoxicity\x20and\x20nephrotoxicity\x20in\x20old\x20and\x20young\x20patients</span></p>','GNAmU','BGjBZ','bCTKp','<p><strong><u>Bicyclic\x20Nitroimidazoles</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Delamanid\x20and\x20Pretomanid\x20</strong>are\x20bicyclic\x20nitroimidazopyrans\x20that\x20are\x20being\x20used\x20in\x20the\x20treatment\x20of\x20XDR-\x20and\x20MDR-TB.</li>\x0d\x0a<li><strong><u>Pretomanid\x20is\x20FDA-approved\x20for\x20the\x20treatment\x20of\x20XDR-TB\x20in\x20combination\x20with\x20bedaquiline\x20and\x20linezolid.\x20</u></strong></li>\x0d\x0a<li>Delamanid\x20is\x20licensed\x20by\x20the\x20European\x20Medicines\x20Agency\x20for\x20the\x20treatment\x20of\x20MDR-TB.</li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Mechanisms\x20of\x20Action</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><u>Pretomanid\x20has\x20two\x20mechanisms\x20of\x20action.\x20First,\x20under\x20aerobic\x20conditions,\x20it\x20inhibits\x20M.\x20tuberculosis\x20mycolic\x20acid\x20and\x20protein\x20synthesis\x20at\x20the\x20step\x20between\x20hydroxymycolate\x20and\x20ketomycolate\x20</u></li>\x0d\x0a<li>Systemic\x20exposures\x20of\x20pretomanid\x20and\x20delamanid\x20increase\x20when\x20taken\x20with\x20food.\x20Delamanid\x20metabolism\x20involves\x20albumin.</li>\x0d\x0a<li>Delamanid\x20is\x20not\x20metabolized\x20by\x20CYP4s.</li>\x0d\x0a<li><strong>Pretomanid\x20is\x20metabolized\x20approximately\x2020%\x20by\x20CYP3A;\x20coadministration\x20of\x20rifampin\x20reduces\x20pretomanid\x20exposures</strong></li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Untoward\x20Effects\x20</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li>Delamanid\x20can\x20cause\x20headaches\x20and\x20insomnia.\x20It\x20has\x20a\x20modest\x20effect\x20on\x20the\x20QT\x20interval\x20on\x20ECG.</li>\x0d\x0a<li>Pretomanid\x20has\x20been\x20associated\x20with\x20hepatotoxicity</li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Drug\x20interactions</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Pretomanid\x20is\x20metabolized\x20in\x20part\x20by\x20CYP3A,\x20so\x20coadministration\x20with\x20strong\x20or\x20moderate\x20CYP3A\x20inducers\x20should\x20be\x20avoided.\x20</strong></li>\x0d\x0a<li>Delamanid\x20displays\x20low\x20bioavailability,\x20so\x20to\x20maximize\x20absorption,\x20it\x20should\x20be\x20taken\x20with\x20food\x20and\x20separated\x20from\x20dosing\x20of\x20other\x20medications,\x20if\x20possible.</li>\x0d\x0a</ul>\x0d\x0a<p><strong>Incorrect\x20Choices\x20Explanation:</strong></p>\x0d\x0a<p><strong>(Choice\x20B)\x20Contraindicated\x20in\x20patients\x20taking\x20drugs\x20inducing\x20CYP2C19\x20enzymes\x20&rarr;\x20Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Pretomanid\x20is\x20primarily\x20metabolized\x20by\x20CYP3A,\x20not\x20CYP2C19.</strong></li>\x0d\x0a<li><strong>Drugs\x20that\x20induce\x20CYP3A\x20(e.g.,\x20rifampin)\x20reduce\x20pretomanid\x20levels</strong>,\x20leading\x20to\x20decreased\x20efficacy.</li>\x0d\x0a<li>There\x20is\x20<strong>no\x20major\x20contraindication\x20specifically\x20related\x20to\x20CYP2C19\x20enzyme\x20induction.</strong></li>\x0d\x0a</ul>\x0d\x0a<p><strong>(Choice\x20C)\x20Acts\x20by\x20reactive\x20oxygen\x20species\x20&rarr;\x20Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Pretomanid\x20has\x20two\x20mechanisms\x20of\x20action:</strong>\x0d\x0a<ol>\x0d\x0a<li><strong>Aerobic\x20conditions:</strong>\x20Inhibits\x20mycolic\x20acid\x20and\x20protein\x20synthesis,\x20disrupting\x20<strong>cell\x20wall\x20formation</strong>\x20of\x20Mycobacterium\x20tuberculosis.</li>\x0d\x0a<li><strong>Anaerobic\x20conditions:</strong>\x20Leads\x20to\x20<strong>formation\x20of\x20nitric\x20oxide</strong>,\x20which\x20is\x20toxic\x20to\x20the\x20bacteria.</li>\x0d\x0a</ol>\x0d\x0a</li>\x0d\x0a<li>While\x20nitric\x20oxide\x20plays\x20a\x20role\x20in\x20its\x20action,\x20<strong>it\x20does\x20not\x20directly\x20act\x20through\x20reactive\x20oxygen\x20species\x20(ROS).</strong></li>\x0d\x0a</ul>\x0d\x0a<p><strong>(Choice\x20D)\x20For\x20resistant\x20malaria\x20&rarr;\x20Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Pretomanid\x20is\x20not\x20used\x20for\x20malaria-</strong>it\x20is\x20exclusively\x20indicated\x20for\x20<strong>drug-resistant\x20tuberculosis.</strong></li>\x0d\x0a<li><strong>Antimalarial\x20drugs\x20(e.g.,\x20artemisinin-based\x20combination\x20therapies,\x20quinine,\x20mefloquine)</strong>\x20are\x20the\x20standard\x20treatments\x20for\x20resistant\x20malaria,\x20not\x20pretomanid.</li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Key\x20takeaway</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Pretomanid\x20is\x20FDA-approved\x20for\x20the\x20treatment\x20of\x20XDR-TB\x20in\x20combination\x20with\x20bedaquiline\x20and\x20linezolid.\x20</strong></li>\x0d\x0a<li><strong>Pretomanid\x20is\x20metabolized\x20in\x20part\x20by\x20CYP3A,\x20so\x20co-administration\x20with\x20strong\x20or\x20moderate\x20CYP3A\x20inducers\x20should\x20be\x20avoided.\x20</strong></li>\x0d\x0a</ul>','<p><span\x20style=\x22font-size:12.0pt;\x22>True\x20statement\x20for\x20pretomanid:</span></p>','currentQuestion','GUvOb','quizHierarchy','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','toLowerCase','GJAZk','floor','fSCWG','<p><span\x20style=\x22font-size:12.0pt;\x22>Mebendazole</span></p>','YtRjo','dWbyP','jCnDp','error','FXlpe','AHBFn','answered','CvjQe','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22','questionStates','trace','explanation_video','BOKNI','nav-btn-current','DmQwD','ZJbZr','snocN','constructor','sZbeI','IQXzq','YYGZe','eYPrM','split','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','<p><strong><u>ENTRY\x20inhibitors</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Gp41\x20present\x20on\x20envelope\x20of\x20HIV\x20binds\x20to\x20CD4\x20receptors\x20on\x20the\x20surface\x20of\x20CD4\x20cells.\x20The\x20entry\x20of\x20the\x20virus\x20inside\x20the\x20cell\x20is\x20facilitated\x20by\x20co-receptors\x20(CCR5\x20or\x20CXCR-4)\x20present\x20on\x20CD4\x20cells.</strong></li>\x0d\x0a<li><strong>Ibalizumab\x20is\x20a\x20monoclonal\x20antibody\x20against\x20CD4\x20receptors.\x20When\x20given\x20</strong><strong>intravenously,\x20it\x20can\x20inhibit\x20the\x20fusion\x20of\x20HIV\x20with\x20CD4\x20cells.</strong></li>\x0d\x0a<li><strong>Enfuvirtide\x20</strong>is\x20a\x20drug\x20that\x20<strong>binds\x20to\x20Gp\x2041\x20subunit\x20of\x20HIV\x20</strong>envelope\x20protein\x20and\x20inhibits\x20the\x20fusion\x20of\x20viral\x20and\x20host\x20cell\x20membranes.\x20It\x20is\x20not\x20effective\x20against\x20HIV-2</li>\x0d\x0a<li><strong>Maraviroc\x20</strong>is\x20the\x20first\x20CCR5\x20co-receptor\x20antagonist\x20to\x20be\x20approved\x20for\x20use.</li>\x0d\x0a<li>It\x20is\x20only\x20active\x20against\x20\x22CCR-5-tropic\x20virus\x22\x20and\x20thus,\x20a\x20co-receptor\x20tropism\x20assay\x20should\x20be\x20performed\x20before\x20starting\x20maraviroc.</li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Ibalizumab\x20</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Ibalizumab\x20is\x20a\x20humanized\x20monoclonal\x20antibody\x20that\x20binds\x20to\x20the\x20CD4\x20extracellular\x20domain\x202,\x20causing\x20steric\x20hindrance\x20of\x20a\x20conformational\x20change\x20in\x20the\x20gp120-CD4\x20complex\x20necessary\x20for\x20HIV\x20fusion\x20and\x20entry</strong></li>\x0d\x0a<li><u>Ibalizumab\x20is\x20approved\x20for\x20use\x20in\x20heavily\x20treatment-experienced\x20adults\x20with\x20multidrug-resistant\x20HIV-1\x20infection\x20who\x20are\x20failing\x20their\x20current\x20antiretroviral\x20regimen.</u></li>\x0d\x0a<li>Ibalizumab\x20retains\x20activity\x20against\x20viruses\x20that\x20have\x20become\x20resistant\x20to\x20antiretroviral\x20agents\x20of\x20other\x20classes\x20because\x20of\x20its\x20unique\x20mechanism\x20of\x20action.</li>\x0d\x0a</ul>\x0d\x0a<p><strong>Incorrect\x20Choices\x20Explanation:</strong></p>\x0d\x0a<p><strong>(Choice\x20B)\x20Maraviroc</strong>\x20-\x20Maraviroc\x20is\x20a\x20<strong>CCR5\x20co-receptor\x20antagonist</strong>\x20that\x20blocks\x20the\x20interaction\x20between\x20HIV\x20gp120\x20and\x20<strong>CCR5</strong>.\x20However,\x20it\x20is\x20<strong>not\x20active\x20against\x20CXCR4-tropic\x20HIV</strong>,\x20so\x20a\x20<strong>co-receptor\x20tropism\x20assay</strong>\x20is\x20required\x20before\x20use.</p>\x0d\x0a<p><strong>(Choice\x20C)\x20Elvitegravir</strong>\x20-\x20Elvitegravir\x20is\x20an\x20<strong>integrase\x20inhibitor</strong>,\x20meaning\x20it\x20blocks\x20the\x20integration\x20of\x20viral\x20DNA\x20into\x20the\x20host\x20genome.\x20It\x20does\x20not\x20function\x20at\x20the\x20entry\x20stage\x20and\x20has\x20no\x20effect\x20on\x20<strong>CCR5\x20or\x20CXCR4\x20tropic\x20HIV</strong>.</p>\x0d\x0a<p><strong>(Choice\x20D)\x20Fosamprenavir</strong>\x20-\x20Fosamprenavir\x20is\x20a\x20<strong>protease\x20inhibitor</strong>\x20that\x20prevents\x20the\x20cleavage\x20of\x20viral\x20polyproteins\x20needed\x20for\x20the\x20maturation\x20of\x20new\x20viral\x20particles.\x20It\x20does\x20not\x20target\x20HIV\x20entry\x20mechanisms.</p>\x0d\x0a<p><strong><u>Key\x20takeaway</u></strong></p>\x0d\x0a<p><strong>Ibalizumab\x20is\x20a\x20monoclonal\x20antibody\x20against\x20CD4\x20receptors.\x20When\x20given\x20</strong><strong>intravenously,\x20it\x20can\x20inhibit\x20the\x20fusion\x20of\x20HIV\x20with\x20CD4\x20cells.</strong></p>','OQhgQ','bDsEo','MzSFq','testModeReviewLegend','sJNTj','eeWXP','<p><span\x20style=\x22font-size:12.0pt;\x22>4\x20hours\x20</span></p>','createElement','uJSLx','solution','zkaHJ','lhfkY','CUNbw','wRznR','NYcon','reevI','iYOhI','FaLlt','UxRwj','GLfND','ZoZFr','log','<p><span\x20style=\x22font-size:12.0pt;\x22>Choose\x20the\x20correct\x20option\x20regarding\x20phenytoin:\x20</span></p>','totalQuestions','riGij','<p><span\x20style=\x22font-size:12.0pt;\x22>The\x20complications\x20can\x20be\x20minimized\x20by\x20administering\x20fosphenytoin\x20at\x20a\x20rate\x20of\x20less\x20than\x20250\x20mg\x20of\x20phenytoin\x20sodium\x20equivalent\x20per\x20minute\x20</span></p>','TbKdC','isArray','src','JvDek','HcJic','avgTimeResult','text','oTwcD','questionReviewSection','<p><span\x20style=\x22font-size:12.0pt;\x22>Which\x20drug\x20acts\x20on\x20the\x20marked\x20receptor\x20(image:\x20showed\x20GAT\x20inhibition)?\x20<br><img\x20class=\x22w-100\x22\x20style=\x22height:auto;\x20display:block;\x20vertical-align:middle;\x20border:0;\x20\x22src=\x22https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/2025020809c51056-581f-4f0f-9fe4-22e9a6c5b4be.jpg\x22></span></p>','<p><span\x20style=\x22font-size:12.0pt;\x22>Loss\x20of\x20lumbar\x20sympathetic\x20outflow</span></p>','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','dommj','<p><span\x20style=\x22font-size:12.0pt;\x22>Filgotinib</span></p>','addEventListener','<p><span\x20style=\x22font-size:12.0pt;\x22>Given\x20for\x20XDR-TB\x20with\x20bedaquiline\x20and\x20linezolid</span></p>','RkGYu','IHMPe','GLRBc','selectedAnswer','nkMjL','<p><span\x20style=\x22font-size:12.0pt;\x22>Acts\x20by\x20reactive\x20oxygen\x20species\x20</span></p>','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','<p><span\x20style=\x22font-size:12.0pt;\x22>Rucaparib</span></p>','questionIndex','fDjup','Trnpt','correct','PrvKc','vwLCS','AYYOD','387385LcmcVt','MCLzl','get','27GleQcF','duhfl','explanation_audio_eng','iCuLN','GAOZp','\x22><span\x20class=\x22font-bold\x20mr-3\x22>','totalTime','nJgKX','markReviewText','MymAo','oqPpS','YNaPi','reviewQuestionsContainer','<p><span\x20style=\x22font-size:12.0pt;\x22>Tofacitinib</span></p>','location','HLERi','szJRQ','<p><span\x20style=\x22font-size:12.0pt;\x22>Tiagabine</span></p>','tLyor','closest','MNJNx','wqtDw','AqJNH','bookmarked','jvstj','NYgoe','<p><span\x20style=\x22font-size:12.0pt;\x22>Triclabendazole</span></p>','RwnTj','kgAMY','WHhCL','qclLy','return\x20(function()\x20','rGxQj','giCui','CULzK','getElementById','<p><span\x20style=\x22font-size:12.0pt;\x22>Phenytoin</span></p>','YNsBz','gzKgV','GVNpz','<p><span\x20style=\x22font-size:12.0pt;\x22>1,\x202,\x20and\x204\x20</span></p>','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','info','(((.+)+)+)+$','isHFN','iSfjv','Cshnk','tlQIV','<p><span\x20style=\x22font-size:12.0pt;\x22>Praziquantel</span></p>','<p><span\x20style=\x22font-size:12.0pt;\x22>Artemether</span></p>','<p><span\x20style=\x22font-size:12.0pt;\x22>Infliximab</span></p>','AgGZA','mlLPL','wqdRh','XdGGj','completed','YiJAR','geNqY','study','Mykih','hierarchy','xIdjT','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','yRjpK','.m3u8','No\x20solution\x20available.','bHgfx','canPlayType','test','WFsvf','vCbTh','DDRyy','LlTxr','EQGbI','explanation_images','data-option-index','forEach','mMDZc','lvsiE','Progress\x20loaded.','xcuit','getAttribute','srvFq','ztUZt','uToij','DT1317862','baAqm','iKClA','currentMode','BCLxQ','navBtn_','round','hHRxb','strokeDashoffset','EkUGp','nmnQW','wMfcJ','Incorrect','wYSyu','\x22\x20data-option-index=\x22','qKpdH','\x20-\x20Brain\x20And\x20Scalpel','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','ZjegQ','DezFc','pExTt','yTroB','bottom','table','<p><span\x20style=\x22font-size:12.0pt;\x22>Correctly\x20match\x20antidote\x20with\x20toxicity:\x20</span></p>','pFdbR','WggsA','getItem','fill','JCjKo','studyModeLegend','length','nav-btn-bookmarked','<p><span\x20style=\x22font-size:12.0pt;\x22>Which\x20of\x20the\x20following\x20drugs\x20is\x20not\x20given\x20in\x20uncomplicated\x20malaria?</span></p>','title','mujRl','SftsG','irKKm','112752VBufCS','TxgNe','DT1317854','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','keydown','XaApy','UmqJQ','DT1317857','AvvAe','yXeRQ','classList','not_attempted','Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','OIelu','jCWbJ','wBOdi','solutionVideo','includes','PcFGX','isSupported','suOqD','ncFPt','kWOTC','<p><span\x20style=\x22font-size:12.0pt;\x22>Regorafenib</span></p>','OpNSu','jupZs','solutionText','timed_exam','</span><span>','124172dFrdVU','onclick','PntEd','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','stats','4|0|5|2|3|1','yBWdz','VhLVa','xzppC','questionNav','bRiRe','push','nav-btn-correct','TUOfk','hVHka','<p><span\x20style=\x22font-size:12.0pt;\x22>Palbociclib</span></p>','wezNA','IwRyX','FizNU','yDqKE','fcbTV','630128FjxJsv','nav-btn-incorrect','<p><strong><u>Lacosamide\x20</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li>This\x20recently\x20introduced\x20<strong>antiseizure\x20drug\x20is\x20indicated\x20in\x20adults\x20only\x20for\x20add-on\x20therapy\x20of\x20partial\x20seizures\x20with\x20or\x20without\x20generalization.</strong></li>\x0d\x0a<li>It\x20<strong>acts\x20by\x20enhancing\x20Na+\x20channel\x20inactivation\x20and\x20suppressing\x20repetitive\x20firing\x20of\x20neurones.</strong></li>\x0d\x0a<li>Lacosamide\x20is\x20metabolized\x20by\x20CYP2C19\x20and\x20excreted\x20in\x20urine\x20with\x20t&frac12;\x20~\x2012\x20hours.</li>\x0d\x0a<li>No\x20alteration\x20in\x20dose\x20of\x20companion\x20antiepileptic\x20drug\x20is\x20needed,\x20because\x20it\x20neither\x20induces\x20nor\x20inhibits\x20drug\x20metabolizing\x20enzymes.</li>\x0d\x0a<li>Adverse\x20effects\x20are\x20<u>ataxia,\x20vertigo,\x20diplopia,\x20tremor,\x20depression\x20and\x20cardiac\x20arrhythmia.</u></li>\x0d\x0a</ul>\x0d\x0a<p><strong>Incorrect\x20Choices\x20Explanation:</strong></p>\x0d\x0a<p><strong>(Choice\x20B)\x20Lamotrigine</strong>\x20-\x20Lamotrigine\x20also\x20acts\x20on\x20<strong>sodium\x20channels</strong>,\x20but\x20it\x20primarily\x20inhibits\x20<strong>fast\x20inactivation</strong>\x20rather\x20than\x20potentiating\x20<strong>slow\x20sodium\x20inactivation</strong>.\x20Additionally,\x20it\x20inhibits\x20<strong>glutamate\x20release</strong>,\x20contributing\x20to\x20its\x20broad-spectrum\x20antiepileptic\x20effect.</p>\x0d\x0a<p><strong>(Choice\x20C)\x20Topiramate</strong>\x20-\x20Topiramate\x20has\x20multiple\x20mechanisms\x20of\x20action,\x20including\x20<strong>blocking\x20sodium\x20channels</strong>,\x20<strong>enhancing\x20GABA\x20activity</strong>,\x20and\x20<strong>inhibiting\x20AMPA/kainate\x20glutamate\x20receptors</strong>.\x20However,\x20it\x20does\x20not\x20specifically\x20<strong>potentiate\x20slow\x20sodium\x20inactivation</strong>\x20like\x20lacosamide.</p>\x0d\x0a<p><strong>(Choice\x20D)\x20Phenytoin</strong>\x20-\x20Phenytoin\x20is\x20a\x20<strong>classic\x20sodium\x20channel\x20blocker</strong>\x20that\x20primarily\x20works\x20by\x20<strong>stabilizing\x20fast\x20inactivation</strong>\x20of\x20Na+\x20channels,\x20reducing\x20neuronal\x20excitability.\x20It\x20does\x20not\x20<strong>enhance\x20slow\x20sodium\x20inactivation</strong>\x20like\x20lacosamide.</p>\x0d\x0a<p><strong><u>Key\x20takeaway</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Lacosamide\x20is\x20an\x20antiseizure\x20drug\x20is\x20indicated\x20in\x20adults\x20only\x20for\x20add-on\x20therapy\x20of\x20partial\x20seizures\x20with\x20or\x20without\x20generalization.\x20</strong></li>\x0d\x0a<li><strong>It\x20acts\x20by\x20enhancing\x20Na+\x20channel\x20inactivation\x20and\x20suppressing\x20repetitive\x20firing\x20of\x20neurones.\x20</strong></li>\x0d\x0a</ul>','yUiZu','yvHjv','aQsch','nav-btn-marked-review','<p><span\x20style=\x22font-size:12.0pt;\x22>Fosamprenavir</span></p>','timed_study','submitSection','correctAnswers','wxQsF','NKPcM','<p><strong><u>Over\x20dose\x20toxicity\x20due\x20to\x20higher\x20plasma\x20concentration\x20of\x20phenytoin\x20produces</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Cerebellar\x20and\x20vestibular\x20manifestations:\x20ataxia,\x20vertigo,\x20diplopia,\x20nystagmus.</strong></li>\x0d\x0a<li><strong>Drowsiness,\x20behavioural\x20alterations,\x20mental\x20confusion,\x20hallucinations,\x20disorientation\x20and\x20rigidity</strong></li>\x0d\x0a<li>Epigastric\x20pain,\x20nausea\x20and\x20vomiting</li>\x0d\x0a<li>Intravenous\x20injection\x20of\x20phenytoin\x20sodium\x20can\x20cause\x20local\x20<strong>vascular\x20injury\x20&rarr;\x20intimal\x20damage\x20and\x20thrombosis\x20of\x20the\x20vein\x20&rarr;\x20edema\x20and&nbsp;</strong><strong>discolouration</strong>\x20of\x20the\x20injected\x20limb.\x20Tissue\x20necrosis\x20occurs\x20if\x20the\x20solution\x20extravasates.</li>\x0d\x0a<li><u>Fall\x20in\x20BP\x20and\x20cardiac\x20arrhythmias\x20occur\x20only\x20on\x20i.v.\x20injection\x20which,\x20therefore,\x20must\x20be\x20given\x20under\x20continuous\x20ECG\x20monitoring.</u></li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Adverse\x20effects\x20of\x20Phenytoin</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Gum\x20hypertrophy</strong>:\x20Commonest\x20(20%\x20incidence),\x20more\x20in\x20younger\x20patients.\x20It\x20is\x20due\x20to\x20<strong>overgrowth\x20of\x20gingival\x20collagen\x20fibres.</strong></li>\x0d\x0a<li><strong>Hirsutism,\x20coarsening\x20of\x20facial\x20features</strong>\x20(troublesome\x20in\x20young\x20girls),\x20acne.</li>\x0d\x0a<li><strong>Hypersensitivity\x20reactions</strong>\x20are-rashes,\x20<strong>DLE,\x20lymphadenopathy;\x20neutropenia\x20</strong>is\x20rare\x20but\x20requires\x20discontinuation\x20of\x20therapy.</li>\x0d\x0a<li><strong>Megaloblastic\x20anaemia\x20and\x20osteomalacia</strong>\x20can\x20occur\x20on\x20long\x20term\x20use\x20due\x20to\x20<u>interference\x20with\x20folate\x20absorption\x20and\x20vit.\x20D\x20activation\x20respectively.</u></li>\x0d\x0a<li>Administered\x20during\x20pregnancy,\x20phenytoin\x20can\x20produce\x20<strong>\x27foetal\x20hydantoin\x20syndrome\x27\x20(hypoplastic\x20phalanges,\x20cleft\x20palate,\x20harelip,\x20microcephaly),\x20which\x20is\x20probably\x20caused\x20by\x20its\x20arene-oxide\x20metabolite</strong>.</li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>ADRs\x20of\x20Phenytoin</u></strong></p>\x0d\x0a<p><strong><u>Mnemonic\x20[HOT\x20MALIKA]</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>H\x20</strong>-\x20<strong>H</strong>irsutism,\x20Hypertrophy\x20of\x20gums</li>\x0d\x0a<li><strong>O</strong>\x20-<strong>\x20O</strong>steomalacia</li>\x0d\x0a<li><strong>T</strong>\x20-\x20<strong>T</strong>eratogenicity\x20[Fetal\x20Hydantoin\x20syndrome]</li>\x0d\x0a<li><strong>M\x20-\x20M</strong>egaloblastic\x20Anemia\x20[&darr;\x20Folate\x20levels]</li>\x0d\x0a<li><strong>A\x20-\x20A</strong>rrhythmia\x20[Only\x20in\x20overdose]</li>\x0d\x0a<li><strong>L\x20-\x20L</strong>ymph\x20node\x20enlargement</li>\x0d\x0a<li><strong>I\x20-\x20&darr;\x20I</strong>nsulin\x20(avoided\x20in\x20Diabetus\x20mellitus-\x20Precipitates\x20hyperglycemia)</li>\x0d\x0a<li><strong>K\x20-</strong>\x20&darr;\x20Vitamin\x20<strong>K\x20</strong>levels</li>\x0d\x0a<li><strong>A\x20-\x20A</strong><strong>taxias,\x20vertigo\x20[cerebellar\x20symptoms</strong><strong>]\x20[only\x20at\x20high\x20dose]</strong></li>\x0d\x0a</ul>\x0d\x0a<p><strong>Incorrect\x20Choices\x20Explanation:</strong></p>\x0d\x0a<p><strong>(Choice\x20B)\x20Phenytoin\x20causes\x20cardiotoxicity\x20and\x20nephrotoxicity\x20in\x20old\x20and\x20young\x20patients\x20&rarr;\x20Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Phenytoin\x20is\x20primarily\x20associated\x20with\x20cardiovascular\x20toxicity\x20in\x20IV\x20form,\x20not\x20oral\x20use.</strong>\x0d\x0a<ul>\x0d\x0a<li>IV\x20<strong>phenytoin</strong>\x20can\x20cause\x20<strong>hypotension,\x20cardiac\x20arrhythmias,\x20and\x20AV\x20block</strong>,\x20especially\x20if\x20administered\x20too\x20rapidly.</li>\x0d\x0a<li><strong>Oral\x20phenytoin\x20does\x20not\x20typically\x20cause\x20significant\x20cardiotoxicity</strong>\x20at\x20therapeutic\x20doses.</li>\x0d\x0a</ul>\x0d\x0a</li>\x0d\x0a<li><strong>Nephrotoxicity\x20is\x20not\x20a\x20common\x20adverse\x20effect</strong>\x20of\x20phenytoin.</li>\x0d\x0a</ul>\x0d\x0a<p><strong>(Choice\x20C)\x20The\x20complications\x20can\x20be\x20minimized\x20by\x20administering\x20fosphenytoin\x20at\x20a\x20rate\x20of\x20less\x20than\x20250\x20mg\x20of\x20phenytoin\x20sodium\x20equivalent\x20per\x20minute\x20&rarr;\x20Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Fosphenytoin\x20(a\x20prodrug\x20of\x20phenytoin)\x20is\x20safer\x20for\x20IV\x20use</strong>\x20and\x20is\x20preferred\x20over\x20phenytoin\x20due\x20to\x20lower\x20risk\x20of\x20local\x20tissue\x20injury.</li>\x0d\x0a<li><strong>Recommended\x20administration\x20rate:</strong>\x0d\x0a<ul>\x0d\x0a<li><strong>Fosphenytoin:</strong>\x20Should\x20not\x20exceed\x20<strong>150\x20mg\x20of\x20phenytoin\x20sodium\x20equivalent\x20(PE)\x20per\x20minute</strong>\x20to\x20prevent\x20cardiovascular\x20complications.</li>\x0d\x0a<li><strong>Phenytoin:</strong>\x20Should\x20not\x20exceed\x20<strong>50\x20mg/min</strong>\x20due\x20to\x20the\x20risk\x20of\x20<strong>severe\x20hypotension\x20and\x20arrhythmias</strong>.</li>\x0d\x0a</ul>\x0d\x0a</li>\x0d\x0a<li>The\x20<strong>\x22250\x20mg/min\x22\x20value\x20is\x20incorrect</strong>\x20and\x20would\x20be\x20dangerously\x20high.</li>\x0d\x0a</ul>\x0d\x0a<p><strong>(Choice\x20D)\x20Given\x20to\x20all\x20patients\x20with\x20seizures\x20regardless\x20of\x20cardiac\x20arrhythmia,\x20hypotension,\x20and/or\x20sinus\x20depression\x20&rarr;\x20Incorrect</strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Phenytoin\x20should\x20be\x20avoided\x20in\x20patients\x20with\x20pre-existing\x20cardiac\x20conduction\x20abnormalities</strong>\x20such\x20as:\x0d\x0a<ul>\x0d\x0a<li><strong>Bradycardia</strong></li>\x0d\x0a<li><strong>Heart\x20block</strong></li>\x0d\x0a<li><strong>Hypotension</strong></li>\x0d\x0a<li><strong>Sinus\x20node\x20dysfunction</strong></li>\x0d\x0a</ul>\x0d\x0a</li>\x0d\x0a<li><strong>Phenytoin\x20can\x20cause\x20dose-dependent\x20cardiac\x20toxicity,\x20especially\x20with\x20rapid\x20IV\x20administration.</strong></li>\x0d\x0a</ul>\x0d\x0a<p><strong><u>Key\x20takeaway</u></strong></p>\x0d\x0a<ul>\x0d\x0a<li><strong>Over\x20dose\x20toxicity\x20due\x20to\x20higher\x20plasma\x20concentration\x20of\x20phenytoin\x20produces\x20Cerebellar\x20and\x20vestibular\x20manifestations:\x20ataxia,\x20vertigo,\x20diplopia,\x20nystagmus</strong></li>\x0d\x0a<li><strong>Drowsiness,\x20behavioural\x20alterations,\x20mental\x20confusion,\x20hallucinations,\x20disorientation\x20and\x20rigidity</strong></li>\x0d\x0a</ul>\x0d\x0a','evjPv'];_0x53e1=function(){return _0x5d8072;};return _0x53e1();}let hierarchy=[_0x5a4239(0x37e),'PYQ','Pharmacology'];if(window[_0x5a4239(0x223)][_0x5a4239(0x325)][_0x5a4239(0x2ec)](_0x5a4239(0x3cc))){const customData=JSON[_0x5a4239(0x35d)](localStorage[_0x5a4239(0x285)](_0x5a4239(0x351)));customData&&(questionsData=customData[_0x5a4239(0x36d)],quizName=customData[_0x5a4239(0x42b)],hierarchy=customData[_0x5a4239(0x251)],document[_0x5a4239(0x28c)]=quizName+_0x5a4239(0x27a),document[_0x5a4239(0x238)]('totalQuestions')[_0x5a4239(0x446)]=questionsData[_0x5a4239(0x289)],document['getElementById'](_0x5a4239(0x1b9))['textContent']=hierarchy['join'](_0x5a4239(0x3b4)));}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x5a4239(0x24f),timer=null,timeRemaining=0x0,questionStartTime=Date[_0x5a4239(0x338)](),quizStartTime=Date[_0x5a4239(0x338)](),isQuizCompleted=![],questionStates=new Array(questionsData[_0x5a4239(0x289)])[_0x5a4239(0x286)](null)[_0x5a4239(0x33a)](()=>({'status':_0x5a4239(0x29b),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData[_0x5a4239(0x289)]};function saveProgress(){const _0x2c84e2=_0x5a4239,_0x2f16ba={'vwLCS':_0x2c84e2(0x371),'hgYog':_0x2c84e2(0x330)};if(isQuizCompleted)return;const _0x4a76e1=JSON[_0x2c84e2(0x35d)](localStorage[_0x2c84e2(0x285)](_0x2f16ba[_0x2c84e2(0x210)]))||{};_0x4a76e1[quizFilename]={'questionStates':questionStates,'stats':stats,'currentQuestionIndex':currentQuestionIndex,'currentMode':currentMode,'status':_0x2f16ba['hgYog'],'lastSeen':new Date()['toISOString']()},localStorage[_0x2c84e2(0x356)](_0x2f16ba[_0x2c84e2(0x210)],JSON[_0x2c84e2(0x346)](_0x4a76e1));}function loadProgress(){const _0xca756c=_0x5a4239,_0x496a9f={'bDsEo':_0xca756c(0x371),'yXeRQ':function(_0x3761ae,_0x5e3be7){return _0x3761ae===_0x5e3be7;},'nJQaP':_0xca756c(0x407),'rrXLE':'Progress\x20loaded.'},_0x4902be=JSON['parse'](localStorage[_0xca756c(0x285)](_0x496a9f[_0xca756c(0x1da)]))||{},_0x46113c=_0x4902be[quizFilename];if(_0x46113c){if(_0x496a9f[_0xca756c(0x299)]('nPXZo',_0x496a9f['nJQaP']))_0x571495(_0xd42370,_0x22e080);else return questionStates=_0x46113c[_0xca756c(0x1c9)],stats=_0x46113c[_0xca756c(0x2b1)],currentQuestionIndex=_0x46113c[_0xca756c(0x389)],currentMode=_0x46113c[_0xca756c(0x26d)],console[_0xca756c(0x1ee)](_0x496a9f['rrXLE']),!![];}return![];}function clearProgress(){const _0x26c202=_0x5a4239,_0x140406={'AYYOD':_0x26c202(0x371),'LlTxr':'Previous\x20progress\x20cleared.'},_0x2cf9ff=JSON[_0x26c202(0x35d)](localStorage[_0x26c202(0x285)](_0x140406[_0x26c202(0x211)]))||{};_0x2cf9ff[quizFilename]&&(delete _0x2cf9ff[quizFilename],localStorage[_0x26c202(0x356)](_0x26c202(0x371),JSON['stringify'](_0x2cf9ff)),console[_0x26c202(0x1ee)](_0x140406[_0x26c202(0x25d)]));}function markQuizAsCompleted(){const _0x36bf69=_0x5a4239,_0x195f16={'PntEd':_0x36bf69(0x24c)},_0x231215=JSON['parse'](localStorage[_0x36bf69(0x285)](_0x36bf69(0x371)))||{},_0x5e2020=questionsData[_0x36bf69(0x289)],_0x51a509=stats['correctAnswers']||0x0;_0x231215[quizFilename]={'score':_0x51a509,'total':_0x5e2020,'status':_0x195f16[_0x36bf69(0x2af)],'completedOn':new Date()[_0x36bf69(0x305)]()},localStorage[_0x36bf69(0x356)](_0x36bf69(0x371),JSON[_0x36bf69(0x346)](_0x231215));}const urlParams=new URLSearchParams(window['location']['search']),startAt=parseInt(urlParams['get'](_0x5a4239(0x2d3))),resume=urlParams[_0x5a4239(0x214)](_0x5a4239(0x450))===_0x5a4239(0x381);function goBack(){const _0x38b11d=_0x5a4239,_0x25d8ac={'miIVJ':function(_0x19b02a){return _0x19b02a();},'ajvXP':_0x38b11d(0x3ce)};if(!isQuizCompleted)_0x25d8ac[_0x38b11d(0x409)](saveProgress);window['location'][_0x38b11d(0x302)]=document['referrer']||_0x25d8ac['ajvXP'];}function selectMode(_0x5c29af){const _0x27b479=_0x5a4239,_0x2b784c={'RiYPH':function(_0x4c4cda){return _0x4c4cda();}};currentMode=_0x5c29af,document[_0x27b479(0x238)](_0x27b479(0x401))['style']['display']=_0x27b479(0x451),_0x2b784c[_0x27b479(0x2d9)](initializeQuiz);}function initializeQuiz(){const _0x40f702=_0x5a4239,_0x228b2e={'rgUGN':_0x40f702(0x3c2),'tsLZz':_0x40f702(0x45f),'mMDZc':_0x40f702(0x35a),'iYOhI':_0x40f702(0x411),'rnOTh':_0x40f702(0x1dc),'baAqm':_0x40f702(0x259),'dzuNC':_0x40f702(0x2ab),'bkWcj':_0x40f702(0x2d7),'YNaPi':_0x40f702(0x460),'cbHEd':_0x40f702(0x451),'TOyyG':_0x40f702(0x408),'rGeQp':_0x40f702(0x2cb),'NKPcM':_0x40f702(0x2d4),'wqdRh':function(_0x585314,_0x57eff3){return _0x585314===_0x57eff3;},'QjcPc':function(_0x48362a,_0x2c865c){return _0x48362a!==_0x2c865c;},'YpYSL':'CoKuK','jJPfY':'cfGcx','bHgfx':_0x40f702(0x3ca),'dhFbd':function(_0x441db0,_0x5cf4fa){return _0x441db0(_0x5cf4fa);},'pFdbR':function(_0x3681f2,_0x1c735b){return _0x3681f2!==_0x1c735b;},'lGIOp':function(_0x270e31){return _0x270e31();},'kfboJ':function(_0x5d5570){return _0x5d5570();},'dWbyP':function(_0x456d02){return _0x456d02();}};quizStartTime=Date[_0x40f702(0x338)]();const _0x120d5d=document[_0x40f702(0x238)](_0x228b2e[_0x40f702(0x262)]),_0x5f20f0=document['getElementById'](_0x228b2e[_0x40f702(0x1e9)]),_0x396ed8=document[_0x40f702(0x238)](_0x228b2e[_0x40f702(0x426)]),_0x3ebf1a=currentMode===_0x228b2e[_0x40f702(0x26b)]||currentMode===_0x228b2e[_0x40f702(0x3c9)];document[_0x40f702(0x238)](_0x228b2e['bkWcj'])['style'][_0x40f702(0x32b)]=_0x3ebf1a?_0x40f702(0x451):_0x228b2e[_0x40f702(0x220)],document['getElementById'](_0x40f702(0x288))[_0x40f702(0x3e6)]['display']=_0x3ebf1a?_0x228b2e['cbHEd']:_0x40f702(0x460),document['getElementById'](_0x228b2e[_0x40f702(0x329)])[_0x40f702(0x3e6)]['display']=_0x3ebf1a?_0x228b2e[_0x40f702(0x220)]:'none',document[_0x40f702(0x238)](_0x228b2e[_0x40f702(0x3a6)])[_0x40f702(0x3e6)][_0x40f702(0x32b)]=_0x3ebf1a?_0x228b2e[_0x40f702(0x220)]:_0x228b2e[_0x40f702(0x3aa)],_0x120d5d[_0x40f702(0x3e6)]['display']=_0x3ebf1a?_0x40f702(0x451):_0x228b2e[_0x40f702(0x2ce)],_0x5f20f0['style'][_0x40f702(0x32b)]=_0x3ebf1a?_0x228b2e[_0x40f702(0x2ce)]:_0x228b2e[_0x40f702(0x3aa)],_0x396ed8[_0x40f702(0x3e6)][_0x40f702(0x32b)]=_0x3ebf1a?_0x228b2e['NKPcM']:'none',(_0x228b2e[_0x40f702(0x24a)](currentMode,_0x40f702(0x2ca))||currentMode===_0x40f702(0x2ab))&&(_0x228b2e[_0x40f702(0x2e8)](_0x228b2e[_0x40f702(0x42a)],_0x228b2e[_0x40f702(0x3f9)])?document[_0x40f702(0x238)](_0x228b2e[_0x40f702(0x257)])[_0x40f702(0x29a)][_0x40f702(0x37f)](_0x228b2e['tsLZz']):_0x5a3719()),!_0x228b2e['dhFbd'](isNaN,startAt)&&startAt>=0x0&&startAt<questionsData[_0x40f702(0x289)]&&(_0x228b2e[_0x40f702(0x283)]('MJdZV',_0x40f702(0x2bb))?currentQuestionIndex=startAt:_0x40151e[_0x40f702(0x238)](_0x228b2e[_0x40f702(0x32c)])[_0x40f702(0x29a)]['add'](_0x228b2e[_0x40f702(0x3dc)])),_0x228b2e[_0x40f702(0x321)](loadBookmarkedQuestions),_0x228b2e[_0x40f702(0x343)](generateQuestionNav),_0x228b2e[_0x40f702(0x1c1)](updateStats),displayQuestion();}function generateQuestionNav(){const _0x2f2956=_0x5a4239,_0x484234={'CeaFL':_0x2f2956(0x2b6),'rBVeY':_0x2f2956(0x30f),'bMVMx':function(_0x31d00c,_0x4c2476){return _0x31d00c+_0x4c2476;},'gJGsv':_0x2f2956(0x23e),'uCwLJ':function(_0x30d1d4){return _0x30d1d4();}},_0x4edd41=document[_0x2f2956(0x238)](_0x484234['CeaFL']);_0x4edd41[_0x2f2956(0x39f)]='';for(let _0xc4317e=0x0;_0xc4317e<questionsData[_0x2f2956(0x289)];_0xc4317e++){const _0x5f0a50=document['createElement'](_0x484234[_0x2f2956(0x34f)]);_0x5f0a50['textContent']=_0x484234['bMVMx'](_0xc4317e,0x1),_0x5f0a50['className']=_0x484234[_0x2f2956(0x2e9)],_0x5f0a50[_0x2f2956(0x2ae)]=()=>jumpToQuestion(_0xc4317e),_0x5f0a50['id']='navBtn_'+_0xc4317e,_0x4edd41['appendChild'](_0x5f0a50);}_0x484234['uCwLJ'](updateQuestionNav);}function updateQuestionNav(){const _0xb76af3=_0x5a4239,_0x338d5a={'jpApz':_0xb76af3(0x371),'owbVN':_0xb76af3(0x264),'sCoQc':_0xb76af3(0x3fc),'evjPv':function(_0x509757,_0x347c88){return _0x509757!==_0x347c88;},'suOqD':_0xb76af3(0x456),'wxQsF':_0xb76af3(0x312),'WzBwo':function(_0x291fd9,_0x51bf6e){return _0x291fd9===_0x51bf6e;},'pclPK':_0xb76af3(0x1cd),'RKsuz':_0xb76af3(0x28a),'Qtnmb':_0xb76af3(0x1f3),'XuSVS':_0xb76af3(0x24f),'yBWdz':function(_0x1bf5a4,_0x39c014){return _0x1bf5a4===_0x39c014;},'IssKV':_0xb76af3(0x2ca),'qkTvG':function(_0x376373,_0x1e8b6f){return _0x376373===_0x1e8b6f;},'wBOdi':_0xb76af3(0x20e),'BGjBZ':_0xb76af3(0x42c),'fcbTV':_0xb76af3(0x2c3),'Clsck':_0xb76af3(0x2fb)};for(let _0xc925e2=0x0;_0xc925e2<questionsData[_0xb76af3(0x289)];_0xc925e2++){if(_0x338d5a[_0xb76af3(0x2d0)](_0x338d5a[_0xb76af3(0x2a4)],_0x338d5a[_0xb76af3(0x2cd)])){const _0x2ff327=document[_0xb76af3(0x238)](_0xb76af3(0x26f)+_0xc925e2),_0x2f2813=questionStates[_0xc925e2];let _0x4c2b82='';if(_0x338d5a[_0xb76af3(0x43e)](_0xc925e2,currentQuestionIndex))_0x4c2b82=_0x338d5a[_0xb76af3(0x341)];else{if(_0x2f2813[_0xb76af3(0x22c)])_0x4c2b82=_0x338d5a['RKsuz'];else{if(_0x2f2813[_0xb76af3(0x35e)]){if(_0xb76af3(0x25c)!==_0x338d5a['Qtnmb'])_0x4c2b82='nav-btn-marked-review';else{const _0x5dbe74=_0x3dce88['parse'](_0x17db11[_0xb76af3(0x285)](_0x338d5a[_0xb76af3(0x429)]))||{},_0x4c9c6e=_0x5dbe74[_0x43d8b8];if(_0x4c9c6e)return _0x42b65b=_0x4c9c6e[_0xb76af3(0x1c9)],_0x1cca25=_0x4c9c6e[_0xb76af3(0x2b1)],_0x170e80=_0x4c9c6e[_0xb76af3(0x389)],_0x990afb=_0x4c9c6e[_0xb76af3(0x26d)],_0x3f0981['log'](_0x338d5a[_0xb76af3(0x2e6)]),!![];return![];}}else{if(currentMode===_0x338d5a['XuSVS']||_0x338d5a[_0xb76af3(0x2b3)](currentMode,_0x338d5a['IssKV'])){if(_0x338d5a[_0xb76af3(0x41f)](_0x2f2813['status'],_0x338d5a[_0xb76af3(0x29f)]))_0x4c2b82=_0xb76af3(0x2b9);else{if(_0x2f2813[_0xb76af3(0x387)]===_0x338d5a[_0xb76af3(0x1b3)])_0x4c2b82=_0x338d5a[_0xb76af3(0x2c1)];else _0x4c2b82=_0x338d5a[_0xb76af3(0x38e)];}}else{if(_0x2f2813['selectedAnswer']!==null)_0x4c2b82=_0xb76af3(0x440);else _0x4c2b82=_0x338d5a[_0xb76af3(0x38e)];}}}}_0x2ff327[_0xb76af3(0x39b)]='w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20'+_0x4c2b82;}else{const _0x3b0285=_0x338d5a['sCoQc'][_0xb76af3(0x1d6)]('|');let _0xafe589=0x0;while(!![]){switch(_0x3b0285[_0xafe589++]){case'0':_0xac04c0=_0x2898a9[_0xb76af3(0x2b1)];continue;case'1':_0x3049d3[_0xb76af3(0x1ee)](_0xb76af3(0x264));continue;case'2':_0x1f4c72=_0x228c91[_0xb76af3(0x389)];continue;case'3':_0x555b5b=_0x50d4f1[_0xb76af3(0x1c9)];continue;case'4':return!![];case'5':_0xa5ef46=_0x1545a4[_0xb76af3(0x26d)];continue;}break;}}}}function jumpToQuestion(_0x557197){const _0x2730ad=_0x5a4239,_0x29f031={'Mykih':function(_0x57cefa,_0x9cfb4d){return _0x57cefa-_0x9cfb4d;},'HOIkK':function(_0xb67e19,_0x9186c8){return _0xb67e19>=_0x9186c8;},'MyOub':function(_0x2679a5,_0x166849){return _0x2679a5!==_0x166849;},'WhAgl':_0x2730ad(0x249),'GNuWd':_0x2730ad(0x27d),'BJret':function(_0x20e467){return _0x20e467();}};_0x29f031['HOIkK'](_0x557197,0x0)&&_0x557197<questionsData['length']&&(questionStartTime&&(_0x29f031[_0x2730ad(0x30d)](_0x29f031[_0x2730ad(0x40a)],_0x29f031['GNuWd'])?questionStates[currentQuestionIndex][_0x2730ad(0x434)]+=Date['now']()-questionStartTime:_0x16e896[_0x2ba38e]['timeSpent']+=_0x29f031[_0x2730ad(0x250)](_0x4e015e[_0x2730ad(0x338)](),_0x174914)),currentQuestionIndex=_0x557197,_0x29f031['BJret'](displayQuestion),saveProgress());}function updateStats(){const _0x1ecc43=_0x5a4239,_0x560832={'IvUWT':function(_0x262122,_0x12697d){return _0x262122===_0x12697d;},'XSzyp':function(_0x1fdba8,_0x2fcf72){return _0x1fdba8===_0x2fcf72;},'JvDek':_0x1ecc43(0x2f4),'LqQJq':_0x1ecc43(0x439),'fDjup':function(_0x366a68,_0x97d23f){return _0x366a68*_0x97d23f;},'tMOhK':_0x1ecc43(0x303),'HpGrz':function(_0x17c51c,_0x2e9574){return _0x17c51c+_0x2e9574;},'ZmeYF':function(_0x4d1e18,_0x265ac1){return _0x4d1e18/_0x265ac1;},'VWUHA':function(_0x516468,_0x552ac8){return _0x516468%_0x552ac8;}};if(_0x560832[_0x1ecc43(0x2d8)](currentMode,_0x1ecc43(0x24f))||_0x560832['XSzyp'](currentMode,'timed_study')){document[_0x1ecc43(0x238)](_0x560832[_0x1ecc43(0x1f6)])[_0x1ecc43(0x446)]=stats['correctAnswers'],document[_0x1ecc43(0x238)](_0x560832[_0x1ecc43(0x3f1)])[_0x1ecc43(0x446)]=stats[_0x1ecc43(0x435)],document['getElementById']('totalAttempted')[_0x1ecc43(0x446)]=stats[_0x1ecc43(0x344)];const _0x2ca5cd=stats[_0x1ecc43(0x344)]>0x0?Math[_0x1ecc43(0x270)](_0x560832[_0x1ecc43(0x20c)](stats[_0x1ecc43(0x2cc)]/stats[_0x1ecc43(0x344)],0x64)):0x0;document[_0x1ecc43(0x238)](_0x560832[_0x1ecc43(0x386)])[_0x1ecc43(0x446)]=_0x560832[_0x1ecc43(0x40f)](_0x2ca5cd,'%'),stats['totalTime']=questionStates['reduce']((_0x1b4b6a,_0x1abc6a)=>_0x1b4b6a+_0x1abc6a[_0x1ecc43(0x434)],0x0);const _0x19f1d1=Math[_0x1ecc43(0x1bd)](_0x560832[_0x1ecc43(0x3b5)](stats['totalTime'],0x3e8)),_0x3350c5=Math[_0x1ecc43(0x1bd)](_0x560832['ZmeYF'](_0x19f1d1,0x3c)),_0x32d2b4=_0x560832['VWUHA'](_0x19f1d1,0x3c);document[_0x1ecc43(0x238)](_0x1ecc43(0x434))[_0x1ecc43(0x446)]=_0x560832['HpGrz'](_0x560832[_0x1ecc43(0x40f)](_0x3350c5,':'),_0x32d2b4[_0x1ecc43(0x327)]()['padStart'](0x2,'0'));}}function setupVideo(_0xeebbb5,_0x1f99e4){const _0x5cdc9b=_0x5a4239,_0x4e55cd={'reevI':function(_0x41c6cc,_0x59f587){return _0x41c6cc===_0x59f587;},'HcJic':'incorrect','sJNTj':function(_0x564ffa,_0x2a9125){return _0x564ffa!==_0x2a9125;},'AgGZA':_0x5cdc9b(0x384),'eQwPi':_0x5cdc9b(0x443),'iCuLN':'kotio'};if(Hls[_0x5cdc9b(0x2a3)]()){if(_0x4e55cd[_0x5cdc9b(0x1dd)](_0x4e55cd[_0x5cdc9b(0x248)],_0x4e55cd['AgGZA'])){const _0x1597e2={'quizName':_0x139bd6,'quizFile':_0x67f6fe[_0x5cdc9b(0x223)][_0x5cdc9b(0x325)][_0x5cdc9b(0x1d6)]('/')[_0x5cdc9b(0x3f8)](),'questionIndex':_0x1de108,'question':_0x211945[_0x4ff4c3],'hierarchy':_0x59aa31,'timestamp':_0x5d16ec[_0x5cdc9b(0x338)]()};_0x5586ca[_0x5cdc9b(0x2b8)](_0x1597e2);}else{const _0x42750b=new Hls();_0x42750b[_0x5cdc9b(0x3be)](_0x1f99e4),_0x42750b[_0x5cdc9b(0x3dd)](_0xeebbb5);}}else _0xeebbb5[_0x5cdc9b(0x258)](_0x4e55cd['eQwPi'])&&(_0x4e55cd[_0x5cdc9b(0x1dd)](_0x4e55cd[_0x5cdc9b(0x218)],'kotio')?_0x4e55cd[_0x5cdc9b(0x1e8)](_0x3467d7['choices'][_0x181abe[_0x5cdc9b(0x206)]]['id'],_0x981d7b[_0x5cdc9b(0x2fd)])?(_0x178e36++,_0x454aa3['status']=_0x5cdc9b(0x20e)):(_0x19af94++,_0x46c7a0[_0x5cdc9b(0x387)]=_0x4e55cd[_0x5cdc9b(0x1f7)]):_0xeebbb5[_0x5cdc9b(0x1f5)]=_0x1f99e4);}function displayQuestion(){const _0x1b1ff0=_0x5a4239,_0x288ef2={'WbGyC':function(_0x468b54,_0xa76494){return _0x468b54!==_0xa76494;},'DgJEU':_0x1b1ff0(0x3c7),'wezNA':function(_0x2b250d,_0x1e0468){return _0x2b250d+_0x1e0468;},'xOHNC':function(_0x9e8b5e,_0x14ddf2){return _0x9e8b5e===_0x14ddf2;},'JCjKo':_0x1b1ff0(0x398),'HJTfi':_0x1b1ff0(0x3e5),'YDLcy':function(_0x41fd2c,_0x5cbf){return _0x41fd2c+_0x5cbf;},'aMXHQ':'vkRFg','dYfaP':_0x1b1ff0(0x45e),'RufBP':_0x1b1ff0(0x318),'lpAeh':function(_0xf2fd64,_0x2373ad){return _0xf2fd64(_0x2373ad);},'xvKgF':function(_0x3dccaf,_0x3d28ca){return _0x3dccaf(_0x3d28ca);},'VXPUK':'questionText','CqppX':_0x1b1ff0(0x3ad),'PcFGX':function(_0x57389a,_0x3bff62){return _0x57389a*_0x3bff62;},'GNGZG':_0x1b1ff0(0x416),'ZjegQ':function(_0x311095,_0xed93e8){return _0x311095+_0xed93e8;},'CUHAg':_0x1b1ff0(0x1b7),'uJSLx':function(_0x2f00ca){return _0x2f00ca();},'uToij':_0x1b1ff0(0x445),'GdFAU':_0x1b1ff0(0x31b),'csfDS':_0x1b1ff0(0x45f),'duhfl':_0x1b1ff0(0x3cb),'ZTxJI':_0x1b1ff0(0x3ab),'ynPDt':_0x1b1ff0(0x1c6),'uTIVD':function(_0xcc1622){return _0xcc1622();},'yUiZu':function(_0x81fe98,_0x119c07){return _0x81fe98===_0x119c07;},'hHRxb':_0x1b1ff0(0x2ca),'DcXjU':'timed_exam'};if(!questionsData||questionsData['length']===0x0){document[_0x1b1ff0(0x238)](_0x288ef2[_0x1b1ff0(0x306)])[_0x1b1ff0(0x39f)]=_0x288ef2[_0x1b1ff0(0x43f)];return;};const _0x2a01b4=questionsData[currentQuestionIndex];questionStartTime=Date['now'](),selectedOption=questionStates[currentQuestionIndex][_0x1b1ff0(0x206)];const _0x1b0bd7=_0x288ef2[_0x1b1ff0(0x2a2)](_0x288ef2[_0x1b1ff0(0x2bd)](currentQuestionIndex,0x1)/questionsData['length'],0x64);document[_0x1b1ff0(0x238)](_0x288ef2[_0x1b1ff0(0x3ee)])['style']['width']=_0x288ef2[_0x1b1ff0(0x27c)](_0x1b0bd7,'%'),document[_0x1b1ff0(0x238)](_0x288ef2[_0x1b1ff0(0x37b)])[_0x1b1ff0(0x446)]=_0x288ef2['YDLcy'](currentQuestionIndex,0x1),_0x288ef2[_0x1b1ff0(0x1e1)](updateQuestionNav),document[_0x1b1ff0(0x238)](_0x288ef2[_0x1b1ff0(0x269)])['disabled']=_0x288ef2[_0x1b1ff0(0x3ff)](currentQuestionIndex,0x0),document[_0x1b1ff0(0x238)](_0x288ef2['GdFAU'])[_0x1b1ff0(0x29a)][_0x1b1ff0(0x3a0)](_0x288ef2['csfDS']),document[_0x1b1ff0(0x238)](_0x288ef2[_0x1b1ff0(0x306)])[_0x1b1ff0(0x39f)]=_0x2a01b4[_0x1b1ff0(0x1f9)]||_0x288ef2[_0x1b1ff0(0x216)];let _0x11c5e1='';if(_0x2a01b4[_0x1b1ff0(0x2eb)])_0x11c5e1+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22'+_0x2a01b4[_0x1b1ff0(0x2eb)]+_0x1b1ff0(0x27b);if(_0x2a01b4['question_video'])_0x11c5e1+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22'+_0x2a01b4['question_video']+'\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>';_0x2a01b4[_0x1b1ff0(0x310)]&&_0x2a01b4[_0x1b1ff0(0x310)][_0x1b1ff0(0x261)](_0x4d9c00=>{const _0x67550b=_0x1b1ff0,_0xd186be={'qfNmG':_0x67550b(0x28a)};if(_0x288ef2['WbGyC'](_0x67550b(0x3c7),_0x288ef2['DgJEU']))_0x365926=_0xd186be[_0x67550b(0x352)];else{if(_0x4d9c00)_0x11c5e1+=_0x67550b(0x1c8)+_0x4d9c00+_0x67550b(0x253);}});document[_0x1b1ff0(0x238)](_0x1b1ff0(0x40d))[_0x1b1ff0(0x39f)]=_0x11c5e1;const _0x709cd2=document[_0x1b1ff0(0x238)](_0x288ef2['ZTxJI']);_0x709cd2['innerHTML']='',_0x709cd2[_0x1b1ff0(0x29a)][_0x1b1ff0(0x37f)](_0x288ef2[_0x1b1ff0(0x2fe)]),_0x2a01b4['choices']&&Array[_0x1b1ff0(0x1f4)](_0x2a01b4[_0x1b1ff0(0x464)])&&(_0x2a01b4[_0x1b1ff0(0x464)]['forEach']((_0x53c0b6,_0x4af135)=>{const _0x60d334=_0x1b1ff0,_0x32a7a2=String[_0x60d334(0x34c)](_0x288ef2[_0x60d334(0x2bd)](0x41,_0x4af135)),_0x4afe81=_0x288ef2[_0x60d334(0x3ff)](selectedOption,_0x4af135),_0x226c43=document[_0x60d334(0x1e0)](_0x288ef2[_0x60d334(0x287)]);_0x226c43[_0x60d334(0x39f)]=_0x60d334(0x307)+(_0x4afe81?_0x60d334(0x3de):'')+_0x60d334(0x278)+_0x4af135+_0x60d334(0x3df)+_0x32a7a2+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>'+(_0x53c0b6['text']||_0x288ef2[_0x60d334(0x367)]+_0x288ef2[_0x60d334(0x432)](_0x4af135,0x1))+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20',_0x709cd2[_0x60d334(0x400)](_0x226c43);}),_0x709cd2[_0x1b1ff0(0x201)](_0x1b1ff0(0x350),function(_0x3bd874){const _0x14eff2=_0x1b1ff0;if(_0x288ef2['aMXHQ']!==_0x288ef2[_0x14eff2(0x37c)]){const _0x5446c7=_0x3bd874['target'][_0x14eff2(0x228)](_0x288ef2['RufBP']);if(_0x5446c7){const _0xccce28=_0x288ef2['lpAeh'](parseInt,_0x5446c7[_0x14eff2(0x266)](_0x14eff2(0x260)));_0x288ef2['xvKgF'](selectOption,_0xccce28);}}else _0x970e12[_0x17af64['questionIndex']][_0x14eff2(0x22c)]=!![];})),_0x288ef2[_0x1b1ff0(0x1e1)](updateBookmarkButton),_0x288ef2[_0x1b1ff0(0x40e)](updateMarkReviewButton),(_0x288ef2[_0x1b1ff0(0x2c5)](currentMode,_0x288ef2[_0x1b1ff0(0x271)])||_0x288ef2[_0x1b1ff0(0x3ff)](currentMode,_0x288ef2[_0x1b1ff0(0x364)]))&&!isQuizCompleted&&_0x288ef2['uJSLx'](startTimer);}function selectOption(_0x20ea59){const _0x3439ca=_0x5a4239,_0x2847a8={'OBhCP':function(_0x21e7dd,_0x4e786d){return _0x21e7dd===_0x4e786d;},'HIift':_0x3439ca(0x20e),'ktVkp':function(_0x112135,_0x5b9b90){return _0x112135===_0x5b9b90;},'HDYaD':_0x3439ca(0x42c),'CrVcd':function(_0x16400a,_0x24c900){return _0x16400a!==_0x24c900;},'SyAes':_0x3439ca(0x24f),'NlnKM':_0x3439ca(0x2ca),'gzKgV':_0x3439ca(0x3ab),'rjQZX':_0x3439ca(0x318),'lchXF':'answered','yBGwc':function(_0x221e41){return _0x221e41();},'ZJbZr':function(_0x3a4ed0,_0x5d142c){return _0x3a4ed0===_0x5d142c;},'sJLzP':_0x3439ca(0x38c),'prjAM':'hqrdG','kqvLB':function(_0x3a6c4b,_0x534648){return _0x3a6c4b===_0x534648;},'txVOs':'bENpH','FizNU':_0x3439ca(0x29b),'zhvyQ':function(_0x2d99c6){return _0x2d99c6();}},_0x37472f=document[_0x3439ca(0x238)](_0x2847a8['gzKgV']);if(_0x37472f[_0x3439ca(0x29a)]['contains'](_0x3439ca(0x1c6)))return;if(questionStartTime){if(_0x2847a8[_0x3439ca(0x1cf)](_0x2847a8[_0x3439ca(0x33b)],_0x2847a8[_0x3439ca(0x3a9)])){if(_0x2847a8['CrVcd'](_0x330cfb,_0x2847a8[_0x3439ca(0x45d)])&&_0x5ca39b!==_0x2847a8[_0x3439ca(0x3a8)])return;const _0x22bd16=_0x5bc85d['getElementById'](_0x2847a8[_0x3439ca(0x23b)]),_0x62bef6=_0x22bd16[_0x3439ca(0x3b9)](_0x2847a8[_0x3439ca(0x427)]),_0x3b1e39=_0x32de88[_0x237b77],_0xf6461=_0x3b1e39['correct_choice_id'];let _0x276754=_0x3b1e39[_0x3439ca(0x464)]['findIndex'](_0x3bfc5d=>_0x3bfc5d['id']===_0xf6461);_0x22bd16['classList'][_0x3439ca(0x3a0)](_0x2847a8[_0x3439ca(0x457)]),_0x62bef6['forEach']((_0x32932f,_0x4ba21d)=>{const _0x16336d=_0x3439ca;_0x32932f['classList'][_0x16336d(0x37f)]('selected');if(_0x2847a8[_0x16336d(0x431)](_0x4ba21d,_0x276754))_0x32932f[_0x16336d(0x29a)][_0x16336d(0x3a0)](_0x2847a8[_0x16336d(0x458)]);else{if(_0x2847a8[_0x16336d(0x41b)](_0x4ba21d,_0x1a407b)&&!_0xb701e9)_0x32932f[_0x16336d(0x29a)][_0x16336d(0x3a0)](_0x2847a8[_0x16336d(0x2e3)]);}}),_0x2847a8[_0x3439ca(0x32e)](_0x3eba9a);}else questionStates[currentQuestionIndex]['timeSpent']+=Date[_0x3439ca(0x338)]()-questionStartTime,questionStartTime=Date[_0x3439ca(0x338)]();}selectedOption=_0x20ea59,questionStates[currentQuestionIndex][_0x3439ca(0x206)]=_0x20ea59,document[_0x3439ca(0x3b9)](_0x2847a8[_0x3439ca(0x427)])[_0x3439ca(0x261)]((_0xc80b10,_0x2bb90e)=>{const _0x11d54f=_0x3439ca;_0xc80b10['classList'][_0x11d54f(0x3f5)](_0x11d54f(0x3de),_0x2847a8[_0x11d54f(0x431)](_0x2bb90e,_0x20ea59));}),_0x2847a8['kqvLB'](currentMode,_0x2847a8[_0x3439ca(0x45d)])||_0x2847a8[_0x3439ca(0x1cf)](currentMode,_0x2847a8[_0x3439ca(0x3a8)])?_0x2847a8[_0x3439ca(0x428)](_0x2847a8[_0x3439ca(0x30a)],_0x2847a8[_0x3439ca(0x30a)])?_0x2847a8[_0x3439ca(0x32e)](processAnswer):_0x4bc117[_0x3439ca(0x310)][_0x3439ca(0x261)](_0x41d33a=>{const _0x10d6aa=_0x3439ca;if(_0x41d33a)_0x212af6+=_0x10d6aa(0x1c8)+_0x41d33a+_0x10d6aa(0x253);}):(questionStates[currentQuestionIndex][_0x3439ca(0x387)]===_0x2847a8[_0x3439ca(0x2bf)]&&(questionStates[currentQuestionIndex][_0x3439ca(0x387)]='answered',stats['totalAttempted']++,stats[_0x3439ca(0x3ef)]--),_0x2847a8['yBGwc'](updateQuestionNav)),_0x2847a8['zhvyQ'](saveProgress);}function processAnswer(){const _0x16d57a=_0x5a4239,_0x1da955={'OSJLM':_0x16d57a(0x3cc),'xzppC':_0x16d57a(0x351),'FbDfr':function(_0x41353d,_0x487f76){return _0x41353d===_0x487f76;},'gsYOp':_0x16d57a(0x29b),'dyuWb':function(_0x55ebcc,_0x22e70c){return _0x55ebcc!==_0x22e70c;},'HxFKQ':_0x16d57a(0x1bc),'dCame':_0x16d57a(0x20e),'DCOTa':_0x16d57a(0x42c),'llGfb':function(_0x1617e9){return _0x1617e9();},'AqJNH':function(_0x85543b,_0x25755f){return _0x85543b(_0x25755f);}},_0x25100b=questionsData[currentQuestionIndex],_0x29a97d=_0x25100b[_0x16d57a(0x2fd)];if(selectedOption===null)return;const _0x4088a6=_0x25100b[_0x16d57a(0x464)][selectedOption],_0x438036=_0x1da955[_0x16d57a(0x36c)](_0x4088a6['id'],_0x29a97d);if(questionStates[currentQuestionIndex]['status']===_0x1da955['gsYOp']){if(_0x1da955[_0x16d57a(0x331)](_0x1da955[_0x16d57a(0x38d)],_0x16d57a(0x1bc)))_0x223531[_0x16d57a(0x223)][_0x16d57a(0x325)][_0x16d57a(0x2ec)](_0x1da955[_0x16d57a(0x2f2)])&&_0x5e486c[_0x16d57a(0x362)](_0x1da955[_0x16d57a(0x2b5)]),_0x45fbcc(),_0x2ad0c3['reload']();else{stats[_0x16d57a(0x344)]++,stats['notAttempted']--;if(_0x438036)stats[_0x16d57a(0x2cc)]++;else stats[_0x16d57a(0x435)]++;}}questionStates[currentQuestionIndex][_0x16d57a(0x387)]=_0x438036?_0x1da955[_0x16d57a(0x353)]:_0x1da955[_0x16d57a(0x452)],_0x1da955['llGfb'](updateStats),_0x1da955[_0x16d57a(0x22b)](showInlineFeedback,_0x438036),updateQuestionNav();}function showInlineFeedback(_0x46c794){const _0x498d1b=_0x5a4239,_0x27555f={'dommj':function(_0x35e9ae,_0x16a51c){return _0x35e9ae===_0x16a51c;},'HLERi':_0x498d1b(0x44e),'fwSVb':_0x498d1b(0x20e),'zjvwS':function(_0x102665,_0x464ebf){return _0x102665===_0x464ebf;},'DIkHP':_0x498d1b(0x42c),'ZIMAv':function(_0x52d9ae,_0x3bcc1b){return _0x52d9ae!==_0x3bcc1b;},'ztUZt':'study','AvvAe':function(_0x517d14,_0x490210){return _0x517d14!==_0x490210;},'cwWkJ':_0x498d1b(0x2ca),'GAOZp':'optionsContainer','opgPy':_0x498d1b(0x318),'wqtDw':_0x498d1b(0x1c6),'qKpdH':function(_0x303ac0){return _0x303ac0();}};if(_0x27555f[_0x498d1b(0x332)](currentMode,_0x27555f[_0x498d1b(0x268)])&&_0x27555f[_0x498d1b(0x298)](currentMode,_0x27555f[_0x498d1b(0x36f)]))return;const _0x1f0e4a=document[_0x498d1b(0x238)](_0x27555f[_0x498d1b(0x219)]),_0x427b31=_0x1f0e4a['querySelectorAll'](_0x27555f['opgPy']),_0x48fb81=questionsData[currentQuestionIndex],_0x2ee036=_0x48fb81[_0x498d1b(0x2fd)];let _0x3f0547=_0x48fb81[_0x498d1b(0x464)][_0x498d1b(0x34a)](_0x3b6f20=>_0x3b6f20['id']===_0x2ee036);_0x1f0e4a['classList'][_0x498d1b(0x3a0)](_0x27555f[_0x498d1b(0x22a)]),_0x427b31[_0x498d1b(0x261)]((_0x1b4136,_0x3a64e7)=>{const _0x2830f1=_0x498d1b;if(_0x27555f[_0x2830f1(0x1ff)](_0x27555f[_0x2830f1(0x224)],_0x27555f['HLERi'])){_0x1b4136['classList']['remove']('selected');if(_0x27555f[_0x2830f1(0x1ff)](_0x3a64e7,_0x3f0547))_0x1b4136['classList']['add'](_0x27555f[_0x2830f1(0x375)]);else{if(_0x27555f[_0x2830f1(0x2db)](_0x3a64e7,selectedOption)&&!_0x46c794)_0x1b4136[_0x2830f1(0x29a)]['add'](_0x27555f['DIkHP']);}}else _0x35cb5b();}),_0x27555f[_0x498d1b(0x279)](showSolution);}function showSolution(){const _0x561779=_0x5a4239,_0x11686d={'GVNpz':function(_0x110e0a,_0x2215bb){return _0x110e0a===_0x2215bb;},'fSCWG':'study','DmQwD':'correctCount','yvHjv':_0x561779(0x344),'NLbqD':function(_0x5e91df,_0x4acd1d){return _0x5e91df>_0x4acd1d;},'irKKm':function(_0x4a576b,_0x2ca324){return _0x4a576b*_0x2ca324;},'GngeF':function(_0x1ec62f,_0x39a4bb){return _0x1ec62f/_0x39a4bb;},'lhfkY':_0x561779(0x303),'zaPtI':function(_0x581ce9,_0x4d39be){return _0x581ce9%_0x4d39be;},'oqPpS':function(_0x2a62e6,_0x3709ad){return _0x2a62e6+_0x3709ad;},'wPttY':function(_0x3c561a,_0x4ac10e){return _0x3c561a===_0x4ac10e;},'nPVOv':_0x561779(0x25e),'OPWRW':function(_0x4f645d,_0x234d18){return _0x4f645d!==_0x234d18;},'xyceb':'timed_study','ojidr':_0x561779(0x2aa),'PPmrF':_0x561779(0x3d1),'iSfjv':_0x561779(0x2a0),'aBWSo':'explanationVideoPlayer','YNsBz':function(_0xfae3ce,_0x3d5bad){return _0xfae3ce===_0x3d5bad;},'aqSqZ':'bMvVI','rMIHI':'AENJd','nMtnT':'hidden','jCnDp':'.m3u8','xIdjT':function(_0x3665e4,_0x10e9a0,_0x521eb6){return _0x3665e4(_0x10e9a0,_0x521eb6);},'BenFV':'solutionAudio','yRjpK':_0x561779(0x31b)};if(currentMode!==_0x11686d[_0x561779(0x1be)]&&_0x11686d['OPWRW'](currentMode,_0x11686d[_0x561779(0x3f3)]))return;const _0x89fde7=questionsData[currentQuestionIndex];document[_0x561779(0x238)](_0x11686d[_0x561779(0x3ea)])['innerHTML']=_0x89fde7[_0x561779(0x1e2)]||_0x11686d['PPmrF'];const _0x3e93a7=document[_0x561779(0x238)](_0x11686d[_0x561779(0x242)]),_0x4655d9=document[_0x561779(0x238)](_0x11686d[_0x561779(0x3a3)]),_0x45754b=_0x89fde7[_0x561779(0x1cb)];if(_0x45754b){if(_0x11686d[_0x561779(0x23a)](_0x11686d[_0x561779(0x462)],_0x11686d['rMIHI'])){if(_0x11686d['GVNpz'](_0x326d7f,_0x11686d[_0x561779(0x1be)])||_0x11686d[_0x561779(0x23c)](_0x23f456,'timed_study')){_0x31c48a[_0x561779(0x238)](_0x11686d[_0x561779(0x1ce)])[_0x561779(0x446)]=_0x5b2964['correctAnswers'],_0x4d4d57[_0x561779(0x238)](_0x561779(0x439))[_0x561779(0x446)]=_0x13d123['incorrectAnswers'],_0xf4442[_0x561779(0x238)](_0x11686d[_0x561779(0x2c6)])[_0x561779(0x446)]=_0x4fd64['totalAttempted'];const _0x5f59c9=_0x11686d[_0x561779(0x44b)](_0x21e5c5[_0x561779(0x344)],0x0)?_0x5b7ea6[_0x561779(0x270)](_0x11686d[_0x561779(0x28f)](_0x11686d[_0x561779(0x348)](_0x38263f[_0x561779(0x2cc)],_0x2c4583[_0x561779(0x344)]),0x64)):0x0;_0x5f44f7['getElementById'](_0x11686d[_0x561779(0x1e4)])[_0x561779(0x446)]=_0x5f59c9+'%',_0x52eeb9[_0x561779(0x21b)]=_0x394237[_0x561779(0x35f)]((_0x50b92e,_0x22d995)=>_0x50b92e+_0x22d995[_0x561779(0x434)],0x0);const _0x6d0c19=_0x21251c['floor'](_0x49de42[_0x561779(0x21b)]/0x3e8),_0x47a712=_0x54bf7e['floor'](_0x11686d['GngeF'](_0x6d0c19,0x3c)),_0x4ca557=_0x11686d[_0x561779(0x436)](_0x6d0c19,0x3c);_0x2fb0f3[_0x561779(0x238)](_0x561779(0x434))[_0x561779(0x446)]=_0x11686d[_0x561779(0x21f)](_0x11686d[_0x561779(0x21f)](_0x47a712,':'),_0x4ca557['toString']()[_0x561779(0x44f)](0x2,'0'));}}else{_0x3e93a7['classList'][_0x561779(0x37f)](_0x11686d['nMtnT']);if(_0x45754b[_0x561779(0x2a1)](_0x11686d[_0x561779(0x1c2)]))_0x11686d[_0x561779(0x252)](setupVideo,_0x4655d9,_0x45754b);else _0x4655d9[_0x561779(0x1f5)]=_0x45754b;}}else _0x3e93a7[_0x561779(0x29a)][_0x561779(0x3a0)](_0x11686d[_0x561779(0x3d6)]);const _0x4c9205=document[_0x561779(0x238)](_0x11686d['BenFV']);_0x4c9205[_0x561779(0x39f)]='';_0x89fde7['explanation_audio_eng']&&(_0x4c9205[_0x561779(0x39f)]+=_0x561779(0x3bf)+_0x89fde7[_0x561779(0x217)]+_0x561779(0x27b));_0x89fde7['explanation_audio_hin']&&(_0x4c9205['innerHTML']+=_0x561779(0x376)+_0x89fde7[_0x561779(0x2df)]+_0x561779(0x27b));const _0x9ef864=document[_0x561779(0x238)](_0x561779(0x3ed));_0x9ef864[_0x561779(0x39f)]='',_0x89fde7[_0x561779(0x25f)]&&_0x89fde7['explanation_images'][_0x561779(0x261)](_0x23f370=>{const _0x343cd9=_0x561779;if(_0x11686d['wPttY'](_0x11686d[_0x343cd9(0x38f)],_0x343cd9(0x395))){const _0x115b28=_0x2864d4[_0x343cd9(0x1d1)][_0x343cd9(0x422)][_0x343cd9(0x373)](_0x4b42d7),_0x133be1=_0x3d9699[_0x7ff3d8],_0x2292fa=_0x5dc99d[_0x133be1]||_0x115b28;_0x115b28['__proto__']=_0xee10bf[_0x343cd9(0x373)](_0x5a2fb8),_0x115b28[_0x343cd9(0x327)]=_0x2292fa[_0x343cd9(0x327)][_0x343cd9(0x373)](_0x2292fa),_0x252c22[_0x133be1]=_0x115b28;}else{if(_0x23f370)_0x9ef864[_0x343cd9(0x39f)]+=_0x343cd9(0x421)+_0x23f370+'\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>';}}),document[_0x561779(0x238)](_0x11686d[_0x561779(0x254)])[_0x561779(0x29a)][_0x561779(0x37f)](_0x11686d['nMtnT']);}function submitQuiz(){const _0x1ac797=_0x5a4239,_0x990044={'DzhmY':function(_0x47a3c3,_0x510a61){return _0x47a3c3(_0x510a61);},'kWOTC':function(_0x44a093,_0x57de1b){return _0x44a093!==_0x57de1b;},'oLPHA':'GRoSw','RDUVO':function(_0x12b95c,_0x16ba47){return _0x12b95c!==_0x16ba47;},'TqgiA':_0x1ac797(0x20e),'JzbLy':_0x1ac797(0x42c),'gdQMf':function(_0x6806d5,_0x47ca79){return _0x6806d5(_0x47ca79);},'pzOWW':_0x1ac797(0x29c),'QwlwK':function(_0x5c3851,_0x441162){return _0x5c3851-_0x441162;},'ETmAg':'quizPerformanceData','QSvSV':function(_0x4f84f1,_0x1e1434){return _0x4f84f1-_0x1e1434;},'AiUgV':function(_0x5d2be9,_0x1027bb){return _0x5d2be9+_0x1027bb;},'etgfV':function(_0xd63c50,_0x1083aa,_0x5b781a,_0x4e5f99,_0x11973c){return _0xd63c50(_0x1083aa,_0x5b781a,_0x4e5f99,_0x11973c);},'UpPyp':function(_0x569173,_0x32eebe){return _0x569173-_0x32eebe;}};if(timer)_0x990044[_0x1ac797(0x3cd)](clearInterval,timer);if(!confirm(_0x990044['pzOWW']))return;isQuizCompleted=!![];let _0x11335b=0x0,_0x2d2898=0x0;const _0x18bb32=_0x990044[_0x1ac797(0x3d3)](Date[_0x1ac797(0x338)](),quizStartTime);questionsData['forEach']((_0x30b725,_0xb28e28)=>{const _0x3ffb82=_0x1ac797,_0x587fba={'qCbhf':function(_0x349ef1,_0x303619){return _0x990044['DzhmY'](_0x349ef1,_0x303619);},'nCuOk':_0x3ffb82(0x260)};if(_0x990044[_0x3ffb82(0x2a6)](_0x3ffb82(0x2ef),_0x990044[_0x3ffb82(0x301)])){const _0x18bcbb=questionStates[_0xb28e28];_0x990044[_0x3ffb82(0x3a1)](_0x18bcbb[_0x3ffb82(0x206)],null)&&(_0x30b725[_0x3ffb82(0x464)][_0x18bcbb['selectedAnswer']]['id']===_0x30b725['correct_choice_id']?(_0x11335b++,_0x18bcbb['status']=_0x990044[_0x3ffb82(0x311)]):(_0x2d2898++,_0x18bcbb[_0x3ffb82(0x387)]=_0x990044['JzbLy']));}else{const _0xb53f52=_0x587fba[_0x3ffb82(0x3d5)](_0x2ddd86,_0xf347e7['getAttribute'](_0x587fba['nCuOk']));_0x1e5cac(_0xb53f52);}});const _0x280f36=JSON['parse'](localStorage[_0x1ac797(0x285)](_0x990044[_0x1ac797(0x30c)]))||[];_0x280f36[_0x1ac797(0x2b8)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x1ac797(0x338)](),'totalTime':_0x18bb32,'stats':{'correct':_0x11335b,'incorrect':_0x2d2898,'notAttempted':_0x990044[_0x1ac797(0x2d1)](questionsData[_0x1ac797(0x289)],_0x990044[_0x1ac797(0x44c)](_0x11335b,_0x2d2898))}}),localStorage['setItem'](_0x990044[_0x1ac797(0x30c)],JSON['stringify'](_0x280f36)),stats[_0x1ac797(0x2cc)]=_0x11335b,stats[_0x1ac797(0x435)]=_0x2d2898,markQuizAsCompleted(),_0x990044[_0x1ac797(0x393)](showPerformanceAnalysis,_0x11335b,_0x2d2898,_0x990044[_0x1ac797(0x3bb)](questionsData[_0x1ac797(0x289)],_0x990044[_0x1ac797(0x44c)](_0x11335b,_0x2d2898)),_0x18bb32);}function showPerformanceAnalysis(_0x289a98,_0x2d7abc,_0xe2d21c,_0x3a60d6){const _0x4d062f=_0x5a4239,_0x4e1e40={'OIelu':_0x4d062f(0x3c2),'srvFq':function(_0x8800d9,_0x2a100f){return _0x8800d9*_0x2a100f;},'JzCAZ':function(_0x3e2a2c,_0x593541){return _0x3e2a2c/_0x593541;},'IQXzq':function(_0x16aff8,_0x1e00d7){return _0x16aff8+_0x1e00d7;},'XaApy':function(_0x4f48f5,_0x1d6e0e){return _0x4f48f5*_0x1d6e0e;},'Zfgub':function(_0x245f71,_0x2c1ebe){return _0x245f71-_0x2c1ebe;},'azzZn':function(_0x1200e7,_0x27fb25){return _0x1200e7*_0x27fb25;},'PRDOj':_0x4d062f(0x465),'YtRjo':_0x4d062f(0x2d2),'nuTMR':function(_0x26a2ed,_0x5a4ec2){return _0x26a2ed/_0x5a4ec2;},'ZkGZA':'totalTimeResult','QHcWa':function(_0x54eae6,_0x1e3d93){return _0x54eae6%_0x1e3d93;},'mujRl':'hidden'},_0x53a594=document[_0x4d062f(0x238)](_0x4e1e40[_0x4d062f(0x29d)]),_0x14f43d=_0x289a98+_0x2d7abc>0x0?Math[_0x4d062f(0x270)](_0x4e1e40[_0x4d062f(0x267)](_0x4e1e40[_0x4d062f(0x357)](_0x289a98,_0x4e1e40[_0x4d062f(0x1d3)](_0x289a98,_0x2d7abc)),0x64)):0x0,_0x235131=_0x4e1e40['srvFq'](_0x4e1e40[_0x4d062f(0x295)](0x2,Math['PI']),0x41),_0xa52a4b=document['getElementById'](_0x4d062f(0x345));_0xa52a4b['style']['strokeDasharray']=_0x235131+'\x20'+_0x235131,_0xa52a4b[_0x4d062f(0x3e6)][_0x4d062f(0x272)]=_0x4e1e40[_0x4d062f(0x30e)](_0x235131,_0x4e1e40['azzZn'](_0x4e1e40[_0x4d062f(0x357)](_0x14f43d,0x64),_0x235131)),document['getElementById'](_0x4e1e40[_0x4d062f(0x34e)])[_0x4d062f(0x446)]=_0x14f43d+'%',document[_0x4d062f(0x238)](_0x4e1e40[_0x4d062f(0x1c0)])[_0x4d062f(0x446)]=questionsData[_0x4d062f(0x289)],document[_0x4d062f(0x238)](_0x4d062f(0x34b))[_0x4d062f(0x446)]=_0x289a98,document[_0x4d062f(0x238)](_0x4d062f(0x3f2))['textContent']=_0x2d7abc,document[_0x4d062f(0x238)](_0x4d062f(0x32f))[_0x4d062f(0x446)]=_0xe2d21c;const _0x5a2798=Math[_0x4d062f(0x1bd)](_0x4e1e40[_0x4d062f(0x419)](_0x3a60d6,0xea60)),_0x39d636=Math[_0x4d062f(0x1bd)](_0x4e1e40[_0x4d062f(0x357)](_0x3a60d6%0xea60,0x3e8));document[_0x4d062f(0x238)](_0x4e1e40['ZkGZA'])[_0x4d062f(0x446)]=_0x5a2798+':'+_0x39d636['toString']()[_0x4d062f(0x44f)](0x2,'0');const _0x212a3f=_0x4e1e40[_0x4d062f(0x419)](_0x3a60d6,questionsData[_0x4d062f(0x289)]),_0x38d5cb=Math[_0x4d062f(0x1bd)](_0x4e1e40[_0x4d062f(0x357)](_0x212a3f,0xea60)),_0x561fd5=Math[_0x4d062f(0x1bd)](_0x4e1e40[_0x4d062f(0x3d8)](_0x212a3f,0xea60)/0x3e8);document['getElementById'](_0x4d062f(0x1f8))[_0x4d062f(0x446)]=_0x38d5cb+':'+_0x561fd5[_0x4d062f(0x327)]()[_0x4d062f(0x44f)](0x2,'0'),_0x53a594['classList']['remove'](_0x4e1e40[_0x4d062f(0x28d)]);}function closePerformanceModal(){const _0x2e829b=_0x5a4239,_0x5a7d9f={'WFsvf':'performanceModal'};document[_0x2e829b(0x238)](_0x5a7d9f[_0x2e829b(0x25a)])[_0x2e829b(0x29a)][_0x2e829b(0x3a0)]('hidden');}function reviewQuestions(){const _0x1e1315=_0x5a4239,_0x11d488={'TUOfk':function(_0x2a28ba,_0x159858){return _0x2a28ba<=_0x159858;},'hNCDg':function(_0x4be5f3,_0x205970){return _0x4be5f3(_0x205970);},'yTroB':_0x1e1315(0x2ab),'qSWnb':'customQuizData','mvrQl':function(_0x50aec9){return _0x50aec9();},'IwRyX':function(_0x555a95,_0x597b86){return _0x555a95!==_0x597b86;},'iFGXK':_0x1e1315(0x3fe),'WYDkg':_0x1e1315(0x2da),'WggsA':_0x1e1315(0x313),'AKMJQ':_0x1e1315(0x3c5),'HgAIb':_0x1e1315(0x24e),'VnfGj':_0x1e1315(0x20e),'dcuPs':_0x1e1315(0x2b4),'ajjDa':_0x1e1315(0x42c),'puphf':_0x1e1315(0x276),'tLyor':_0x1e1315(0x398),'OUzvE':function(_0x2b2c1e,_0x6ac79e){return _0x2b2c1e+_0x6ac79e;},'hmcWl':_0x1e1315(0x2f7),'strAv':function(_0x56dc10,_0xb448cf){return _0x56dc10===_0xb448cf;},'OQhgQ':_0x1e1315(0x3f7),'ElQOa':_0x1e1315(0x256),'vrkNS':_0x1e1315(0x1fb),'ZoZFr':_0x1e1315(0x221)};document['getElementById'](_0x11d488[_0x1e1315(0x42d)])['classList'][_0x1e1315(0x37f)](_0x1e1315(0x45f));const _0xd216ad=document[_0x1e1315(0x238)](_0x11d488[_0x1e1315(0x1ed)]);_0xd216ad[_0x1e1315(0x39f)]='',questionsData['forEach']((_0x35ebcc,_0x1bf96c)=>{const _0x42bc7f=_0x1e1315,_0x3c0a5a={'xvNzw':function(_0x5778a1){return _0x5778a1();},'LBLMA':function(_0x87f13f,_0x55b246){const _0x30d6bc=_0x4fd0;return _0x11d488[_0x30d6bc(0x2ba)](_0x87f13f,_0x55b246);},'UmqJQ':function(_0x337161,_0x2399d6){return _0x11d488['hNCDg'](_0x337161,_0x2399d6);},'FLVOm':function(_0x10f6ed,_0x414919){return _0x10f6ed===_0x414919;},'szJRQ':_0x11d488[_0x42bc7f(0x27f)],'SfPdG':_0x42bc7f(0x418),'IHMPe':_0x11d488[_0x42bc7f(0x326)],'YGlFn':function(_0x37762c){const _0x360e53=_0x42bc7f;return _0x11d488[_0x360e53(0x2fa)](_0x37762c);},'wYSyu':function(_0x3f4203,_0xb11411){const _0x44e10e=_0x42bc7f;return _0x11d488[_0x44e10e(0x2be)](_0x3f4203,_0xb11411);},'HagQN':_0x42bc7f(0x1db),'giCui':_0x42bc7f(0x3e3),'MCLzl':function(_0xb921d7,_0x5e9fa3){return _0xb921d7===_0x5e9fa3;},'GLfND':_0x11d488[_0x42bc7f(0x2e5)],'hhReM':_0x11d488[_0x42bc7f(0x366)]};if(_0x11d488[_0x42bc7f(0x2be)](_0x11d488[_0x42bc7f(0x284)],_0x11d488[_0x42bc7f(0x284)]))_0x286aeb--,_0x3c0a5a['xvNzw'](_0x381f5c),_0x3c0a5a[_0x42bc7f(0x414)](_0x4a6612,0x0)&&(_0x3c0a5a[_0x42bc7f(0x296)](_0x5e0d68,_0x33859e),_0x3c0a5a[_0x42bc7f(0x2d5)](_0x22d9af,_0x3c0a5a[_0x42bc7f(0x225)])?_0x55aa8a():_0x3c0a5a[_0x42bc7f(0x3b8)](_0x21df44));else{const _0x4a7d16=questionStates[_0x1bf96c],_0x1f2cb1=_0x35ebcc[_0x42bc7f(0x2fd)];let _0x4144c7=_0x11d488[_0x42bc7f(0x39d)],_0x1ad1bb='Not\x20Attempted';if(_0x11d488[_0x42bc7f(0x2be)](_0x4a7d16[_0x42bc7f(0x206)],null)){if(_0x11d488['HgAIb']!==_0x11d488[_0x42bc7f(0x2e2)])_0x174e06(_0x3c0a5a['SfPdG'])&&(_0x2f29ee['location']['pathname'][_0x42bc7f(0x2ec)]('custom_quiz.html')&&_0x4ac8ba[_0x42bc7f(0x362)](_0x3c0a5a[_0x42bc7f(0x204)]),_0x3c0a5a['YGlFn'](_0x1b7044),_0xe0101d[_0x42bc7f(0x31c)]());else{const _0x3da382=_0x35ebcc[_0x42bc7f(0x464)][_0x4a7d16['selectedAnswer']];_0x3da382['id']===_0x1f2cb1?(_0x4144c7=_0x11d488[_0x42bc7f(0x423)],_0x1ad1bb=_0x42bc7f(0x2de)):_0x11d488['dcuPs']===_0x42bc7f(0x361)?_0x15e2e7[_0x42bc7f(0x1f5)]=_0x559e6b:(_0x4144c7=_0x11d488[_0x42bc7f(0x43d)],_0x1ad1bb=_0x11d488['puphf']);}}const _0x10a4c7=document[_0x42bc7f(0x1e0)](_0x11d488[_0x42bc7f(0x227)]);_0x10a4c7[_0x42bc7f(0x39b)]=_0x42bc7f(0x3a7)+_0x4144c7;let _0x5e4d7f=(_0x35ebcc['choices']||[])[_0x42bc7f(0x33a)]((_0x56e7b6,_0x30eed7)=>{const _0x372d61=_0x42bc7f;if(_0x3c0a5a[_0x372d61(0x277)](_0x3c0a5a[_0x372d61(0x2dc)],_0x3c0a5a[_0x372d61(0x236)])){const _0x2e96e5=_0x4a7d16['selectedAnswer']===_0x30eed7,_0x1f3db1=_0x3c0a5a[_0x372d61(0x213)](_0x56e7b6['id'],_0x1f2cb1);let _0xbb4f92=_0x3c0a5a[_0x372d61(0x1ec)];if(_0x1f3db1)_0xbb4f92=_0x372d61(0x2ed);else{if(_0x2e96e5)_0xbb4f92=_0x3c0a5a[_0x372d61(0x430)];}return _0x372d61(0x44d)+_0xbb4f92+_0x372d61(0x21a)+String[_0x372d61(0x34c)](0x41+_0x30eed7)+_0x372d61(0x2ac)+_0x56e7b6[_0x372d61(0x1f9)]+_0x372d61(0x3c8);}else _0x3c0a5a[_0x372d61(0x441)](_0x884133);})['join']('');const _0x2a28a0=_0x35ebcc[_0x42bc7f(0x1cb)]?_0x42bc7f(0x3c3)+_0x1bf96c+'\x22\x20data-src=\x22'+_0x35ebcc[_0x42bc7f(0x1cb)]+'\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>':'';let _0x30581e='';if(_0x35ebcc['explanation_audio_eng'])_0x30581e+=_0x42bc7f(0x209)+_0x35ebcc[_0x42bc7f(0x217)]+_0x42bc7f(0x27b);if(_0x35ebcc[_0x42bc7f(0x2df)])_0x30581e+=_0x42bc7f(0x3c6)+_0x35ebcc[_0x42bc7f(0x2df)]+_0x42bc7f(0x27b);let _0x8603dd=(_0x35ebcc['explanation_images']||[])['map'](_0x378529=>_0x378529?_0x42bc7f(0x421)+_0x378529+_0x42bc7f(0x369):'')[_0x42bc7f(0x2e7)]('');_0x10a4c7[_0x42bc7f(0x39f)]='\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20'+_0x11d488[_0x42bc7f(0x35b)](_0x1bf96c,0x1)+_0x42bc7f(0x334)+(_0x4144c7===_0x11d488[_0x42bc7f(0x423)]?_0x11d488[_0x42bc7f(0x3e7)]:_0x11d488['strAv'](_0x4144c7,'incorrect')?_0x42bc7f(0x3e2):_0x11d488[_0x42bc7f(0x1d9)])+'-600\x20text-white\x22>'+_0x1ad1bb+'</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>'+_0x35ebcc[_0x42bc7f(0x1f9)]+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>'+_0x5e4d7f+_0x42bc7f(0x1d7)+(_0x35ebcc[_0x42bc7f(0x1e2)]||_0x11d488[_0x42bc7f(0x3ba)])+_0x42bc7f(0x317)+_0x2a28a0+_0x42bc7f(0x2b0)+_0x30581e+_0x42bc7f(0x2b0)+_0x8603dd+_0x42bc7f(0x370),_0xd216ad[_0x42bc7f(0x400)](_0x10a4c7);}}),initializeReviewVideos();}function initializeReviewVideos(){const _0x1a9de2=_0x5a4239,_0x5829f8={'xgRch':function(_0x1bc5ee,_0x33e717){return _0x1bc5ee===_0x33e717;},'rfbEh':_0x1a9de2(0x1e7),'oZTOs':_0x1a9de2(0x27e),'QuMel':function(_0x26a2f2,_0x5252a0,_0x807717){return _0x26a2f2(_0x5252a0,_0x807717);},'jlFCR':_0x1a9de2(0x2f9)};document[_0x1a9de2(0x3b9)](_0x5829f8[_0x1a9de2(0x415)])[_0x1a9de2(0x261)](_0x1a06ba=>{const _0x19d539=_0x1a9de2;if(_0x5829f8['xgRch'](_0x5829f8['rfbEh'],_0x5829f8['oZTOs']))_0x489ca0['src']=_0x55926d;else{const _0x33001b=_0x1a06ba[_0x19d539(0x397)][_0x19d539(0x1f5)];if(_0x33001b&&_0x33001b[_0x19d539(0x2a1)](_0x19d539(0x255)))_0x5829f8['QuMel'](setupVideo,_0x1a06ba,_0x33001b);else _0x33001b&&(_0x1a06ba[_0x19d539(0x1f5)]=_0x33001b);}});}function retakeQuiz(){const _0x2fb1c3=_0x5a4239,_0x4e2f9c={'isHFN':function(_0x1a3bf1,_0x1352ba){return _0x1a3bf1(_0x1352ba);},'MJEek':_0x2fb1c3(0x418),'EsQmK':_0x2fb1c3(0x3cc),'rDQZs':_0x2fb1c3(0x351),'lvsiE':function(_0x4ee1a5){return _0x4ee1a5();}};_0x4e2f9c[_0x2fb1c3(0x241)](confirm,_0x4e2f9c['MJEek'])&&(window[_0x2fb1c3(0x223)]['pathname'][_0x2fb1c3(0x2ec)](_0x4e2f9c[_0x2fb1c3(0x2ea)])&&localStorage['removeItem'](_0x4e2f9c[_0x2fb1c3(0x38b)]),_0x4e2f9c[_0x2fb1c3(0x263)](clearProgress),location[_0x2fb1c3(0x31c)]());}function loadBookmarkedQuestions(){const _0x2be431=_0x5a4239,_0x250eb7={'rJazH':function(_0x27e194,_0x4b6ed1){return _0x27e194===_0x4b6ed1;},'GUvOb':'correct','CULzK':_0x2be431(0x2b9),'TYibR':_0x2be431(0x42c),'SvNzw':_0x2be431(0x2c3),'RkGYu':_0x2be431(0x2fb),'LkULv':function(_0x6dec10,_0x302296){return _0x6dec10!==_0x302296;},'QvrEF':'uogNt','TEMgQ':function(_0x3ce129,_0x488354){return _0x3ce129!==_0x488354;},'NnPzy':_0x2be431(0x315)},_0x944293=JSON[_0x2be431(0x35d)](localStorage[_0x2be431(0x285)](_0x2be431(0x31e)))||[];_0x944293['forEach'](_0x3283a1=>{const _0x27adc0=_0x2be431;if(_0x250eb7[_0x27adc0(0x425)](_0x250eb7['QvrEF'],_0x27adc0(0x340)))_0x3283a1[_0x27adc0(0x40b)]['includes'](quizName[_0x27adc0(0x1bb)]()['replace'](/ /g,'-'))&&(_0x250eb7['TEMgQ'](_0x250eb7[_0x27adc0(0x39c)],_0x27adc0(0x3af))?_0x3283a1['questionIndex']<questionsData[_0x27adc0(0x289)]&&(questionStates[_0x3283a1[_0x27adc0(0x20b)]]['bookmarked']=!![]):_0x17b93f[_0x27adc0(0x39f)]+=_0x27adc0(0x376)+_0x1fcbde['explanation_audio_hin']+_0x27adc0(0x27b));else{if(_0x250eb7['rJazH'](_0x2e56cf[_0x27adc0(0x387)],_0x250eb7[_0x27adc0(0x1b8)]))_0xc2851=_0x250eb7[_0x27adc0(0x237)];else{if(_0x250eb7[_0x27adc0(0x328)](_0x1db9f8[_0x27adc0(0x387)],_0x250eb7[_0x27adc0(0x2f0)]))_0x376fa7=_0x250eb7['SvNzw'];else _0x5f141b=_0x250eb7[_0x27adc0(0x203)];}}});}function toggleBookmark(){const _0x46d18b=_0x5a4239,_0x154097={'bCTKp':function(_0xd61d10,_0x3715e1){return _0xd61d10===_0x3715e1;},'LLOcS':'correct','XdGGj':_0x46d18b(0x2de),'LKDFc':'incorrect','bRiRe':_0x46d18b(0x276),'sdFAY':_0x46d18b(0x31e),'LLfyN':function(_0x59951c,_0x4efdb3){return _0x59951c!==_0x4efdb3;},'BAsdb':'sIwld','owWmf':function(_0xc4bae2){return _0xc4bae2();}},_0xb00611=!questionStates[currentQuestionIndex][_0x46d18b(0x22c)];questionStates[currentQuestionIndex][_0x46d18b(0x22c)]=_0xb00611;let _0x199837=JSON[_0x46d18b(0x35d)](localStorage[_0x46d18b(0x285)](_0x154097[_0x46d18b(0x3a4)]))||[];if(_0xb00611){const _0x5d1eb0={'quizName':quizName,'quizFile':window[_0x46d18b(0x223)][_0x46d18b(0x325)][_0x46d18b(0x1d6)]('/')[_0x46d18b(0x3f8)](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x46d18b(0x338)]()};_0x199837['push'](_0x5d1eb0);}else{if(_0x154097['LLfyN'](_0x154097[_0x46d18b(0x2ee)],_0x46d18b(0x1de)))_0x199837=_0x199837['filter'](_0x1efaee=>!(_0x1efaee[_0x46d18b(0x40b)][_0x46d18b(0x2a1)](quizName[_0x46d18b(0x1bb)]()[_0x46d18b(0x444)](/ /g,'-'))&&_0x1efaee[_0x46d18b(0x20b)]===currentQuestionIndex));else{const _0x2b94df=_0x4e5070[_0x46d18b(0x464)][_0x5d81b8[_0x46d18b(0x206)]];_0x154097[_0x46d18b(0x1b4)](_0x2b94df['id'],_0x112ac6)?(_0x1a2bc9=_0x154097[_0x46d18b(0x2e0)],_0x5b2897=_0x154097[_0x46d18b(0x24b)]):(_0x46488a=_0x154097[_0x46d18b(0x3e4)],_0x47f8b5=_0x154097[_0x46d18b(0x2b7)]);}}localStorage[_0x46d18b(0x356)](_0x154097['sdFAY'],JSON[_0x46d18b(0x346)](_0x199837)),updateBookmarkButton(),_0x154097['owWmf'](updateQuestionNav);}function updateBookmarkButton(){const _0x5f17c5=_0x5a4239,_0x370cda={'pyDQG':'bookmarkBtn','LcriT':_0x5f17c5(0x324),'GNAmU':_0x5f17c5(0x1fe),'PgaMK':_0x5f17c5(0x453),'hDYUR':_0x5f17c5(0x314)},_0x90ea85=document[_0x5f17c5(0x238)](_0x370cda['pyDQG']),_0x3e5ee4=document[_0x5f17c5(0x238)](_0x370cda['LcriT']),_0x4429b4=questionStates[currentQuestionIndex][_0x5f17c5(0x22c)];_0x90ea85['className']=_0x4429b4?_0x370cda[_0x5f17c5(0x1b2)]:_0x370cda[_0x5f17c5(0x2dd)],_0x3e5ee4[_0x5f17c5(0x446)]=_0x4429b4?'Bookmarked':_0x370cda[_0x5f17c5(0x378)];}function toggleMarkForReview(){const _0x4ce1c5=_0x5a4239,_0x29f7c0={'UocSa':function(_0x122f5a){return _0x122f5a();},'kJGaR':function(_0x38a639){return _0x38a639();}};questionStates[currentQuestionIndex][_0x4ce1c5(0x35e)]=!questionStates[currentQuestionIndex][_0x4ce1c5(0x35e)],_0x29f7c0[_0x4ce1c5(0x322)](updateMarkReviewButton),_0x29f7c0['kJGaR'](updateQuestionNav);}function updateMarkReviewButton(){const _0x1f7b05=_0x5a4239,_0x3f7050={'DFbef':'gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','LwCtv':'glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','OtzJH':_0x1f7b05(0x360),'pbZgt':_0x1f7b05(0x454)},_0x589cfe=document[_0x1f7b05(0x238)](_0x1f7b05(0x411)),_0x4a8b85=document[_0x1f7b05(0x238)](_0x1f7b05(0x21d)),_0x56c632=questionStates[currentQuestionIndex]['markedForReview'];_0x589cfe[_0x1f7b05(0x39b)]=_0x56c632?_0x3f7050[_0x1f7b05(0x3b1)]:_0x3f7050['LwCtv'],_0x4a8b85[_0x1f7b05(0x446)]=_0x56c632?_0x3f7050['OtzJH']:_0x3f7050[_0x1f7b05(0x3cf)];}function previousQuestion(){const _0x3fea0d=_0x5a4239,_0x43098a={'riGij':_0x3fea0d(0x351),'ynCjp':_0x3fea0d(0x2b2),'ynGfl':'quizHierarchy','CpuRW':_0x3fea0d(0x3b4),'qOcNy':function(_0x40aa79,_0x13a7ca){return _0x40aa79+_0x13a7ca;},'YRcAr':_0x3fea0d(0x27a),'TvHXF':_0x3fea0d(0x1f0),'Gkrek':function(_0xeac2a0,_0x2f129c){return _0xeac2a0>_0x2f129c;},'sVNKQ':function(_0x16be59,_0x225703){return _0x16be59!==_0x225703;},'IufFI':_0x3fea0d(0x1d5),'bAvmh':function(_0xeaf573){return _0xeaf573();}};if(_0x43098a[_0x3fea0d(0x3f4)](currentQuestionIndex,0x0)){if(_0x43098a['sVNKQ'](_0x3fea0d(0x230),_0x43098a[_0x3fea0d(0x44a)]))questionStartTime&&(questionStates[currentQuestionIndex][_0x3fea0d(0x434)]+=Date[_0x3fea0d(0x338)]()-questionStartTime),currentQuestionIndex--,_0x43098a['bAvmh'](displayQuestion),saveProgress();else{const _0x517183=_0x170a7d[_0x3fea0d(0x35d)](_0x21a769['getItem'](_0x43098a[_0x3fea0d(0x1f1)]));if(_0x517183){const _0xe69e93=_0x43098a[_0x3fea0d(0x3e9)][_0x3fea0d(0x1d6)]('|');let _0x39d4c8=0x0;while(!![]){switch(_0xe69e93[_0x39d4c8++]){case'0':_0x3cf7a3=_0x517183['name'];continue;case'1':_0x37d8c6['getElementById'](_0x43098a[_0x3fea0d(0x2f6)])[_0x3fea0d(0x446)]=_0x1647c4[_0x3fea0d(0x2e7)](_0x43098a['CpuRW']);continue;case'2':_0x549b71[_0x3fea0d(0x28c)]=_0x43098a['qOcNy'](_0x3555a6,_0x43098a[_0x3fea0d(0x3fa)]);continue;case'3':_0x365f9a[_0x3fea0d(0x238)](_0x43098a['TvHXF'])[_0x3fea0d(0x446)]=_0x3a7cf7[_0x3fea0d(0x289)];continue;case'4':_0x19db0c=_0x517183[_0x3fea0d(0x36d)];continue;case'5':_0x56fd6c=_0x517183['hierarchy'];continue;}break;}}}}}function nextQuestion(){const _0x583c6e=_0x5a4239,_0x5cab69={'qpnfP':function(_0x4ad8e3,_0x1257cb){return _0x4ad8e3+_0x1257cb;},'jupZs':'div','XVodp':_0x583c6e(0x3de),'KIDqI':'Option\x20','cFbxx':function(_0x2207c2,_0x1710a5){return _0x2207c2+_0x1710a5;},'RwsjP':function(_0x73680,_0x4546d7){return _0x73680+_0x4546d7;},'vCbTh':_0x583c6e(0x31f),'HsRrZ':function(_0x41ce09){return _0x41ce09();},'CvjQe':_0x583c6e(0x1ee),'BCLxQ':_0x583c6e(0x316),'gmNpT':_0x583c6e(0x1c3),'qxGLu':_0x583c6e(0x281),'PrvKc':'trace','trVKB':_0x583c6e(0x1ba),'YJMdK':function(_0x442d6e){return _0x442d6e();},'HKoFH':function(_0x1c5739,_0xd65ace){return _0x1c5739-_0xd65ace;},'dSsvd':function(_0x18e5e5,_0x5a0c2b){return _0x18e5e5-_0x5a0c2b;},'asXUz':function(_0x3866d8,_0x304773){return _0x3866d8!==_0x304773;},'VNPsk':_0x583c6e(0x3da),'Ktdkc':_0x583c6e(0x205),'nkMjL':function(_0x46374e){return _0x46374e();},'PeerN':_0x583c6e(0x36a),'aQsch':function(_0x3eb40e,_0x1ee713){return _0x3eb40e===_0x1ee713;},'NnisG':_0x583c6e(0x259),'nJgKX':_0x583c6e(0x2ab),'CUNbw':'TXjBG','pPAHB':function(_0x319618,_0x25cacc){return _0x319618(_0x25cacc);},'vogdi':function(_0x52331f){return _0x52331f();},'VSQzu':_0x583c6e(0x229),'YYGZe':function(_0x3e71d4,_0x4e460a){return _0x3e71d4(_0x4e460a);},'LxAAA':function(_0x4045b5){return _0x4045b5();}};questionStartTime&&(questionStates[currentQuestionIndex][_0x583c6e(0x434)]+=_0x5cab69[_0x583c6e(0x3b3)](Date[_0x583c6e(0x338)](),questionStartTime));if(currentQuestionIndex<_0x5cab69[_0x583c6e(0x32d)](questionsData[_0x583c6e(0x289)],0x1)){if(_0x5cab69['asXUz'](_0x5cab69[_0x583c6e(0x333)],_0x5cab69[_0x583c6e(0x3c0)]))currentQuestionIndex++,_0x5cab69[_0x583c6e(0x207)](displayQuestion),saveProgress();else{const _0x1bacf9=_0x1c3671[_0x583c6e(0x34c)](_0x5cab69['qpnfP'](0x41,_0x7345ef)),_0x57f06d=_0x282540===_0x5ee36a,_0x59dfd0=_0x4b26f1['createElement'](_0x5cab69[_0x583c6e(0x2a9)]);_0x59dfd0[_0x583c6e(0x39f)]=_0x583c6e(0x307)+(_0x57f06d?_0x5cab69[_0x583c6e(0x394)]:'')+'\x22\x20data-option-index=\x22'+_0xea14cf+_0x583c6e(0x3df)+_0x1bacf9+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>'+(_0x280a43['text']||_0x5cab69[_0x583c6e(0x45b)](_0x5cab69[_0x583c6e(0x32a)],_0x5cab69[_0x583c6e(0x3bd)](_0x5a3849,0x1)))+_0x583c6e(0x308),_0x14457f['appendChild'](_0x59dfd0);}}else{if(_0x5cab69[_0x583c6e(0x2f3)]===_0x5cab69[_0x583c6e(0x2f3)]){if(_0x5cab69[_0x583c6e(0x2c7)](currentMode,_0x5cab69[_0x583c6e(0x442)])||_0x5cab69[_0x583c6e(0x2c7)](currentMode,_0x5cab69[_0x583c6e(0x21c)])){if(_0x5cab69['aQsch'](_0x5cab69['CUNbw'],_0x5cab69[_0x583c6e(0x1e5)]))_0x5cab69[_0x583c6e(0x359)](confirm,_0x5cab69[_0x583c6e(0x2fc)])&&_0x5cab69[_0x583c6e(0x320)](submitQuiz);else{let _0x1fcfbd;try{const _0x25a064=_0x6b1e8d(sHXQfl[_0x583c6e(0x39a)](_0x583c6e(0x234),sHXQfl[_0x583c6e(0x25b)])+');');_0x1fcfbd=sHXQfl[_0x583c6e(0x309)](_0x25a064);}catch(_0x710660){_0x1fcfbd=_0x572088;}const _0x5f47bb=_0x1fcfbd[_0x583c6e(0x449)]=_0x1fcfbd[_0x583c6e(0x449)]||{},_0x7b671a=[sHXQfl[_0x583c6e(0x1c7)],sHXQfl[_0x583c6e(0x26e)],_0x583c6e(0x23f),sHXQfl[_0x583c6e(0x372)],_0x583c6e(0x388),sHXQfl[_0x583c6e(0x447)],sHXQfl[_0x583c6e(0x20f)]];for(let _0x5c6cf2=0x0;_0x5c6cf2<_0x7b671a['length'];_0x5c6cf2++){const _0x24abca=_0x551bec[_0x583c6e(0x1d1)][_0x583c6e(0x422)][_0x583c6e(0x373)](_0x41be30),_0x55dccb=_0x7b671a[_0x5c6cf2],_0x30aed3=_0x5f47bb[_0x55dccb]||_0x24abca;_0x24abca['__proto__']=_0x2cf95e[_0x583c6e(0x373)](_0x2da6d8),_0x24abca['toString']=_0x30aed3['toString'][_0x583c6e(0x373)](_0x30aed3),_0x5f47bb[_0x55dccb]=_0x24abca;}}}else _0x5cab69[_0x583c6e(0x347)]===_0x583c6e(0x22e)?(_0x3fd446++,_0x1a6c70['status']='incorrect'):_0x5cab69[_0x583c6e(0x1d4)](confirm,_0x583c6e(0x293))&&(currentQuestionIndex=0x0,_0x5cab69[_0x583c6e(0x41c)](displayQuestion),_0x5cab69['LxAAA'](saveProgress));}else _0x8c9628(_0x5cab69[_0x583c6e(0x2fc)])&&_0x5cab69[_0x583c6e(0x41c)](_0x4ba42a);}}function startTimer(){const _0x16fe9e=_0x5a4239,_0x5db592={'HQGPy':_0x16fe9e(0x401),'eOTjo':'none','igZEL':function(_0x45c0c0){return _0x45c0c0();},'YehSw':_0x16fe9e(0x2d4),'LhwcF':function(_0x4a2f8e){return _0x4a2f8e();},'vMVyK':function(_0x22f302,_0x1ec80d){return _0x22f302<=_0x1ec80d;},'KPWeO':function(_0x2cd0f5,_0x3ec861){return _0x2cd0f5!==_0x3ec861;},'gGXHh':_0x16fe9e(0x275),'HGnLi':'GrddI','oDdDA':function(_0x43b071,_0x13222c){return _0x43b071===_0x13222c;},'TxgNe':_0x16fe9e(0x2ab),'pJvwx':_0x16fe9e(0x37d),'qXfXo':function(_0x199368){return _0x199368();},'xAWKS':function(_0x54aa06){return _0x54aa06();},'sOLDB':function(_0x25d9bf,_0x474405){return _0x25d9bf(_0x474405);},'kSWLt':function(_0x239b59,_0x548167,_0x45df00){return _0x239b59(_0x548167,_0x45df00);}};if(timer)_0x5db592[_0x16fe9e(0x349)](clearInterval,timer);timeRemaining=0x78,updateTimerDisplay(),timer=_0x5db592[_0x16fe9e(0x437)](setInterval,()=>{const _0x39a938=_0x16fe9e;timeRemaining--,_0x5db592['LhwcF'](updateTimerDisplay);if(_0x5db592[_0x39a938(0x3e0)](timeRemaining,0x0)){if(_0x5db592[_0x39a938(0x455)](_0x5db592[_0x39a938(0x355)],_0x5db592['HGnLi'])){clearInterval(timer);if(_0x5db592['oDdDA'](currentMode,_0x5db592[_0x39a938(0x291)])){if(_0x5db592['KPWeO']('EWtUL',_0x5db592['pJvwx']))_0x5db592[_0x39a938(0x417)](submitQuiz);else{const _0x2c621c=_0x4d94b8?function(){const _0xe51dad=_0x39a938;if(_0x57edbd){const _0x7e4905=_0x2184bf[_0xe51dad(0x3ec)](_0x275de3,arguments);return _0x2bda39=null,_0x7e4905;}}:function(){};return _0x1c0d29=![],_0x2c621c;}}else _0x5db592[_0x39a938(0x3d4)](nextQuestion);}else _0x1ac296()?(_0x206674[_0x39a938(0x238)](_0x5db592[_0x39a938(0x2ff)])[_0x39a938(0x3e6)][_0x39a938(0x32b)]=_0x5db592[_0x39a938(0x406)],_0x540c56()):(_0x5db592['igZEL'](_0xd0b14e),_0x2566d3[_0x39a938(0x238)](_0x5db592[_0x39a938(0x2ff)])[_0x39a938(0x3e6)]['display']=_0x5db592['YehSw']);}},0x3e8);}function updateTimerDisplay(){const _0x156776=_0x5a4239,_0x216060={'ilNDS':function(_0x2d5cc6,_0x503e67){return _0x2d5cc6/_0x503e67;},'qclLy':function(_0x5d868b,_0x37874a){return _0x5d868b%_0x37874a;},'oseJn':_0x156776(0x354),'OpCSS':function(_0x1f2ab6,_0x308a9c){return _0x1f2ab6+_0x308a9c;}},_0x7d65f5=Math['floor'](_0x216060['ilNDS'](timeRemaining,0x3c)),_0x266f73=_0x216060[_0x156776(0x233)](timeRemaining,0x3c);document[_0x156776(0x238)](_0x216060[_0x156776(0x33c)])['textContent']=_0x216060['OpCSS'](_0x216060[_0x156776(0x3eb)](_0x7d65f5,':'),_0x266f73[_0x156776(0x327)]()[_0x156776(0x44f)](0x2,'0'));}function toggleSidebar(){const _0x7a1e46=_0x5a4239,_0x26f53e={'dZRLk':_0x7a1e46(0x335),'SzDmU':'open'};document[_0x7a1e46(0x238)](_0x26f53e['dZRLk'])[_0x7a1e46(0x29a)]['toggle'](_0x26f53e['SzDmU']);}document[_0x5a4239(0x201)]('DOMContentLoaded',()=>{const _0x5dd177=_0x5a4239,_0x53d4bc={'snocN':function(_0x100285){return _0x100285();},'Trnpt':_0x5dd177(0x401),'TPxFB':_0x5dd177(0x451),'pKwUC':_0x5dd177(0x2d4),'UxRwj':_0x5dd177(0x3cc),'yDqKE':function(_0x39eb97,_0x3cbe64){return _0x39eb97===_0x3cbe64;},'ygGmW':'TIZnv','QcGhE':function(_0x527231){return _0x527231();}};if(resume)_0x53d4bc[_0x5dd177(0x1d0)](loadProgress)?(document[_0x5dd177(0x238)](_0x53d4bc[_0x5dd177(0x20d)])[_0x5dd177(0x3e6)][_0x5dd177(0x32b)]=_0x53d4bc['TPxFB'],initializeQuiz()):(_0x53d4bc[_0x5dd177(0x1d0)](clearProgress),document[_0x5dd177(0x238)]('modeModal')[_0x5dd177(0x3e6)][_0x5dd177(0x32b)]=_0x53d4bc[_0x5dd177(0x402)]);else!window[_0x5dd177(0x223)][_0x5dd177(0x325)][_0x5dd177(0x2ec)](_0x53d4bc[_0x5dd177(0x1eb)])?_0x53d4bc[_0x5dd177(0x2c0)](_0x53d4bc['ygGmW'],_0x53d4bc[_0x5dd177(0x304)])?(_0x53d4bc['snocN'](clearProgress),document[_0x5dd177(0x238)](_0x53d4bc[_0x5dd177(0x20d)])['style']['display']=_0x5dd177(0x2d4)):_0x4983d0():_0x53d4bc[_0x5dd177(0x383)](initializeQuiz);}),document['addEventListener'](_0x5a4239(0x294),function(_0x463951){const _0x21ff73=_0x5a4239,_0x449b49={'SftsG':_0x21ff73(0x2b6),'wtIZn':function(_0x32bc79,_0x2bcb49){return _0x32bc79<_0x2bcb49;},'jCWbJ':function(_0x56513f){return _0x56513f();},'vBNLy':_0x21ff73(0x1fe),'KYEaQ':_0x21ff73(0x3e1),'kgAMY':function(_0x5f0484,_0x467425){return _0x5f0484!==_0x467425;},'NILbS':_0x21ff73(0x401),'LRXNg':_0x21ff73(0x451),'xcuit':function(_0x2f373b,_0x5dc837){return _0x2f373b===_0x5dc837;},'ncFPt':_0x21ff73(0x45f),'tfFJE':function(_0x1483f3,_0x57f5c0){return _0x1483f3>=_0x57f5c0;},'BeOAQ':function(_0x32c47e,_0x47fcda){return _0x32c47e<=_0x47fcda;},'DNjbV':function(_0x2ff917,_0x24a1bb){return _0x2ff917-_0x24a1bb;},'CawJi':function(_0x1565c6,_0x5a009c){return _0x1565c6(_0x5a009c);},'XVQHa':function(_0x494bd0,_0x1e0d97){return _0x494bd0<_0x1e0d97;},'gOTVR':_0x21ff73(0x382),'zkaHJ':function(_0x194881,_0x3f1774){return _0x194881===_0x3f1774;},'nWSKU':function(_0x26a0f2,_0x54f7e4){return _0x26a0f2===_0x54f7e4;},'WKdBT':_0x21ff73(0x24f),'tUwXc':function(_0x37112d,_0x49e1bd){return _0x37112d===_0x49e1bd;},'UdUoC':_0x21ff73(0x2ca),'iKClA':'mgrPo','pSnUD':function(_0x198322){return _0x198322();},'aUSVC':function(_0x20a6f3,_0x2da802){return _0x20a6f3===_0x2da802;},'pxuIO':'test','iTATi':_0x21ff73(0x2ab)};if(_0x449b49[_0x21ff73(0x231)](document[_0x21ff73(0x238)](_0x449b49[_0x21ff73(0x3a2)])[_0x21ff73(0x3e6)]['display'],_0x449b49[_0x21ff73(0x396)]))return;if(_0x449b49[_0x21ff73(0x265)](document['getElementById']('performanceModal')[_0x21ff73(0x29a)]['contains'](_0x449b49[_0x21ff73(0x2a5)]),![]))return;if(_0x449b49[_0x21ff73(0x379)](_0x463951[_0x21ff73(0x300)],'1')&&_0x449b49['BeOAQ'](_0x463951[_0x21ff73(0x300)],'4')){const _0x5bc0c6=_0x449b49[_0x21ff73(0x438)](_0x449b49['CawJi'](parseInt,_0x463951[_0x21ff73(0x300)]),0x1),_0x433526=document[_0x21ff73(0x3b9)](_0x21ff73(0x318));if(_0x449b49['XVQHa'](_0x5bc0c6,_0x433526[_0x21ff73(0x289)]))_0x449b49[_0x21ff73(0x399)](selectOption,_0x5bc0c6);}else{if(_0x449b49[_0x21ff73(0x265)](_0x463951['key'],_0x449b49[_0x21ff73(0x33f)])){if(_0x21ff73(0x22d)==='jvstj')_0x449b49[_0x21ff73(0x29e)](previousQuestion);else{const _0x1694fa=_0x386026[_0x21ff73(0x238)](_0x449b49[_0x21ff73(0x28e)]);_0x1694fa['innerHTML']='';for(let _0x341df3=0x0;_0x449b49['wtIZn'](_0x341df3,_0x554a60[_0x21ff73(0x289)]);_0x341df3++){const _0x9823ed=_0x2f3d97[_0x21ff73(0x1e0)](_0x21ff73(0x30f));_0x9823ed[_0x21ff73(0x446)]=_0x341df3+0x1,_0x9823ed[_0x21ff73(0x39b)]='w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200',_0x9823ed['onclick']=()=>_0x5df930(_0x341df3),_0x9823ed['id']=_0x21ff73(0x26f)+_0x341df3,_0x1694fa[_0x21ff73(0x400)](_0x9823ed);}_0x449b49[_0x21ff73(0x29e)](_0x3f9b47);}}else{if(_0x463951[_0x21ff73(0x300)]===_0x21ff73(0x3b0)||_0x449b49[_0x21ff73(0x1e3)](_0x463951[_0x21ff73(0x300)],'\x20'))_0x463951['preventDefault'](),nextQuestion();else{if(_0x449b49[_0x21ff73(0x380)](_0x463951['key'][_0x21ff73(0x1bb)](),'b')&&(currentMode===_0x449b49[_0x21ff73(0x34d)]||_0x449b49[_0x21ff73(0x342)](currentMode,_0x449b49['UdUoC']))){if(_0x449b49['kgAMY'](_0x21ff73(0x358),_0x449b49[_0x21ff73(0x26c)]))_0x449b49[_0x21ff73(0x33e)](toggleBookmark);else{const _0x1dd183=_0x55d21e[_0x21ff73(0x238)]('bookmarkBtn'),_0xb17fcf=_0xf43637[_0x21ff73(0x238)](_0x21ff73(0x324)),_0xd19b6b=_0x16676b[_0x342dfb][_0x21ff73(0x22c)];_0x1dd183[_0x21ff73(0x39b)]=_0xd19b6b?_0x449b49[_0x21ff73(0x319)]:_0x21ff73(0x453),_0xb17fcf[_0x21ff73(0x446)]=_0xd19b6b?_0x449b49[_0x21ff73(0x3bc)]:_0x21ff73(0x314);}}else{if(_0x449b49[_0x21ff73(0x2e1)](_0x463951['key'][_0x21ff73(0x1bb)](),'m')&&(currentMode===_0x449b49['pxuIO']||_0x449b49['zkaHJ'](currentMode,_0x449b49[_0x21ff73(0x41e)])))_0x449b49[_0x21ff73(0x29e)](toggleMarkForReview);else _0x463951['key'][_0x21ff73(0x1bb)]()==='s'&&(currentMode===_0x21ff73(0x259)||currentMode===_0x449b49['iTATi'])&&_0x449b49[_0x21ff73(0x33e)](submitQuiz);}}}}});</script>

</body></html>